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THE PORTUGUESE UNIVERSAL HEALTH SYSTEM
Preface
PAULA LOBATO DE FARIA
The Second Biennial Seminar in Health Law and Bioethics on
“Law and Ethics in Rationing Access to Care in a High-Cost
Global Economy” was held on May 30 and 31 in Boston, US.
This seminar was a joint venture of  the Boston University School
of  Public Health department of  Health Law, Bioethics, and
Human Rights (directed by Edward R. Utley Professor George J.
Annas) and the Discipline of  Health Law, Ethics, and Biolaw of
the National School of  Public Health of  the New University of
Lisbon (Universidade Nova de Lisboa) — Portugal.
The first seminar was held in 2005 in Lisbon and resulted in the
publication of  the book The Role of  Health Law, Bioethics and Human
Rights to Promote a Safer and Healthier World, a collaborative look at the
issues presented at the mentioned colloquium with the same title.
These series of  seminars are designed to create scientific and
academic bridges between US and Portuguese institutions in the
fields of  health law, bioethics, and human rights.
The 2007 seminar focused specifically on issues surrounding
the rationing of  health care within perspectives from both sides
of  the Atlantic.
The United States has dealt with rationing in the past, such as
the well known case, in the late 1960s, of  the Seattle medical
community struggling to determine which renal failure patients to
give preference to for the limited availability of  a new treatment
called dialysis. Nevertheless, dilemmas like these are continuing
not only in the scenario of global health but also in the daily
practice of  medical care units.
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Quoting George J. Annas “unless you give everybody
everything or nobody anything, you’re rationing, even if  you don’t
call it rationing”1 and therefore society needs more than basic
rules or a public process on rationing to include the human rights
dimension, since this dimension will be able to provide the
qualitative counterpart of  a problem that tends more and more to
be dealt with by economists in a quantitative perspective.
During the two days of the Second Biennial Seminar in Health
Law and Bioethics 10 speakers presented US and European views
on the fundamental right to healthcare, patients rights, ethics of
health costs rationing, citizen’s health duties, healthcare delivery
national systems and other related topics. The text that follows
contains the majority of  these presentations by alphabetical order.
It is also important to mention and thank the financial support
of  the Calouste Gulbenkian Foundation, the Luso-American Foundation
for the Development and the Ministry of  Health (Portugal) to the
traveling of  the Portuguese speakers.
We hope this book will spread the interest on the scientific
developing in Health Law and Bioethics as a main contributor to
a better distribution and delivery of  healthcare in global and
national levels, and to the understanding of the significance to
humankind of the recognition of healthcare as a fundamental
human right.
1 In: Nicole Laskowski, Health Care as a Human Right-US. and Portuguese
professors meet for seminar on health law and bioethics, BUToday, June 6,
2007.
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Introduction
WENDY K. MARINER
Can basic legal and ethical principles assuring equitable access
to care survive growing pressure to control costs? At a time of
increasing global economic competition, European and North
American countries face rising health care costs. These costs are
driven in part by the proliferation of  biomedical technologies,
increased longevity, aging populations, and aspirations for better
health in general for all people around the world. The pressure to
control costs poses significant challenges to ensuring access to
care. Can countries ensure universal access to care without unfair
rationing? What role should insurance play in rationing access to
care itself? Should individuals assume more responsibility for their
own health or their own costs? What kinds of  cost controls can
be justified, and on what grounds? Should new technologies be
subjected to more stringent rules than existing health services?
Are some groups more likely than others to be disadvantaged by
different market and regulatory regimes?
These questions were the subject of  the 2nd Biennial Seminar
in Health Law and Bioethics, held in Boston, Massachusetts, USA,
on 30-31 May 2007. The papers presented at the Seminar and
collected in this volume examine key legal and ethical principles
that govern access to care and ask whether they can continue to
do so in the future without significant modification. Because this
question is common to so many countries, meaningful answers are
most likely to be developed by sharing the scholarship,
perspectives, and experience of  different nations. This work offers
a sample of current scholarship in Portugal and the United States,
WENDY K. MARINER
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and demonstrates both common and different (although
sometimes complementary) perspectives on the concept of
rationing care.
Choosing a legal and ethical framework for access to care
The first three chapters examine how the legal framework for
a country’s health care system is created, highlighting tensions
between social solidarity and personal responsibility in organizing
a national health system. Paula Lobato de Faria lays the
groundwork with a comprehensive description of  Portugal’s
health system, which illustrates several modern trends. Like other
countries in the OECD, Portugal has been increasing the
percentage of  its gross domestic product spent on health. It has
also begun to expand the role of  the private sector in managing
its National Health Service, in part, perhaps, to gain more control
over rising costs. Portugal’s political changes have also modified
the legal framework for its health care system, although the
reforms do not necessarily ref lect a consistent political
philosophy. Both political and structural reforms may affect the
conception of  patients’ rights and whether patients have duties or
whether the idea of  patient duties are more properly characterized
as inherent limits on the scope of  patient rights.
Rising costs are testing conceptions of  social solidarity
elsewhere in Europe. Jorge Simões and Sofia Nogueira da Silva
place the national experience in the context of the European
Union, where most countries face similar cost pressures. They
note a degree of  convergence in the cost-containment measures
adopted by EU member states, but there are conflicting trends in
the harmonization of  social institutions. On the one hand, as the
number of  EU member countries grows, national sovereignty is
carefully guarded and consistency sometimes seems possible only
9
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at the level of  general principles. On the other hand, the
jurisprudence of  the Court of  Justice of  the European
Communities has been developing “the foundations for the
possibility of  free choice of  health care providers.” They conclude
that Europe must make better use of  resources if  it is to preserve
its welfare state model.
The United States has yet to build a truly universal model of
health care or social insurance. Yet, as Wendy Mariner writes, public
opinion in the United States increasingly favors a more rational
system of universal access to affordable care. Her chapter takes a
fresh look at how the pressures of  rising costs and public demands
for access to care may pull reform in quite different directions,
either toward more universal access or toward more personal
responsibility for costs. Examining the role of  insurance in
financing care, she cautions that shifting responsibility for costs to
patients — especially in the form of  penalties or rewards for staying
healthy — may lead reforms farther away from social solidarity and
back to the idea that everyone should pay for her own care.
Access to biotechnology in a global economy
The chapters in this section consider discrepancies in access to
care in and their justifications. Professor George Annas examines
how new biotechnologies — especially experimental drugs for
currently untreatable diseases — exacerbate the pressure on costs.
He analyzes Americans’ resistance to recognizing how health care
is rationed, using as an example the case of  Abigail Alliance v. Von
Eschenbach, in which patients sought a constitutional right to
obtain drugs that had not been approved by the Food and Drug
Administration. Even without considering costs, he argues that




Professor Patricia Roche explores the dilemmas presented by
the development of  new drugs for specific races of  people,
analyzing the approval of  BiDil to treat heart failure in African-
Americans. Both the science and the controversy over approval
raise important questions about the meaning of  “race”,
particularly the relationship between race and genetic variation.
Limiting drugs to a particular “race” of  people has cost
implications, but more importantly, it may encourage artificial
divisions in the health system and violations of  the fundamental
human right of non-discrimination.
Perspectives on rights to health and health care
The final three chapters explore how fundamental legal
principles relate to the broader principles of human rights and
how they are codified and implemented in international
covenants, constitutions and other laws. Dr. Michael Grodin
provides a useful introduction to the concept of  the human right
to health, as embodied in the Universal Declaration of  Human
Rights (UDHR) and the International Covenant for Economic,
Social and Cultural Rights (ICESCR). He argues that health and
human rights are mutually reinforcing; population health depends
upon respect for human rights, and human rights cannot be fully
protected unless the population is healthy. Although he recognizes
that the historical distinction between negative and positive rights
is a false dichotomy, he argues for greater attention to the positive
aspects of  the human right to health in order to encourage
governments to respect, protect and fulfill their obligations.
Professor Eleanor Kinney provides an overview of  the legal
implementation of  the international human right to health,
focusing on the provisions of  national constitutions. It is
troubling, if  not surprising, that a country’s explicit commitment,
11
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in the text of its constitution, to protecting health does not
necessarily mean that the country adequately addresses the health
care needs of  its population. Other laws, however, may carry out
the obligations of  states parties to the UDHR and ICESCR and
other treaties and conventions. As she concludes, the “real work”
of  implementing the human right to health may come from policy
makers and health care practitioners who create genuine access to
high quality, affordable health care for all. To that we might add
lawyers, who can develop the more specific legal framework and
enforcement mechanisms to protect the right for all.
Helena Melo examines concepts of  patient rights in European
law, providing a comprehensive description of  the sources of  the
rights of patients in the European Union. Her chapter emphasizes
the importance of  respecting these hard won rights, even in the
face of  cost pressures. Biomedical progress, such as that discussed
in the chapters by Professors Annas and Roche, not only offers
the potential for saving lives and increasing costs, but also the risk
of  ignoring human dimension in the physician-patient
relationship. Professor Melo calls for preserving the right to
respect and dignity as human being. It is possible that, by
respecting this most fundamental right, legal systems can preserve
both the dignity of their people and their scarce health care
resources.
Common themes
Three themes emerge from these contributions. First, all the
countries described in this volume face similar demographic and
economic pressures, yet they continue the perennial search for
better quality health care for all, in spite of the relentless rise in
costs. European countries are trying to preserve social solidarity
while introducing cost control measures that challenge traditional
WENDY K. MARINER
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conceptions of  social insurance. The United States may be
proceeding toward the same goal, albeit coming from a different
direction. These common concerns and goals suggest that there is
much to be gained from international cooperation and sharing
both conceptual models and practical experiences.
Second, health system reform movements that respond to cost
pressures may affect the legal structure governing the rights of
patients and the obligations of  providers, either deliberately or
inadvertently. Despite differences in national health care systems,
the United States and OECD countries are changing the financial
incentives for both patients and providers in ways that are likely
to influence the legal definitions of  patient rights.
And finally, despite the focus on changes at the macro level, all
the authors recognize the importance of  respecting the rights of
individuals within the health care system. This last is not simply
a matter of tradition, but an essential element of any social
structure that purports to benefit human beings. Here, both
scholarship and experience urge renewed attention to the
freedoms and entitlements contained within the human to health.
As health care systems adapt to the challenges of the twenty-first
century, legal systems must preserve and protect the human rights
that form the foundation for health.
The health law and bioethics seminars
This volume celebrates an ongoing collaboration among health
law and bioethics scholars in Portugal and the United States. The
Biennial Health Law and Bioethics Seminar series is a joint
venture of  the Department of  Health Law, Bioethics and Human
Rights at the Boston University School of  Public Health, and the
Discipline of  Health Law, Ethics and Biolaw at the National
School of  Public Health, New University of  Lisbon. The
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seminars are designed to build more solid scientific bridges
between American and Portuguese institutions and to facilitate the
exchange of  knowledge among academics and researchers in the
fields of  health law, bioethics, and human rights. Participating
faculty share ideas in an open forum to enhance teaching and
scholarship and enrich the public conversation about health issues
of  common concern around the globe.
The Seminar series was inspired by Paula Lobato de Faria,
Associate Professor of  Health Law and Biolaw, National School
of  Public Health, New University of  Lisbon, when she was a
Visiting Scholar in the Department of  Health Law, Bioethics &
Human Rights, Boston University School of  Public Health in
2004. Professor Lobato de Faria chaired the first Seminar in
Health Law and Bioethics in Lisbon, Portugal, 2-3 June 2005, with
generous support from the Luso-American Foundation. In
keeping with the goal of  sharing knowledge, the papers presented
at the 1st Biennial Seminar in Health Law and Bioethics were
published in The Role of  Health Law, Bioethics and Human Rights to
Promote a Safer and Healthier World, edited by Professor Lobato de
Faria. We are pleased to continue the tradition with the
publication of  this second volume of  papers from the 2nd Biennal
Seminar in Health Law and Bioethics.
We are grateful to the Calouste Gulbenkian Foundation for its
support of the publication of  papers presented at the 2nd Biennial
Seminar.
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The Portuguese universal health system
PAULA LOBATO DE FARIA*
“Human anatomy and physiology are the same
worldwide, but the organization and delivery of  health
care reflect individual cultures.”
In Annas, J. G. et al. (1990), Preface — p. xxxi.
I. General data
Considering the last available data (2005) Portugal health
expenditure in relation to GDP is currently 10.2%1. Portugal has
been increasing the amount of  gross domestic product (GDP)**
spent on health, which has grown 24.4% percent in the period
1995-20012. In 2005 the spending on health level was just right
below the OECD average considering the health expenditure per
capita notwithstanding spending almost 2000 euro per capita. In
terms of  GDP and income inequality Portugal GDP per capita is
20,030 USD PPP3.
* Associate Professor of  Health Law and Biolaw, National School of  Public
Health, New University of  Lisbon; Law Degree by the Faculty of  Law of  the
University of  Lisbon, Portugal, Master’s and PhD in Health Law by the
Montesquieu University, Bordeaux, France with recognition as a PhD in Public
Law by the Faculty of  Law of  the New University of  Lisbon, Portugal.
The author would like to thank the most valuable collaboration in this
article of  João Pereira da Costa (Health Law jurist), Sara Vera Jardim (LL.M in
Law) and Hilson Cunha Filho (Masters in Public Health).
** A list of  the abbreviations used is presented in the end of  this chapter.
Copyright © 2008 Paula Lobato de Faria, All Rights Reserved.
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Health care in Portugal is mainly financed by public funds (direct
and indirect taxes). However, private expenditure (essentially out of
pocket payments and private health insurance) in health has been
around a quarter of  the total expenditure on health (2.8% in a total
of 10.0% of GDP spent on health care in 2004)4.
Other relevant information may derive from the analysis of  the
OECD data on “health expenditure by functions of  health care”.
At this level, in 2005, Portugal spent: 61% in curative and
rehabilitation medicine; 1% in long-term care (OECD average is
11%); 25% in medical goods; 10% in ancillary services and 3% in
public health and administration5.
In Portugal the public health and prevention policies were never
considered as a main priority by the State. Consequently, in 2005,
and despite the fact that average OECD countries spend 3.1% of
their public share in health expenditure, Portugal is only spending
1.4%. Pharmaceutical expenditure is a major health budget problem
considering the most needed health sustainability. In the same year,
Portugal spent 436 USD PPP in pharmaceuticals 60% of  this value
being assumed by the public sector. If  we consider the period
between 1995 and 2005 it is possible to determine the annual
growth in pharmaceutical spending, which in Portugal is increasing
in an annual average growth rate of  3.7%5.
Also according to the last available data, in 2001 the
employment rate in the health sector was 3.4 percent of  the active
population6. By the year 2004, there are 377 Health Centres in the
country, with a further 1,940 extensions and 1,102 beds (primary
health care), 75 general hospitals with a total of  22,634 beds and
95 psychiatric, alcoholics and drug abusers institutions with a
capacity of  2,809 beds. In these institutions were working 24,697
physicians, 39,429 nurses and 7,475 paramedical professionals.
Approximately 35,751 medical doctors, 4691 dentists, 9,395
pharmacists and 45,906 nurses were listed as members of  their
respective professional associations.7
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In 2005 the main health indicators were: 4.6 nurses per 1,000
inhabitants; 3.4 physicians per 1000 inhabitants (1.7 general
practitioners and 1.7 specialists per 1000 population8); 0.3
pharmacies per 1,000 inhabitants; 116.5 hospital admissions per
1000 inhabitants; 1,938.8 large or medium surgical procedures per
day and 3.9 medical consultations per inhabitant.9
There are strong regional asymmetries in what concerns the
health condition of  the population showing that poverty is still
associated with less quality of  life and health care access.10
Portugal has 10,6 million of  total population and has a
population average annual growth rate of  0.5%.The mortality
average age is getting higher every year. Life expectancy at birth
in Portugal in 2006 was 75.2 years for men and 80.4 for women.
This evolution brought the country from 7.7% of  the population
aged over 65 in 1960 to 17.0% in 2005 (over the OECD
average)11.
A dramatic and well known change in Portuguese health
indicators can be found in the infant mortality rate which has
decreased over the past 30 years from the concerning 10.9 per
1,000 in 1990 to 3.9 per 1000 in 2004. This positive evolution is
due to the good policies and strategies that where set over the
years12.
A negative indicator is the AIDS incidence rate which puts
Portugal in second place in the list of new cases year per million
(79.5%). The USA is currently number one with 137 new cases;
the OECD average is 18.8%.
A very concerning indicator is the mortality from road
accidents putting Portugal in second place of  all OECD countries
with 17.4 dead per 100,000 population13. In 2005, the main causes
of  death for the Portuguese are cardiovascular diseases (211.7/
100,000 individuals) and malignant tumors (156.1/100,000
individuals) of  a total standardized mortality rate of  676.9/
100,000 individuals14.
PAULA LOBATO DE FARIA
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The perceived health status gives us some concerning
information because only 39% of  the population aged 15 and
over reported to be in good health. The OECD average is 69%15.
II. The Portuguese health care system
Historical note on medical care16
Health services in Portugal have an historical Christian
background, based in the charity spirit of  helping the poor, the sick
and the handicapped17. The embryo of  the schools of  medicine in
Portugal may be found in an ancient (around the XII century) type
of  hostelry, built near pilgrims’ roads that gave shelter to people in
need. The existence and maintenance of  these places were mainly
due to the first Portuguese Queens, since Kings and other noble
men were engaged in the war against the moors and other
neighbour kingdoms. Those hostelries that started as regular shelter
facilities were at a point divided into two different areas, in which
one was only for the sick lodgers. These areas where the sick were
treated by people with some kind of  experience in the art of
healing (normally monks), correspond to the first “hospitals”18 in
the country and hence to the very first schools of  medicine.
Medicine was first taught in Portugal in a XII century
monastery (Mosteiro de Santa Cruz) where it was part of a non
systematized curricula among other subjects such as theology,
mathematics and grammar. A man named Mendo Dias is the first
person who is known to have studied medicine in Paris and to
teach what he had learned back in Portugal in that monastery at
that time. Frei Gil de Santarém (1185-1265) from whom there are
numerous medical writings in the Évora Library and Pedro
Hispano (1216-1276) who became Pope John XXI, where two of
the first famous Portuguese who studied medicine in Paris19.
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The first University in the country was founded in Lisbon
(General Study of  Lisbon), in 1290 by the King D. Dinis. Since
the very start it had medicine in its curricula but this subject was
considered inferior to other courses, like law, letters or art.
Medicine was taught by only one professor until 1493 when it
begun to be taught by two professors. In 1537 the University
moved to Coimbra.
In 1503-1504 under the King D. Manuel, the first reform of
the medical course was made with the objective of  improving
education and efficiency amongst its students. The course begin to
have the duration of  five years and in the end of  this one the
graduated had to pass an examination done by the físico-mor
(“major physician”), in order to get the “habilitation letter”, prior
condition to the practice of  medicine.
The organization of  the medical profession in Portugal dates
from 1898, when the Association of the Portuguese Physicians
was created. This Association changed its name to Ordem dos
Medicos (Order of Physicians) in 1938.
The Order of  Physicians was established by the decree-law
29 172 dated November 24th, of  1938 and succeeded the
Association of  the Portuguese Physicians. At the time it embraced
only the physicians who practiced medicine as a liberal profession.
This legal instrument was replaced by decree-law 40 651 dated
June 21st, of  1956 and later amended three times by respectively,
decree-law 48 587 of September 23rd, 1968, decree-law 48 879 of
February 22nd, of  1969 and decree-law 333/70 of  July 14th. With
the democratic revolution the need for new rules increased.
In 1977, Decree-Law 282/77 of  July 5th approved the present
Statute of  the Order of  Physicians. The preamble of  the statute
recognizes disciplinary competence to the Order of  Physicians
and determines its jurisdiction over all the physicians.
The Order of  Physicians is a public law professional
association, consisted of  all the physicians as single persons. As a
PAULA LOBATO DE FARIA
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public law association it expresses the constitutional desideratum
for the participation of  the citizens in the general government. It
allows an articulation between the public interest, concerning the
manner in which certain activities — as the medical activity —
should be exercised, and the private interests of  its professionals.
The professional orders find, since 1982, a constitutional
legitimation in article 267/4 of  the Portuguese Constitution
(before, their existence, and particularly the restricted access to the
profession, were highly discussed and controversial). According to
article 267/4 of  the Portuguese Constitution, public associations
can only be created to perform specific functions (principle of
specification) and necessarily different from the ones of the
Unions (non-competition principle). Additionally they must have
an internal organisation based upon democratic principles and on
the respect for its member’s rights. As a public law association, the
Order of Physicians was created by a legislative act (in the case,
by Decree-law 282/77, of  July 5th). The extent and scope of  its
powers is determined by this legislative act.
Its primary object is the representation of the interests of  its
members — physicians. Simultaneously they must regulate the
profession and stipulate its disciplinary rules. In order to
accomplish these last nominated functions, and because it is a
public association, the Order of  Physicians has received, by law,
administrative powers and the necessary instruments from the
state to exercise a truly public administration function, even if
restricted to its members.
As it happens in general with other professional public
associations, the Order of  Physicians is based upon the principles
of  the obligation of  inscription and quotas system. That also
means that the organization of  the physicians obeys the principle
of the control of the access to the profession (as already stated
above). Moreover the Order involves a whole particular
deontological system and its inherent sanctions panel.
23
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As part of  the so-called “autonomic public administration”,
the Order of  Physicians is granted a major degree of  autonomy
from the state. Despite this autonomy the Order is subjected to
the State’s guardianship in terms of  the control of  legality as any
other public law entity.
The NHS — the National Health Service
Presently, the Portuguese Health Care System is based in the
existence of  a National Health Service (NHS)20 composed of  the
healthcare institutions and units (hospitals and health centres) that
belong to the Public sector, under the control of  the Ministry of
Health21. The NHS22 is considered by Article 64 of  the Portuguese
Constitution as the main element to attain the fulfilment of the
right to health care protection: “Everyone has the right to health
protection and the duty to defend and promote it”, and according
to the same constitutional disposition, is oriented by the principles
of  universal access (accessible to all citizens), comprehensive
health care services (offering all kinds of  healthcare needed),
pending to gratuity, “participated” (managed with the
collaboration of all health care actors) and decentralized
(organized with proximity to the populations served)23.
The NHS is composed of  the health care units that are under
the supervision of  the Ministry of  Health, including two main
entities: hospitals and health centres (Bases XXII/2 and XXXVI
of  Health Bases Law — Law 48/90, August 24th). It is important
to note at this point that the current concept of  hospitals had
their legal existence recognized long ago, in the year 1946 (Law
2011), while the Health Centres model was only conceived after
the health reform of  197124 (DL 413/71, of  September 27th). In
numbers from the National Health Plan, in 2001, 363 health
centres equipped the Portuguese territory, with 1797 extensions,
PAULA LOBATO DE FARIA
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employing 6,961 physicians, 6,850 nurses and 875 paramedics.
A reform of  the primary health care sector is currently under
development.
Nevertheless, Portugal has a considerable private healthcare
sector25 the majority of  which contracts with the State to provide
health care services to NHS beneficiaries.
A very intensive trait of  the Portuguese Health System legal
history has been the constant changing of this reality in each
different government or even sometimes during the same
government. In fact, Portugal passed through different health
policies phases that had a strong effect in the structure of  the
health care system and in the way that its components are
conceived and managed. These phases were more clear in the
past, depending on the ideology of the political party in power,
but nowadays the scenario is more fuzzy, and the type of reforms
do not correspond to any of the ideologies originally connected
to a political party. Traditional leftist political parties can at
present show liberal reforms and vice-versa. The constant
changes, however, are a very strong characteristic of  the health
legislation field. Going back and forth in some of  the reforms has
happened very often as we will see in the description below.
The first phase, from 1976 to 1990, based in the original
version of  Article 64 of  the CRP, was a post-revolutionary
period where the prevalent idea was to subordinate the private
sector to a social medicine concept26, to make the NHS the only
healthcare provider in the country. This was expressed in a
paragraph of the original version of  Article 64, where it was said
that the State should “orient its actions to the socialization of
medicine” (this principle was substituted grosso modo in the
constitutional amendment of  1989 by the sentence
“socialization of  costs” which has prevailed up to the present
days). In 1986, Portugal became member of  the European
Economic Community (now European Union) and became
25
THE PORTUGUESE UNIVERSAL HEALTH SYSTEM
eligible for European funding for social and economic
infrastructure development which included the health sector.
Since then the Portuguese NHS facilities were able to expand in
better and more sustained way as the country’s increasing wealth
significantly benefited the health sector.
A second phase may be identified from 1990 to 2002. In
199027, with a liberal politics party in power, the Health Bases Law
(Law 48/90, of August 24th) was enacted, giving to the health
sector an entrepreneurial orientation legal framework for the first
time. This legal reform had two crucial points:
i) The integration of  the NHS in a “Health System’s” context
The 1979 NHS legislation ignored the existence of  an
important private and social sector in the health framework.
The above-mentioned 1990 Health Bases Law, created for
the first time in Portuguese Health Law the concept of
“Health System”, inserting in this one, besides Ministry of
Health dependent public hospitals and health centers, i.e.
the NHS, also the private health care institutions, which had
contracts with the latter (see Base XII, ibid.).
ii) The birth of  private management in the public health sector
The 1990 new law aimed at stimulating the Portuguese
private health sector and mainly the private management of
NHS facilities. The starting point was the Hospital Fernando
da Fonseca28, a new 600 bed public hospital near Lisbon built
by the State and opened in 1995, under a management
contract with a private consortium. This modality is still
unique but other forms of private management within the
NHS started at this point. Besides the Fernando da Fonseca
Hospital, and other few isolated experiences of  private
management in public hospitals, there were no more
consequences of  the 1990 law in what concerns the NHS
main structure and organisation.
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The beginning of  a third phase is marked by the first and only
amendment to the Health Bases Law in 2002 (Law 27/2002, of
November 8th) and is still going on. In fact, the mentioned
amendment allowed the transformation of  33 public hospitals in
SA companies (Sociedades Anónimas — Joint Stock Companies),
switching these institutions from the state administrative sector
(public statute and management) to the state entrepreneurial
sector (private statute and management). From January 1, 2003,
approximately 30% of  Portuguese public hospitals (corresponding
to close to 50% of  the public sector bed capacity) were managed
under a private legal framework.
Nevertheless, the changing of  Government in 2005 led to a
new switch in the legal nature of  hospitals. The DL 233/2005 of
December 29th transformed the hospitals SA into hospitals
“EPEs”, i.e., “Entrepreneurial Public Entities”, meaning that the
management of  these hospitals was again integrated in the public
sector rules.
This period, although punctuated by health policy divergences
between the two main political parties, has been marked by a
solidification of  an entrepreneurial management scheme in public
health units. This assertion may be seen in hospitals by the PPPs
initiative and in health centers with the creation of  the USFs, as
described in the two following points:
i) The PPPs
Ten new public funded and owned hospitals are expected to
be constructed over the next few years within a “PPPs —
private investment, public financing and private
management”29 framework30. The PPPs are defined by
Article 2/1 of  DL 86/2003, of  April 26th as a Union of
Contracts under which private entities (named as “private
partners”) oblige themselves before a “public partner”, to a
lasting performance of  a collective need. The financing,
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investment and management of  the specific developed
activity belong, altogether or partly, to the “private partner”.
In the Health sector, the PPP’s object is a lasting association
of  “private partners” to the provision of  health care.
These partnerships consist of  one or more of  the following
activities: conception, construction, financing, conservation
and management of  the health units. The main principles
and tools of  the Heath PPP’s are defined by DL 185/2002,
of  August 20th, amended by DL 141/2006, of  July 27th,
while DR 14/2003, of  June 30th has approved a standard
specif ication contract.  The development and
implementation of  the PPP’s in the health sector is an
assignment of an “ad hoc” Mission Unit nominated
“Parcerias. Saúde”, created by Resolução do Conselho de
Ministros 1627/2001, of  November 16th.
ii) The USFs
The Unidades de Saúde Familiar (Family General Practicioner’s
Units) or USFs constitute the main innovation of  the
ongoing national reform of the management of  primary
health care units31, by using a range of  market mechanisms
within the public sector. Having a strong and close relation
with the local Health Centers (Centros de Saúde), although
they are technically and functionally autonomous, the USFs
are primary health care units that use mainly contract based
management tools to set a basic series of  health services32
that ought to be accessible by the populations.
Although the Health Bases Law33 sets primary health care as a
priority, the Portuguese Healthcare System has been up to now
too Hospital centered. The USFs represent some of  the new
implemented policies with the aim of  reducing Hospital over-
utilization, rationing the use of  resources and create incentives
for people to have a family doctor, offering a range of  basic
health care services in close proximity to the patients.
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The performance contracts celebrated by the USFs brought
stronger incentives34, which had repercussions in the
implementation of  the first USFs, as in just a few years the
number of  these units in the country has grown
dramatically35.
The USFs management model is considered a breakthrough36
in the primary care public sector strategies, mainly because it
introduces a new dynamic in the system by reinforcing the
shared responsibility between different health care
professionals, to comply with the performance agreements.
This reality is different from traditional health centers which
are mainly focused on the physicians’ responsibility and
which management is not based on performance levels.
USFs may assume three different models/forms. Each
model (A, B or C) offers different levels of  autonomy and
goals. A team/group of health care professionals (led by a
physician) must apply37 to constitute an USF, providing the
fulfillment of  all legal requirements.
To conclude, it is pertinent to note that although the
Primary Health Care sector is still undergoing the
development of  the still recent introduction of  the USFs, a
new reform has already been set. This occurred based on
the norms approved by DL 28/2008, of  February 22nd,
which created the Agrupamentos de Centros de Saúde or ACES
(Health Centers’ Clusters).
Article 2/1 of  this statute defines the ACES as “health
services with administrative autonomy constituted by several
functional units belonging to one or more health centers”
(author’s translation).
It is still early to conclude if  the USFs are going to continue
to be the basic model of  a new management paradigm in
Portuguese primary health care units or if  they are going to be
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diluted in the latest forms of  health centers’ organization
prescribed in the 2008 ACES mentioned statute.
III. The National Health Plan
The Ministry of Health, by the auspices of  the Portuguese
Directorate-General for Health, has published a National Health
Plan for the period 2004-201038, based on the fundamental values
and principles of human dignity, solidarity, social justice, citizens’
empowerment, equity, sustainability and continuity of  care setting
the necessary interventions and recommended strategies.
This Plan points out the strategic guidelines for the minimum
range of  activities that the institutions of  the Ministry of  Health
should assure within the context of an agenda to improve health
gains and efficiency. The Plan presents a state of  the art in several
areas of  the health sector, both in a global view and in a healthcare
system perspective. It aims to comprise all the fundamental health
issues along the life cycle, mentioning in particular areas such as
transmissible diseases, cancer, cardio-vascular diseases, chronic-
degenerative diseases, mental health and psychiatric diseases, pain
and traumatic lesions. Every section of  the plan analyses the current
figures on each issue, the existing regional interventions and
national programs. The Regional Office of  WHO supervised and
assessed the conception and contents of  the document.
IV. Main administrative structure of  the Ministry of  Health
A) Organic statute of  the Ministry of  Health
In 2006, the structure of  the Ministry of  Health (MH) central
services and dependent bodies was the object of  an important
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administrative reform by a new statute (DL 212/2006, of  October
27th, approving the Ministry of  Health Organic Statute). This
Ministry is the governmental department that has the
responsibility to define and promote national health policies39,
using its normative functions while having the obligation to
provide the assessment of  its policies outcomes (Article 1, ibid.).
To achieve the aforementioned goals the MH must regulate all
health care activities (public and private) as well as to plan, to
audit, to inspect and to assess all the NHS related issues (Article
2 of  the mentioned Organic Statute). This body is also
responsible for the financing of the NHS (ibid.)
According to the Health Bases Law, the MH and the Regional
Health Administration Departments (ARSs) may contract with
private institutions in order to assure NHS beneficiaries the
proper health care services, provided that the institutions
demonstrate the economic benefit and the adequate quality-cost
relation between the health care provided and its cost and assure
equity in the access to care40.
The organic structure of  the Portuguese MH comprises a very
complex and heavy system, which relies on the interaction of
different juridical kinds of  entities41 (central services and
departments; public agencies; enterprises and consulting bodies;
healthcare units) with diverse functions, e.g. bureaucratic,
management or healthcare delivery, towards which the MH
exercise diverse types of  powers42.
The Minister of  Health is the vertex of  the administrative
pyramid of  the Portuguese Health System. Immediately
underneath the Minister, there are five central bodies (Article 4 of
the MH Organic Statute) all with special and diverse powers
including regulation and evaluation powers. These entities, which
are especially regulated by the mentioned organic statute are the
following: the High Commissioner for Health (Article 11, ibid.),
the IGAS — General-Inspectorate for Health Activities (Article
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12, ibid.), the Authority for Blood and Transplantation Services
(Article 15, ibid.), the DGS-Directorate-general for Health (Article
14, ibid.) and the General Secretariat of  the Ministry of  Health
(Article 13, ibid.).
Working under the supervision of  the Minister of  Health,
belonging as such to the “indirect” administration, there are
several public agencies, which execute the objectives of  the MH.
These entities, according to Article 5/1 and 2 of  the MH Organic
Statute, are the following:
— The ACSS — Central Administration for the Health System
(Article 16, ibid.);
— The INFARMED — National Authority of  Medicine and
Health Products (Article 17, ibid.);
— The INEM-National Medical Emergency Institute (Article
18, ibid.);
— The Portuguese Blood Institute (Article 19, ibid.);
— The IDT- Institute for Drugs and Drug-Addiction (Article
20, ibid.);
— The INSA-National Health Institute Ricardo Jorge (Article
21, ibid.), and
— The ARSs — Regional Health Departments43 (Article 22,
ibid.).
B) The General-Directorate for Health
In Chapter III, Section I, Article 14 of  the DL 212/2006, of
October 27th we find the basic structure and responsibilities of  the
Portuguese General-Directorate for Health. This body inherited the
competences and attributions of the entity first established in 1899
with the controversial name Direcção-Geral de Saúde e Beneficência
Pública (General-Directorate of  Health and Public Beneficence)44.
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In 1911, the General-Directorate of Health and Public
Beneficence was transformed into the General-Directorate of
Health (DGS), splitting from the public beneficence services,
which were then integrated in a different public institution. In the
same year Ricardo Jorge, a distinguished physician who had a
crucial role in the spread and promotion of  the Public Health
science and teaching in Portugal was nominated the first
Portuguese General Surgeon (Director-General for Health).
According to the mentioned DL 212/2006, of October 27th
and also in DR 66/2007, of  May 29th (DGS Organic Statute) the
DGS must regulate, orient and coordinate all the health
promotion related issues, especially regarding disease prevention45.
The definition of  the desirable technical conditions for the health
care services is also a crucial DGS responsibility. The DGS is
directed by the General Surgeon (Director-Geral de Saúde), who is
obligatorily a physician, being also the national Health Authority46.
The General Surgeon may nominate up to three sub-directors to
his office (Article 14/3 DL 212/2006, of  October 27th).
The DGS has the responsibility to develop Public Health
programs47, as well as setting orientations for health programs in
order to make them more efficient and with a higher quality
standard (Article 14/2, of  the MH Organic Statute). The national
epidemiologic surveillance, health statistics48 and technical health
care related studies are all in the sphere of responsibility of the
DGS.
Especially considering the quality promotion of all health care
services the DGS shall determine and disseminate guidelines for
the development of  excellence at all levels of  care (Article 2/2/
c) of  The DGS Organic Statute). In this last legal reform the
DGS has also assumed the mission, the responsibilities and the
powers of  the extinguished Institute for Health Quality (Article
10, ibid.). In the same direction, the DGS has today the
responsibility to define the standards of  the best practices, having
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the power to the licensing of  healthcare units in articulation with
the ACSS — Central Administration for the Health System
(Article 2/2 d) ibid.).
To achieve all the goals mentioned above, the DGS may rely
on the collaboration and support of all the Ministry of  Health
services and related institutes, as well as the cooperation of all
healthcare providers (integrated or not in the NHS49).
C) Regional Health Departments (ARS, I.P.)
The already mentioned ARS, I.P. are mentioned in Chapter III,
Section II, Article 22 of  the DL 212/2006, of  October 27th. Here
we found the legal description of  the ARS’s main structure and
powers. The ARS’s are public agencies regulated by Public Law,
integrated in the “indirect” administration, being a legal entity
with administrative and financial autonomy (Article 1/1 of  the
ARSs Organic Statute — DL 222/2007, of  May 29th).
The ARSs mission, if  summarized in a basic and clear goal,
would be to assure the access to health care services to all the
population in their specific region. To achieve this goal the ARSs
must guarantee a level of services adequate to their population
needs, accomplishing along the way the objectives of  the National
Health Plan for their region (Article 22/1, of  DL 212/2006, of
October 27th). The organic statute of the ARSs determines that
these bodies should be composed of  three different organs: a
Directive Board, a Supervising Official (Fiscal Único) and a
Consultant Board (Article 22/3 and 4, ibid.). The Directive Board
has a different structure design depending on the area of  the
specific ARS. In the more populated regions of  the Lisbon and
Tagus Valley ARS and the North ARS the Directive Boards are
composed of one president, one vice-president and three other
members; in the Alentejo, Algarve and Center ARSs the same board
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is composed by a president, one vice-president but only two more
members.
Within their specific regions, the ARSs must coordinate,
evaluate and execute the health policies, accordingly with the
global and sectorial policies with the main objective of  using the
resources adequately. In this sense the ARSs shall participate in
the definition of the coordination measures in intersectorial
grounds (see Article 22/2/a)/b) and c), ibid.).
The ARSs must also assure the human and material resources
planning, including the execution of  necessary investment
projects for the healthcare units under its supervision. These
units, technically supported by the ARSs, also have the crucial
responsibility of  evaluating the healthcare unit’s performance,
providing the national policies and technical demands. The ARSs
are also the competent bodies to provide a technical opinion
regarding the future licensing of  new private health care
institutions (Article 22/2/d)/e) and f), ibid.).
The aforementioned description of  the ARSs structure and
functions in the Ministry of  Health Organic Statute is repeated
and developed in the ARSs own organic statute, the DL 222/2007
of  May 29th. In fact, accordingly to Article 3/2 of  the latter, ARSs
must assure the subsequent actions:
— To coordinate and execute the Ministry of  Health policies
in their own geographic area (ibid./a) and b));
— To cooperate in the elaboration of  the National Health Plan,
as well as in the monitoring of  its application (ibid./c));
— To develop and enhance public health activities to promote
their population’s health (ibid./d));
— To assure the adequate network contracts between health
care providers (ibid./e));
— To plan, coordinate and monitor the human resources
management within their own area of  influence ( ibid./i)).
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— To give advice on the creation, modification and integration
of  health care services (ibid./m));
— To license private health care units (ibid./p)).
Finally, showing how broad the functions of  the ARSs are in
the management and administration of  the Portuguese health
system, these public agencies have also important responsibilities
concerning the laboratory studies and tests for transplantation
purposes. In fact, the ARSs, have the obligation of  maintenance
of  the National Center of  Bone Marrow, Stem Cells and
Umbilical Cord Blood Donors50 (CEDACE), and of  the
computerized waiting list for transplantation (ibid./h)).
V. Legal Framework of  the Private Health Sector
According to Article 64 of  the CRP, the State must provide
adequate conditions to assure the citizen’s right to access quality
health care services. In order to achieve this goal, the State may
act at different levels in the health care chain (financing,
contracting, or providing services itself), working alongside
private institutions. Article 64/3/d) of  the CRP, constitutionally
defines the desirable interaction between the State and the
private health care units. It determines as State priorities the
supervision and the control of  the entrepreneurial and private
forms of  the medical practice, which should operate in
conjunction with the NHS, in order to assure, in public and
private health care units, a high and adequate level of  quality and
efficiency.
The Health Bases Law (Law 48/90, of  August 24th) also sheds
some light on this matter. In Chapter IV, Base XXXVII, it
especially mentions the State’s duty of  supporting the private
health sector development. In this sense, one of the measures
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prescribed by this law is the facilitation for NHS human resources
(working in the public sector), to work in the private sector as well
(Base XXXVII/2, ibid.). Additionally, the ARSs may celebrate
contracts with private health care units to provide specific services
to the NHS beneficiaries (ibid., Base XXVII/3/e).
Moreover, private health care institutions have to meet the
State’s licensing requirements, and to cooperate with the State’s
supervising and surveillance in all the quality related issues to
operate legally. In particular, private hospitalization must act in
conjunction with the NHS (ibid., Base XXXIX/1 and 2).
The legal definition of  private healthcare units is found in
Article 1/2 of  DL 13/93, of  January 15th which states that these
units are not integrated into the NHS, even though they provide
medical, nursing, inpatient or recovery services.
DL 13/93, of  January 15th is the legal framework statute of  the
private health care units, comprising the major principles and
requirements applicable to these units. According to this statute,
private institutions need a Health Minister’s Order authorizing the
licensing of  the private unit (Article 4/1, ibid.). The types of
services provided and the specialties that the private institution
may offer should all be stated in the License Order, as well as the
maximum number of  users/patients permitted (ibid./2).
Two principles must be also assured: the adequacy6 of  the
requiring entity and the quality of  the services provided (ibid.,
Articles 7 and 8).
A final requirement, public control, comprises the
responsibility of  two different bodies, the DGS and the IGAS.
The first has to perform an audit/evaluation prior to the
Minister’s authorization, and the latter may collaborate (when
requested) with the DGS in the supervising and control
activities.
DR 63/94, of  November 2nd prescribes the requirements for
the installation, organization and functioning of  private health
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care units and sets the standards throughout its 46 articles and 11
annexes, as follows:
— Quality promotion system (amongst other norms, see
Article 43, ibid.);
— Location (Section I, Articles 4 and 6, ibid.);
— The terrain (Section II, Articles 6 and 7, ibid.);
— The building (Section III, Articles 8 to 19, ibid.);
— The technical facilities and equipments (Article 35, ibid.);
— Confidentiality issues (Article 41, ibid.);
— Safety issues (amongst other norms, see Article 42, ibid.).
The licensing, functioning and supervision of  several private
medical activities have specific legal regulations. This is the case
of  drug abuse treatment clinics (regulated by DL 16/99, of
January 25th), physical rehabilitation clinics (regulated by DL 500/
99, of  November 19th 52), private dental care clinics (regulated by
DL 233/2001, of  August 25th 53), social support private entities (by
DL 64/2007, of  March 14th).
VI. The National Health System and patient rights
During the Portuguese dictatorship that lasted 48 years (1926-
1974) the country was politically ruled by authoritarian and “anti-
liberal” policies based on a Constitution that deliberately excluded
fundamental rights of  the citizens. This dictatorial repression
explains why the legislator was so reluctant to use the “language
of  rights”, even in the health legislation, and the term “rights”
never appeared during that period. An example of  this is the
Hospital Statutory Law of  1968 (Decree-Law 48,357, dated 27th
of  April 1968), in which we find, in Articles 80 to 82, some of
the main patients rights of  today (privacy, informed consent,
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refusal of  treatment, religious assistance) without ever using
expressions such as “rights” or “patients rights”.
The situation changed after the entering into force of the first
democratic Constitution, in April 1976. In this new Constitution
of  the Portuguese Republic, the importance of  the fundamental
rights increased considerably compared with all former
Portuguese constitutions. The chapters on rights, liberties and
guaranties of  the citizens are now wide and protected from any
subsequent constitutional revisions by article 288/d) of  the
Constitution.
The demystification of  the use of  the word “right” after the
revolution had immediate consequences in the first National
Health Service Law (1979) where some “rights” are already given
to the user of  the system. Surprisingly, the Portuguese citizen had
to wait until the Health Bases Law of  1990 (Law 48/90, dated 24th
of  August) to have a real legal statute of  rights in the health
sector.
In the Base XIV of  this law, there are nine rights attributed to
the users of  the health system: a) the right to choose the deliverer
of  care within some restrictions; b) the right to decide to take or
to refuse health care, unless exceptions exist in the law; c) the
right to be treated by adequate means, with humanity, promptness,
technical accuracy, privacy and respect; d) the right to
confidentiality of the personal data disclosed; e) the right to be
informed about their situation, the possible alternatives of
treatment and the probable evolution of their condition; f) the
right to receive, if  desired, religious assistance; g) the right to
complain and to sue regarding the way they were treated and, if
it is the case, to receive compensation for damage; h) the right to
constitute representative organisations that would defend their
interests; i) the right to constitute organisations that will
collaborate with the health system, like associations for the
promotion and defence of  health or health units friends groups.
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Base XIV/2 continues with the list of  the duties of  the health
system where we find among others, the duty to respect the rights
of the other patients and the duty to collaborate with the health
professionals in relation to their own health.
Patient’s rights in the Portuguese legal framework also include
the “Oviedo Convention” (Council of Europe Convention for the
Protection of  Human Rights and Biomedicine). This convention
is now part of  the internal juridical order after a Presidential
Decree of  the 3rd January 2001.
All the rights inscribed in the Health Bases Law and in the
Oviedo Convention are fundamental rights and are the patrimony
of any citizen in the position of being a user of a public or
private Portuguese health care unit.
Although the laws and declarations exist, doubts persist
whether patients’ rights are truly observed in hospitals and other
health care units of  the country.
There are various reasons for the lack of  implementation of  the
law, the first being the difficulties that come from the deficiencies
of the Portuguese health law. As we saw above, the Law gives
important rights to the citizens as users of  the health services.
Nevertheless, these norms are too vague and general to be of
practical use. There are no specific regulations to guide the health
provider on the detailed contents of the declared rights of  a patient.
Another factor that creates obstacles to patient’s rights
protection is the dilution of responsibility in the present setting
of  healthcare units. The number of health professionals that deal
with one single patient continues to increase. Consider the
classical example of  the medical secret that is no longer a
“medical” but a “shared” secret among numerous different health
professionals. How is it possible to protect the right to
confidentiality in these circumstances?
Patient’s rights are also affected by the crisis of  the
Portuguese justice system, which being particularly slow and
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expensive, makes the citizen reluctant to bring to court actions
to remedy violations of  their rights law or even seek the advice
of  a lawyer. Civil liability regarding damage caused by health
care malpractice in Portugal is still governed under the
“Napoleonic” rule of  the culpa (fault) that demands going to
court in order to get compensation. The judicial difficulties
together with this system, leads Portuguese patients to be very
hesitant to bring attention to violation of  their rights made by
health professionals or health care institutions.
All the mentioned obstacles to a real implementation of
patients’ rights in Portuguese health care units lead to the
conclusion that the patient is still the weakest link in the health
care process. Even if  the law undoubtedly declares his rights, the
Portuguese patient is normally a fearful individual, unaware of his
legal status and with no direct representative organizations in the
civil society.
Several factors seem to point to a higher standard of
protection of  patients’ rights in the future, as these rights
become better known, discussed and respected by health
professionals.
VII. Patients’ duties in Portugal
A) The inheritance of  European fundamental duties theory
The subject of  “patients’  duties” subject cannot be
understood without being linked to the broader issue of
“fundamental rights and duties” because these two issues share
some basic conceptual problems. As we will explain more in
detail, “patients’ duties” have inherited some of  the main
juridical features of fundamental duties in European countries
constitutional law and this fact can partially help to explain some
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of  the problems European laws have to define the concept of
“patient duty” and its scope.
In fundamental rights and duties theory, there is no consensus
on whether to consider fundamental duties as “autonomous
counterparts” to fundamental rights or as a mere “manifestation
of  inherent limits” of  the latter54. There is little express
recognition of the existence of fundamental duties in the majority
of European constitutions and where it does happen, the
mentioned duties are seen as limits upon fundamental rights and
freedoms or as a natural part of  the “socially integrated
individual”, rather than as independent existing and enforceable
duties55.
One of the main reasons for the reluctance of European
democratic constitutions to recognize and to mention
fundamental duties may be historical, as citizens’ duties lists are
still a symbol of  dictatorial political regimes, being a feature of
communist constitutions or reminders of the dark effects of  the
“national duty” so cherished by the Third Reich56.
Therefore, it seems that the absence of  “patients’ duties” in
European health laws follows the general tendency of  avoiding a
written recognition of  citizens’ duties. Not even the crucial
citizens’ duties of  paying taxes or to attend obligatory school have
expression in most of  European Constitutions. Fundamental
duties are mainly considered as an implicit corollary of  a
unwritten rule of  responsibility that all citizens should have
regarding the use of  their rights and freedoms. European case law
treats fundamental duties as “constitutional values”, used for a
proper systematic interpretation of  the constitutional principles
rather than as an independent source of  particular obligations of
the individual57.
In what concerns the European Union Law, we cannot find
any fundamental duties nor in the Treaties or in the derivate law.
These duties which are considered to be historically seen as
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“republican obligations imposed on each citizen for the common
well-being”58 are deeply linked to the concept of citizenship which
is it self  not developed in the Community Law”. Stefan
Kadelbach, in his work on fundamental duties in the perspective
of  the European Court of  Justice, concludes that these duties in
Community Law “do not form autonomous counterparts to
fundamental rights”59.
Nevertheless, despite their rather “subsidiary” nature to rights
and freedoms, citizens’ fundamental duties cannot be considered
as mere moral obligations. We may find some evidence of  this
assertion in some countries case law, e.g. Finland, where two 1997
judgments referred to the constitutional duty to defend the
country regarding criminal guilt and sentencing60 and also in the
German constitutional parental duties which are enforceable by
the law, being considered not as mere limits to parental rights but
rather as one of  the elements that defines parental law61. We also
find European countries (e.g. Portugal) that have included a
fundamental duty to defend and promote health in the
Constitution (Art. 64/1), duty that is repeated in health ordinary
laws, showing that this fundamental duty towards health is not
seen as a mere moral obligation.
The importance of  a balance between patients’ duties and
health professionals’ rights and duties is not very often mentioned
as a tool to the implementation of  patients’ rights, but it was the
main concern of  the European Forum of Medical Associations
Statement on the “Declaration of Amsterdam” (Declaration on
the Promotion of  Patients’ Rights in Europe)62, issued during a
meeting with WHO, held in Stockholm in February 1996. This
statement, as we will show, is evidence that the medical
professionals feel the gap between all the weight given to patients’
rights and the lack of  any importance given to correspondent
patients’ responsibilities, mainly in what concerns their duty to
collaborate with health professionals.
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In the mentioned document, the Forum “recalls” that “an
essential element in the fulfillment of patients’ rights to health
care is mutual confidence between the health care professional
and the patient (implying mutual recognition of  the rights and
obligations of  both parties) and that the relationship between
professional and patient should be one of  partnership, with
the object of  achieving an appropriate improvement in the
health of  the patient” (§6 of  the mentioned document). The
Forum Statement also cherishes that the Declaration of
Amsterdam, in the part entitled “purpose of  the document”
draws attention “in particular to patients’ responsibilities both
to themselves (for their own self  care) and also to health
professionals (for providing them with al l  necessary
information for diagnosis and treatment, as well as for
recognizing that they are entitled to the same rights as other
citizens)” (ibid., §8).
B) The duties of  Portuguese patients
The already mentioned Portuguese Health Bases Law (Law 84/
90, of  the 24th of  August) gives a general responsibility to the
individuals in the accomplishment of  the right to health
protection (Bases I/1 and IV/3 of  the Law), but it also attributes
concrete duties to the patients. In Base XIV/2, the same Law has
a list where we find that the users of the health system have the
following duties:
1) To respect the rights of the other users;
2) To observe the rules of  organisation and functioning of  the
services and institutions;
3) To collaborate with the health professionals in relation to
their own health;
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4) To use the services in accordance with the established rules;
5) To pay the charges that derived from healthcare deliverance
when due.
Being unusual in contemporary European Health Law, we may
find a reason for the list of  Portuguese patients’ duties if  we
consider that these duties where adapted from the Hospital
Statute (Decree Law 48,357, of  the 27th April, art. 81) that dates
from 1968, when Portugal was still not a democracy. This gives
force to the fundamental duties theory that these duties are
connoted as juridical features of  dictatorial regimes. The 1990
adaptation deleted the article of  the 1968 law that mentioned as
a legal obligation of  the patients the duty to comply with the
medical prescriptions and therapeutics prescribed to them.
However the 1968 Law was never explicitly derogated, and this
duty nowadays seems to be against the self-determination
principle and informed consent rules.
Note of the author
Portugal is under a constantly changing legal framework,
mainly in the social sectors of Health, Labor and Education.
Reforms come in rapid succession, sometimes without enough
time to be understood or implemented before being replaced by
a newer reform. An article on the legal framework of  the national
healthcare system has an inherent risk of  being (at least partially)
already outdated at the time it is published.
Health politics is in constant movement these days in Portugal.
Hence, health legislation in our country is constantly changing the
juridical shape of  the Portuguese Health System. The author
recommends that readers check for amendments of  the legislation
mentioned in this chapter before quoting it.
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List of  used abbreviations
ACES Agrupamentos de Centros de Saúde (Health Centers’
Clusters)
ARSs Administrações Regionais de Saúde I.P. (Regional Health
Departments, Public Agencies)
CRP Constituição da República Portuguesa (Constitution of the
Portuguese Republic — Constitutional — Law 1/
2005, of  August 12th)
D.R. Diário da República (Portuguese Official Journal)
DGS Direcção-Geral da Saúde (Directorate-General for
Health)
DL Decreto-Lei (Decree-Law)
DN Despacho Normativo (Order Implementing the law)
DR Decreto-Regulamentar (Decree Implementing the law)
e.g. exempli gratia
EEC European Economic Community
EPEs Entidades Públicas Empresariais (Entrepreneurial Public
Entities)
EU European Union
GDP Gross Domestic Product
i.e. id est
Ibid. ibidem
LO Lei Orgânica (Organic Statute)
MH Ministry of  Health
NHS Serviço Nacional de Saúde (Portuguese National Health
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OECD Organization for Economic Co-operation and
Development
OPSS Observatório Português dos Sistemas de Saúde (Portuguese
Health System Observatory)
PORT Portaria (Implementing Order)
PPPs Parcerias Público-Privadas (Public-Private Partnerships)
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SA Sociedade Anónima (Joint Stock Company)
UNESCO United Nations Educational, Scientific and Cultural
Organization
USD PPP Purchasing Power Parity in US Dollar
USF Unidades de Saúde Familiar (Family General
Practicioner’s Units)
WHO World Health Organization
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The Portuguese universal health system
PAULA LOBATO DE FARIA*
“Human anatomy and physiology are the same
worldwide, but the organization and delivery of  health
care reflect individual cultures.”
In Annas, J. G. et al. (1990), Preface — p. xxxi.
I. General data
Considering the last available data (2005) Portugal health
expenditure in relation to GDP is currently 10.2%1. Portugal has
been increasing the amount of  gross domestic product (GDP)**
spent on health, which has grown 24.4% percent in the period
1995-20012. In 2005 the spending on health level was just right
below the OECD average considering the health expenditure per
capita notwithstanding spending almost 2000 euro per capita. In
terms of  GDP and income inequality Portugal GDP per capita is
20,030 USD PPP3.
* Associate Professor of  Health Law and Biolaw, National School of  Public
Health, New University of  Lisbon; Law Degree by the Faculty of  Law of  the
University of  Lisbon, Portugal, Master’s and PhD in Health Law by the
Montesquieu University, Bordeaux, France with recognition as a PhD in Public
Law by the Faculty of  Law of  the New University of  Lisbon, Portugal.
The author would like to thank the most valuable collaboration in this
article of  João Pereira da Costa (Health Law jurist), Sara Vera Jardim (LL.M in
Law) and Hilson Cunha Filho (Masters in Public Health).
** A list of  the abbreviations used is presented in the end of  this chapter.
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Health care in Portugal is mainly financed by public funds (direct
and indirect taxes). However, private expenditure (essentially out of
pocket payments and private health insurance) in health has been
around a quarter of  the total expenditure on health (2.8% in a total
of 10.0% of GDP spent on health care in 2004)4.
Other relevant information may derive from the analysis of  the
OECD data on “health expenditure by functions of  health care”.
At this level, in 2005, Portugal spent: 61% in curative and
rehabilitation medicine; 1% in long-term care (OECD average is
11%); 25% in medical goods; 10% in ancillary services and 3% in
public health and administration5.
In Portugal the public health and prevention policies were never
considered as a main priority by the State. Consequently, in 2005,
and despite the fact that average OECD countries spend 3.1% of
their public share in health expenditure, Portugal is only spending
1.4%. Pharmaceutical expenditure is a major health budget problem
considering the most needed health sustainability. In the same year,
Portugal spent 436 USD PPP in pharmaceuticals 60% of  this value
being assumed by the public sector. If  we consider the period
between 1995 and 2005 it is possible to determine the annual
growth in pharmaceutical spending, which in Portugal is increasing
in an annual average growth rate of  3.7%5.
Also according to the last available data, in 2001 the
employment rate in the health sector was 3.4 percent of  the active
population6. By the year 2004, there are 377 Health Centres in the
country, with a further 1,940 extensions and 1,102 beds (primary
health care), 75 general hospitals with a total of  22,634 beds and
95 psychiatric, alcoholics and drug abusers institutions with a
capacity of  2,809 beds. In these institutions were working 24,697
physicians, 39,429 nurses and 7,475 paramedical professionals.
Approximately 35,751 medical doctors, 4691 dentists, 9,395
pharmacists and 45,906 nurses were listed as members of  their
respective professional associations.7
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In 2005 the main health indicators were: 4.6 nurses per 1,000
inhabitants; 3.4 physicians per 1000 inhabitants (1.7 general
practitioners and 1.7 specialists per 1000 population8); 0.3
pharmacies per 1,000 inhabitants; 116.5 hospital admissions per
1000 inhabitants; 1,938.8 large or medium surgical procedures per
day and 3.9 medical consultations per inhabitant.9
There are strong regional asymmetries in what concerns the
health condition of  the population showing that poverty is still
associated with less quality of  life and health care access.10
Portugal has 10,6 million of  total population and has a
population average annual growth rate of  0.5%.The mortality
average age is getting higher every year. Life expectancy at birth
in Portugal in 2006 was 75.2 years for men and 80.4 for women.
This evolution brought the country from 7.7% of  the population
aged over 65 in 1960 to 17.0% in 2005 (over the OECD
average)11.
A dramatic and well known change in Portuguese health
indicators can be found in the infant mortality rate which has
decreased over the past 30 years from the concerning 10.9 per
1,000 in 1990 to 3.9 per 1000 in 2004. This positive evolution is
due to the good policies and strategies that where set over the
years12.
A negative indicator is the AIDS incidence rate which puts
Portugal in second place in the list of new cases year per million
(79.5%). The USA is currently number one with 137 new cases;
the OECD average is 18.8%.
A very concerning indicator is the mortality from road
accidents putting Portugal in second place of  all OECD countries
with 17.4 dead per 100,000 population13. In 2005, the main causes
of  death for the Portuguese are cardiovascular diseases (211.7/
100,000 individuals) and malignant tumors (156.1/100,000
individuals) of  a total standardized mortality rate of  676.9/
100,000 individuals14.
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The perceived health status gives us some concerning
information because only 39% of  the population aged 15 and
over reported to be in good health. The OECD average is 69%15.
II. The Portuguese health care system
Historical note on medical care16
Health services in Portugal have an historical Christian
background, based in the charity spirit of  helping the poor, the sick
and the handicapped17. The embryo of  the schools of  medicine in
Portugal may be found in an ancient (around the XII century) type
of  hostelry, built near pilgrims’ roads that gave shelter to people in
need. The existence and maintenance of  these places were mainly
due to the first Portuguese Queens, since Kings and other noble
men were engaged in the war against the moors and other
neighbour kingdoms. Those hostelries that started as regular shelter
facilities were at a point divided into two different areas, in which
one was only for the sick lodgers. These areas where the sick were
treated by people with some kind of  experience in the art of
healing (normally monks), correspond to the first “hospitals”18 in
the country and hence to the very first schools of  medicine.
Medicine was first taught in Portugal in a XII century
monastery (Mosteiro de Santa Cruz) where it was part of a non
systematized curricula among other subjects such as theology,
mathematics and grammar. A man named Mendo Dias is the first
person who is known to have studied medicine in Paris and to
teach what he had learned back in Portugal in that monastery at
that time. Frei Gil de Santarém (1185-1265) from whom there are
numerous medical writings in the Évora Library and Pedro
Hispano (1216-1276) who became Pope John XXI, where two of
the first famous Portuguese who studied medicine in Paris19.
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The first University in the country was founded in Lisbon
(General Study of  Lisbon), in 1290 by the King D. Dinis. Since
the very start it had medicine in its curricula but this subject was
considered inferior to other courses, like law, letters or art.
Medicine was taught by only one professor until 1493 when it
begun to be taught by two professors. In 1537 the University
moved to Coimbra.
In 1503-1504 under the King D. Manuel, the first reform of
the medical course was made with the objective of  improving
education and efficiency amongst its students. The course begin to
have the duration of  five years and in the end of  this one the
graduated had to pass an examination done by the físico-mor
(“major physician”), in order to get the “habilitation letter”, prior
condition to the practice of  medicine.
The organization of  the medical profession in Portugal dates
from 1898, when the Association of the Portuguese Physicians
was created. This Association changed its name to Ordem dos
Medicos (Order of Physicians) in 1938.
The Order of  Physicians was established by the decree-law
29 172 dated November 24th, of  1938 and succeeded the
Association of  the Portuguese Physicians. At the time it embraced
only the physicians who practiced medicine as a liberal profession.
This legal instrument was replaced by decree-law 40 651 dated
June 21st, of  1956 and later amended three times by respectively,
decree-law 48 587 of September 23rd, 1968, decree-law 48 879 of
February 22nd, of  1969 and decree-law 333/70 of  July 14th. With
the democratic revolution the need for new rules increased.
In 1977, Decree-Law 282/77 of  July 5th approved the present
Statute of  the Order of  Physicians. The preamble of  the statute
recognizes disciplinary competence to the Order of  Physicians
and determines its jurisdiction over all the physicians.
The Order of  Physicians is a public law professional
association, consisted of  all the physicians as single persons. As a
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public law association it expresses the constitutional desideratum
for the participation of  the citizens in the general government. It
allows an articulation between the public interest, concerning the
manner in which certain activities — as the medical activity —
should be exercised, and the private interests of  its professionals.
The professional orders find, since 1982, a constitutional
legitimation in article 267/4 of  the Portuguese Constitution
(before, their existence, and particularly the restricted access to the
profession, were highly discussed and controversial). According to
article 267/4 of  the Portuguese Constitution, public associations
can only be created to perform specific functions (principle of
specification) and necessarily different from the ones of the
Unions (non-competition principle). Additionally they must have
an internal organisation based upon democratic principles and on
the respect for its member’s rights. As a public law association, the
Order of Physicians was created by a legislative act (in the case,
by Decree-law 282/77, of  July 5th). The extent and scope of  its
powers is determined by this legislative act.
Its primary object is the representation of the interests of  its
members — physicians. Simultaneously they must regulate the
profession and stipulate its disciplinary rules. In order to
accomplish these last nominated functions, and because it is a
public association, the Order of  Physicians has received, by law,
administrative powers and the necessary instruments from the
state to exercise a truly public administration function, even if
restricted to its members.
As it happens in general with other professional public
associations, the Order of  Physicians is based upon the principles
of  the obligation of  inscription and quotas system. That also
means that the organization of  the physicians obeys the principle
of the control of the access to the profession (as already stated
above). Moreover the Order involves a whole particular
deontological system and its inherent sanctions panel.
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As part of  the so-called “autonomic public administration”,
the Order of  Physicians is granted a major degree of  autonomy
from the state. Despite this autonomy the Order is subjected to
the State’s guardianship in terms of  the control of  legality as any
other public law entity.
The NHS — the National Health Service
Presently, the Portuguese Health Care System is based in the
existence of  a National Health Service (NHS)20 composed of  the
healthcare institutions and units (hospitals and health centres) that
belong to the Public sector, under the control of  the Ministry of
Health21. The NHS22 is considered by Article 64 of  the Portuguese
Constitution as the main element to attain the fulfilment of the
right to health care protection: “Everyone has the right to health
protection and the duty to defend and promote it”, and according
to the same constitutional disposition, is oriented by the principles
of  universal access (accessible to all citizens), comprehensive
health care services (offering all kinds of  healthcare needed),
pending to gratuity, “participated” (managed with the
collaboration of all health care actors) and decentralized
(organized with proximity to the populations served)23.
The NHS is composed of  the health care units that are under
the supervision of  the Ministry of  Health, including two main
entities: hospitals and health centres (Bases XXII/2 and XXXVI
of  Health Bases Law — Law 48/90, August 24th). It is important
to note at this point that the current concept of  hospitals had
their legal existence recognized long ago, in the year 1946 (Law
2011), while the Health Centres model was only conceived after
the health reform of  197124 (DL 413/71, of  September 27th). In
numbers from the National Health Plan, in 2001, 363 health
centres equipped the Portuguese territory, with 1797 extensions,
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employing 6,961 physicians, 6,850 nurses and 875 paramedics.
A reform of  the primary health care sector is currently under
development.
Nevertheless, Portugal has a considerable private healthcare
sector25 the majority of  which contracts with the State to provide
health care services to NHS beneficiaries.
A very intensive trait of  the Portuguese Health System legal
history has been the constant changing of this reality in each
different government or even sometimes during the same
government. In fact, Portugal passed through different health
policies phases that had a strong effect in the structure of  the
health care system and in the way that its components are
conceived and managed. These phases were more clear in the
past, depending on the ideology of the political party in power,
but nowadays the scenario is more fuzzy, and the type of reforms
do not correspond to any of the ideologies originally connected
to a political party. Traditional leftist political parties can at
present show liberal reforms and vice-versa. The constant
changes, however, are a very strong characteristic of  the health
legislation field. Going back and forth in some of  the reforms has
happened very often as we will see in the description below.
The first phase, from 1976 to 1990, based in the original
version of  Article 64 of  the CRP, was a post-revolutionary
period where the prevalent idea was to subordinate the private
sector to a social medicine concept26, to make the NHS the only
healthcare provider in the country. This was expressed in a
paragraph of the original version of  Article 64, where it was said
that the State should “orient its actions to the socialization of
medicine” (this principle was substituted grosso modo in the
constitutional amendment of  1989 by the sentence
“socialization of  costs” which has prevailed up to the present
days). In 1986, Portugal became member of  the European
Economic Community (now European Union) and became
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eligible for European funding for social and economic
infrastructure development which included the health sector.
Since then the Portuguese NHS facilities were able to expand in
better and more sustained way as the country’s increasing wealth
significantly benefited the health sector.
A second phase may be identified from 1990 to 2002. In
199027, with a liberal politics party in power, the Health Bases Law
(Law 48/90, of August 24th) was enacted, giving to the health
sector an entrepreneurial orientation legal framework for the first
time. This legal reform had two crucial points:
i) The integration of  the NHS in a “Health System’s” context
The 1979 NHS legislation ignored the existence of  an
important private and social sector in the health framework.
The above-mentioned 1990 Health Bases Law, created for
the first time in Portuguese Health Law the concept of
“Health System”, inserting in this one, besides Ministry of
Health dependent public hospitals and health centers, i.e.
the NHS, also the private health care institutions, which had
contracts with the latter (see Base XII, ibid.).
ii) The birth of  private management in the public health sector
The 1990 new law aimed at stimulating the Portuguese
private health sector and mainly the private management of
NHS facilities. The starting point was the Hospital Fernando
da Fonseca28, a new 600 bed public hospital near Lisbon built
by the State and opened in 1995, under a management
contract with a private consortium. This modality is still
unique but other forms of private management within the
NHS started at this point. Besides the Fernando da Fonseca
Hospital, and other few isolated experiences of  private
management in public hospitals, there were no more
consequences of  the 1990 law in what concerns the NHS
main structure and organisation.
PAULA LOBATO DE FARIA
26
The beginning of  a third phase is marked by the first and only
amendment to the Health Bases Law in 2002 (Law 27/2002, of
November 8th) and is still going on. In fact, the mentioned
amendment allowed the transformation of  33 public hospitals in
SA companies (Sociedades Anónimas — Joint Stock Companies),
switching these institutions from the state administrative sector
(public statute and management) to the state entrepreneurial
sector (private statute and management). From January 1, 2003,
approximately 30% of  Portuguese public hospitals (corresponding
to close to 50% of  the public sector bed capacity) were managed
under a private legal framework.
Nevertheless, the changing of  Government in 2005 led to a
new switch in the legal nature of  hospitals. The DL 233/2005 of
December 29th transformed the hospitals SA into hospitals
“EPEs”, i.e., “Entrepreneurial Public Entities”, meaning that the
management of  these hospitals was again integrated in the public
sector rules.
This period, although punctuated by health policy divergences
between the two main political parties, has been marked by a
solidification of  an entrepreneurial management scheme in public
health units. This assertion may be seen in hospitals by the PPPs
initiative and in health centers with the creation of  the USFs, as
described in the two following points:
i) The PPPs
Ten new public funded and owned hospitals are expected to
be constructed over the next few years within a “PPPs —
private investment, public financing and private
management”29 framework30. The PPPs are defined by
Article 2/1 of  DL 86/2003, of  April 26th as a Union of
Contracts under which private entities (named as “private
partners”) oblige themselves before a “public partner”, to a
lasting performance of  a collective need. The financing,
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investment and management of  the specific developed
activity belong, altogether or partly, to the “private partner”.
In the Health sector, the PPP’s object is a lasting association
of  “private partners” to the provision of  health care.
These partnerships consist of  one or more of  the following
activities: conception, construction, financing, conservation
and management of  the health units. The main principles
and tools of  the Heath PPP’s are defined by DL 185/2002,
of  August 20th, amended by DL 141/2006, of  July 27th,
while DR 14/2003, of  June 30th has approved a standard
specif ication contract.  The development and
implementation of  the PPP’s in the health sector is an
assignment of an “ad hoc” Mission Unit nominated
“Parcerias. Saúde”, created by Resolução do Conselho de
Ministros 1627/2001, of  November 16th.
ii) The USFs
The Unidades de Saúde Familiar (Family General Practicioner’s
Units) or USFs constitute the main innovation of  the
ongoing national reform of the management of  primary
health care units31, by using a range of  market mechanisms
within the public sector. Having a strong and close relation
with the local Health Centers (Centros de Saúde), although
they are technically and functionally autonomous, the USFs
are primary health care units that use mainly contract based
management tools to set a basic series of  health services32
that ought to be accessible by the populations.
Although the Health Bases Law33 sets primary health care as a
priority, the Portuguese Healthcare System has been up to now
too Hospital centered. The USFs represent some of  the new
implemented policies with the aim of  reducing Hospital over-
utilization, rationing the use of  resources and create incentives
for people to have a family doctor, offering a range of  basic
health care services in close proximity to the patients.
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The performance contracts celebrated by the USFs brought
stronger incentives34, which had repercussions in the
implementation of  the first USFs, as in just a few years the
number of  these units in the country has grown
dramatically35.
The USFs management model is considered a breakthrough36
in the primary care public sector strategies, mainly because it
introduces a new dynamic in the system by reinforcing the
shared responsibility between different health care
professionals, to comply with the performance agreements.
This reality is different from traditional health centers which
are mainly focused on the physicians’ responsibility and
which management is not based on performance levels.
USFs may assume three different models/forms. Each
model (A, B or C) offers different levels of  autonomy and
goals. A team/group of health care professionals (led by a
physician) must apply37 to constitute an USF, providing the
fulfillment of  all legal requirements.
To conclude, it is pertinent to note that although the
Primary Health Care sector is still undergoing the
development of  the still recent introduction of  the USFs, a
new reform has already been set. This occurred based on
the norms approved by DL 28/2008, of  February 22nd,
which created the Agrupamentos de Centros de Saúde or ACES
(Health Centers’ Clusters).
Article 2/1 of  this statute defines the ACES as “health
services with administrative autonomy constituted by several
functional units belonging to one or more health centers”
(author’s translation).
It is still early to conclude if  the USFs are going to continue
to be the basic model of  a new management paradigm in
Portuguese primary health care units or if  they are going to be
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diluted in the latest forms of  health centers’ organization
prescribed in the 2008 ACES mentioned statute.
III. The National Health Plan
The Ministry of Health, by the auspices of  the Portuguese
Directorate-General for Health, has published a National Health
Plan for the period 2004-201038, based on the fundamental values
and principles of human dignity, solidarity, social justice, citizens’
empowerment, equity, sustainability and continuity of  care setting
the necessary interventions and recommended strategies.
This Plan points out the strategic guidelines for the minimum
range of  activities that the institutions of  the Ministry of  Health
should assure within the context of an agenda to improve health
gains and efficiency. The Plan presents a state of  the art in several
areas of  the health sector, both in a global view and in a healthcare
system perspective. It aims to comprise all the fundamental health
issues along the life cycle, mentioning in particular areas such as
transmissible diseases, cancer, cardio-vascular diseases, chronic-
degenerative diseases, mental health and psychiatric diseases, pain
and traumatic lesions. Every section of  the plan analyses the current
figures on each issue, the existing regional interventions and
national programs. The Regional Office of  WHO supervised and
assessed the conception and contents of  the document.
IV. Main administrative structure of  the Ministry of  Health
A) Organic statute of  the Ministry of  Health
In 2006, the structure of  the Ministry of  Health (MH) central
services and dependent bodies was the object of  an important
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administrative reform by a new statute (DL 212/2006, of  October
27th, approving the Ministry of  Health Organic Statute). This
Ministry is the governmental department that has the
responsibility to define and promote national health policies39,
using its normative functions while having the obligation to
provide the assessment of  its policies outcomes (Article 1, ibid.).
To achieve the aforementioned goals the MH must regulate all
health care activities (public and private) as well as to plan, to
audit, to inspect and to assess all the NHS related issues (Article
2 of  the mentioned Organic Statute). This body is also
responsible for the financing of the NHS (ibid.)
According to the Health Bases Law, the MH and the Regional
Health Administration Departments (ARSs) may contract with
private institutions in order to assure NHS beneficiaries the
proper health care services, provided that the institutions
demonstrate the economic benefit and the adequate quality-cost
relation between the health care provided and its cost and assure
equity in the access to care40.
The organic structure of  the Portuguese MH comprises a very
complex and heavy system, which relies on the interaction of
different juridical kinds of  entities41 (central services and
departments; public agencies; enterprises and consulting bodies;
healthcare units) with diverse functions, e.g. bureaucratic,
management or healthcare delivery, towards which the MH
exercise diverse types of  powers42.
The Minister of  Health is the vertex of  the administrative
pyramid of  the Portuguese Health System. Immediately
underneath the Minister, there are five central bodies (Article 4 of
the MH Organic Statute) all with special and diverse powers
including regulation and evaluation powers. These entities, which
are especially regulated by the mentioned organic statute are the
following: the High Commissioner for Health (Article 11, ibid.),
the IGAS — General-Inspectorate for Health Activities (Article
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12, ibid.), the Authority for Blood and Transplantation Services
(Article 15, ibid.), the DGS-Directorate-general for Health (Article
14, ibid.) and the General Secretariat of  the Ministry of  Health
(Article 13, ibid.).
Working under the supervision of  the Minister of  Health,
belonging as such to the “indirect” administration, there are
several public agencies, which execute the objectives of  the MH.
These entities, according to Article 5/1 and 2 of  the MH Organic
Statute, are the following:
— The ACSS — Central Administration for the Health System
(Article 16, ibid.);
— The INFARMED — National Authority of  Medicine and
Health Products (Article 17, ibid.);
— The INEM-National Medical Emergency Institute (Article
18, ibid.);
— The Portuguese Blood Institute (Article 19, ibid.);
— The IDT- Institute for Drugs and Drug-Addiction (Article
20, ibid.);
— The INSA-National Health Institute Ricardo Jorge (Article
21, ibid.), and
— The ARSs — Regional Health Departments43 (Article 22,
ibid.).
B) The General-Directorate for Health
In Chapter III, Section I, Article 14 of  the DL 212/2006, of
October 27th we find the basic structure and responsibilities of  the
Portuguese General-Directorate for Health. This body inherited the
competences and attributions of the entity first established in 1899
with the controversial name Direcção-Geral de Saúde e Beneficência
Pública (General-Directorate of  Health and Public Beneficence)44.
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In 1911, the General-Directorate of Health and Public
Beneficence was transformed into the General-Directorate of
Health (DGS), splitting from the public beneficence services,
which were then integrated in a different public institution. In the
same year Ricardo Jorge, a distinguished physician who had a
crucial role in the spread and promotion of  the Public Health
science and teaching in Portugal was nominated the first
Portuguese General Surgeon (Director-General for Health).
According to the mentioned DL 212/2006, of October 27th
and also in DR 66/2007, of  May 29th (DGS Organic Statute) the
DGS must regulate, orient and coordinate all the health
promotion related issues, especially regarding disease prevention45.
The definition of  the desirable technical conditions for the health
care services is also a crucial DGS responsibility. The DGS is
directed by the General Surgeon (Director-Geral de Saúde), who is
obligatorily a physician, being also the national Health Authority46.
The General Surgeon may nominate up to three sub-directors to
his office (Article 14/3 DL 212/2006, of  October 27th).
The DGS has the responsibility to develop Public Health
programs47, as well as setting orientations for health programs in
order to make them more efficient and with a higher quality
standard (Article 14/2, of  the MH Organic Statute). The national
epidemiologic surveillance, health statistics48 and technical health
care related studies are all in the sphere of responsibility of the
DGS.
Especially considering the quality promotion of all health care
services the DGS shall determine and disseminate guidelines for
the development of  excellence at all levels of  care (Article 2/2/
c) of  The DGS Organic Statute). In this last legal reform the
DGS has also assumed the mission, the responsibilities and the
powers of  the extinguished Institute for Health Quality (Article
10, ibid.). In the same direction, the DGS has today the
responsibility to define the standards of  the best practices, having
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the power to the licensing of  healthcare units in articulation with
the ACSS — Central Administration for the Health System
(Article 2/2 d) ibid.).
To achieve all the goals mentioned above, the DGS may rely
on the collaboration and support of all the Ministry of  Health
services and related institutes, as well as the cooperation of all
healthcare providers (integrated or not in the NHS49).
C) Regional Health Departments (ARS, I.P.)
The already mentioned ARS, I.P. are mentioned in Chapter III,
Section II, Article 22 of  the DL 212/2006, of  October 27th. Here
we found the legal description of  the ARS’s main structure and
powers. The ARS’s are public agencies regulated by Public Law,
integrated in the “indirect” administration, being a legal entity
with administrative and financial autonomy (Article 1/1 of  the
ARSs Organic Statute — DL 222/2007, of  May 29th).
The ARSs mission, if  summarized in a basic and clear goal,
would be to assure the access to health care services to all the
population in their specific region. To achieve this goal the ARSs
must guarantee a level of services adequate to their population
needs, accomplishing along the way the objectives of  the National
Health Plan for their region (Article 22/1, of  DL 212/2006, of
October 27th). The organic statute of the ARSs determines that
these bodies should be composed of  three different organs: a
Directive Board, a Supervising Official (Fiscal Único) and a
Consultant Board (Article 22/3 and 4, ibid.). The Directive Board
has a different structure design depending on the area of  the
specific ARS. In the more populated regions of  the Lisbon and
Tagus Valley ARS and the North ARS the Directive Boards are
composed of one president, one vice-president and three other
members; in the Alentejo, Algarve and Center ARSs the same board
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is composed by a president, one vice-president but only two more
members.
Within their specific regions, the ARSs must coordinate,
evaluate and execute the health policies, accordingly with the
global and sectorial policies with the main objective of  using the
resources adequately. In this sense the ARSs shall participate in
the definition of the coordination measures in intersectorial
grounds (see Article 22/2/a)/b) and c), ibid.).
The ARSs must also assure the human and material resources
planning, including the execution of  necessary investment
projects for the healthcare units under its supervision. These
units, technically supported by the ARSs, also have the crucial
responsibility of  evaluating the healthcare unit’s performance,
providing the national policies and technical demands. The ARSs
are also the competent bodies to provide a technical opinion
regarding the future licensing of  new private health care
institutions (Article 22/2/d)/e) and f), ibid.).
The aforementioned description of  the ARSs structure and
functions in the Ministry of  Health Organic Statute is repeated
and developed in the ARSs own organic statute, the DL 222/2007
of  May 29th. In fact, accordingly to Article 3/2 of  the latter, ARSs
must assure the subsequent actions:
— To coordinate and execute the Ministry of  Health policies
in their own geographic area (ibid./a) and b));
— To cooperate in the elaboration of  the National Health Plan,
as well as in the monitoring of  its application (ibid./c));
— To develop and enhance public health activities to promote
their population’s health (ibid./d));
— To assure the adequate network contracts between health
care providers (ibid./e));
— To plan, coordinate and monitor the human resources
management within their own area of  influence ( ibid./i)).
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— To give advice on the creation, modification and integration
of  health care services (ibid./m));
— To license private health care units (ibid./p)).
Finally, showing how broad the functions of  the ARSs are in
the management and administration of  the Portuguese health
system, these public agencies have also important responsibilities
concerning the laboratory studies and tests for transplantation
purposes. In fact, the ARSs, have the obligation of  maintenance
of  the National Center of  Bone Marrow, Stem Cells and
Umbilical Cord Blood Donors50 (CEDACE), and of  the
computerized waiting list for transplantation (ibid./h)).
V. Legal Framework of  the Private Health Sector
According to Article 64 of  the CRP, the State must provide
adequate conditions to assure the citizen’s right to access quality
health care services. In order to achieve this goal, the State may
act at different levels in the health care chain (financing,
contracting, or providing services itself), working alongside
private institutions. Article 64/3/d) of  the CRP, constitutionally
defines the desirable interaction between the State and the
private health care units. It determines as State priorities the
supervision and the control of  the entrepreneurial and private
forms of  the medical practice, which should operate in
conjunction with the NHS, in order to assure, in public and
private health care units, a high and adequate level of  quality and
efficiency.
The Health Bases Law (Law 48/90, of  August 24th) also sheds
some light on this matter. In Chapter IV, Base XXXVII, it
especially mentions the State’s duty of  supporting the private
health sector development. In this sense, one of the measures
PAULA LOBATO DE FARIA
36
prescribed by this law is the facilitation for NHS human resources
(working in the public sector), to work in the private sector as well
(Base XXXVII/2, ibid.). Additionally, the ARSs may celebrate
contracts with private health care units to provide specific services
to the NHS beneficiaries (ibid., Base XXVII/3/e).
Moreover, private health care institutions have to meet the
State’s licensing requirements, and to cooperate with the State’s
supervising and surveillance in all the quality related issues to
operate legally. In particular, private hospitalization must act in
conjunction with the NHS (ibid., Base XXXIX/1 and 2).
The legal definition of  private healthcare units is found in
Article 1/2 of  DL 13/93, of  January 15th which states that these
units are not integrated into the NHS, even though they provide
medical, nursing, inpatient or recovery services.
DL 13/93, of  January 15th is the legal framework statute of  the
private health care units, comprising the major principles and
requirements applicable to these units. According to this statute,
private institutions need a Health Minister’s Order authorizing the
licensing of  the private unit (Article 4/1, ibid.). The types of
services provided and the specialties that the private institution
may offer should all be stated in the License Order, as well as the
maximum number of  users/patients permitted (ibid./2).
Two principles must be also assured: the adequacy6 of  the
requiring entity and the quality of  the services provided (ibid.,
Articles 7 and 8).
A final requirement, public control, comprises the
responsibility of  two different bodies, the DGS and the IGAS.
The first has to perform an audit/evaluation prior to the
Minister’s authorization, and the latter may collaborate (when
requested) with the DGS in the supervising and control
activities.
DR 63/94, of  November 2nd prescribes the requirements for
the installation, organization and functioning of  private health
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care units and sets the standards throughout its 46 articles and 11
annexes, as follows:
— Quality promotion system (amongst other norms, see
Article 43, ibid.);
— Location (Section I, Articles 4 and 6, ibid.);
— The terrain (Section II, Articles 6 and 7, ibid.);
— The building (Section III, Articles 8 to 19, ibid.);
— The technical facilities and equipments (Article 35, ibid.);
— Confidentiality issues (Article 41, ibid.);
— Safety issues (amongst other norms, see Article 42, ibid.).
The licensing, functioning and supervision of  several private
medical activities have specific legal regulations. This is the case
of  drug abuse treatment clinics (regulated by DL 16/99, of
January 25th), physical rehabilitation clinics (regulated by DL 500/
99, of  November 19th 52), private dental care clinics (regulated by
DL 233/2001, of  August 25th 53), social support private entities (by
DL 64/2007, of  March 14th).
VI. The National Health System and patient rights
During the Portuguese dictatorship that lasted 48 years (1926-
1974) the country was politically ruled by authoritarian and “anti-
liberal” policies based on a Constitution that deliberately excluded
fundamental rights of  the citizens. This dictatorial repression
explains why the legislator was so reluctant to use the “language
of  rights”, even in the health legislation, and the term “rights”
never appeared during that period. An example of  this is the
Hospital Statutory Law of  1968 (Decree-Law 48,357, dated 27th
of  April 1968), in which we find, in Articles 80 to 82, some of
the main patients rights of  today (privacy, informed consent,
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refusal of  treatment, religious assistance) without ever using
expressions such as “rights” or “patients rights”.
The situation changed after the entering into force of the first
democratic Constitution, in April 1976. In this new Constitution
of  the Portuguese Republic, the importance of  the fundamental
rights increased considerably compared with all former
Portuguese constitutions. The chapters on rights, liberties and
guaranties of  the citizens are now wide and protected from any
subsequent constitutional revisions by article 288/d) of  the
Constitution.
The demystification of  the use of  the word “right” after the
revolution had immediate consequences in the first National
Health Service Law (1979) where some “rights” are already given
to the user of  the system. Surprisingly, the Portuguese citizen had
to wait until the Health Bases Law of  1990 (Law 48/90, dated 24th
of  August) to have a real legal statute of  rights in the health
sector.
In the Base XIV of  this law, there are nine rights attributed to
the users of  the health system: a) the right to choose the deliverer
of  care within some restrictions; b) the right to decide to take or
to refuse health care, unless exceptions exist in the law; c) the
right to be treated by adequate means, with humanity, promptness,
technical accuracy, privacy and respect; d) the right to
confidentiality of the personal data disclosed; e) the right to be
informed about their situation, the possible alternatives of
treatment and the probable evolution of their condition; f) the
right to receive, if  desired, religious assistance; g) the right to
complain and to sue regarding the way they were treated and, if
it is the case, to receive compensation for damage; h) the right to
constitute representative organisations that would defend their
interests; i) the right to constitute organisations that will
collaborate with the health system, like associations for the
promotion and defence of  health or health units friends groups.
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Base XIV/2 continues with the list of  the duties of  the health
system where we find among others, the duty to respect the rights
of the other patients and the duty to collaborate with the health
professionals in relation to their own health.
Patient’s rights in the Portuguese legal framework also include
the “Oviedo Convention” (Council of Europe Convention for the
Protection of  Human Rights and Biomedicine). This convention
is now part of  the internal juridical order after a Presidential
Decree of  the 3rd January 2001.
All the rights inscribed in the Health Bases Law and in the
Oviedo Convention are fundamental rights and are the patrimony
of any citizen in the position of being a user of a public or
private Portuguese health care unit.
Although the laws and declarations exist, doubts persist
whether patients’ rights are truly observed in hospitals and other
health care units of  the country.
There are various reasons for the lack of  implementation of  the
law, the first being the difficulties that come from the deficiencies
of the Portuguese health law. As we saw above, the Law gives
important rights to the citizens as users of  the health services.
Nevertheless, these norms are too vague and general to be of
practical use. There are no specific regulations to guide the health
provider on the detailed contents of the declared rights of  a patient.
Another factor that creates obstacles to patient’s rights
protection is the dilution of responsibility in the present setting
of  healthcare units. The number of health professionals that deal
with one single patient continues to increase. Consider the
classical example of  the medical secret that is no longer a
“medical” but a “shared” secret among numerous different health
professionals. How is it possible to protect the right to
confidentiality in these circumstances?
Patient’s rights are also affected by the crisis of  the
Portuguese justice system, which being particularly slow and
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expensive, makes the citizen reluctant to bring to court actions
to remedy violations of  their rights law or even seek the advice
of  a lawyer. Civil liability regarding damage caused by health
care malpractice in Portugal is still governed under the
“Napoleonic” rule of  the culpa (fault) that demands going to
court in order to get compensation. The judicial difficulties
together with this system, leads Portuguese patients to be very
hesitant to bring attention to violation of  their rights made by
health professionals or health care institutions.
All the mentioned obstacles to a real implementation of
patients’ rights in Portuguese health care units lead to the
conclusion that the patient is still the weakest link in the health
care process. Even if  the law undoubtedly declares his rights, the
Portuguese patient is normally a fearful individual, unaware of his
legal status and with no direct representative organizations in the
civil society.
Several factors seem to point to a higher standard of
protection of  patients’ rights in the future, as these rights
become better known, discussed and respected by health
professionals.
VII. Patients’ duties in Portugal
A) The inheritance of  European fundamental duties theory
The subject of  “patients’  duties” subject cannot be
understood without being linked to the broader issue of
“fundamental rights and duties” because these two issues share
some basic conceptual problems. As we will explain more in
detail, “patients’ duties” have inherited some of  the main
juridical features of fundamental duties in European countries
constitutional law and this fact can partially help to explain some
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of  the problems European laws have to define the concept of
“patient duty” and its scope.
In fundamental rights and duties theory, there is no consensus
on whether to consider fundamental duties as “autonomous
counterparts” to fundamental rights or as a mere “manifestation
of  inherent limits” of  the latter54. There is little express
recognition of the existence of fundamental duties in the majority
of European constitutions and where it does happen, the
mentioned duties are seen as limits upon fundamental rights and
freedoms or as a natural part of  the “socially integrated
individual”, rather than as independent existing and enforceable
duties55.
One of the main reasons for the reluctance of European
democratic constitutions to recognize and to mention
fundamental duties may be historical, as citizens’ duties lists are
still a symbol of  dictatorial political regimes, being a feature of
communist constitutions or reminders of the dark effects of  the
“national duty” so cherished by the Third Reich56.
Therefore, it seems that the absence of  “patients’ duties” in
European health laws follows the general tendency of  avoiding a
written recognition of  citizens’ duties. Not even the crucial
citizens’ duties of  paying taxes or to attend obligatory school have
expression in most of  European Constitutions. Fundamental
duties are mainly considered as an implicit corollary of  a
unwritten rule of  responsibility that all citizens should have
regarding the use of  their rights and freedoms. European case law
treats fundamental duties as “constitutional values”, used for a
proper systematic interpretation of  the constitutional principles
rather than as an independent source of  particular obligations of
the individual57.
In what concerns the European Union Law, we cannot find
any fundamental duties nor in the Treaties or in the derivate law.
These duties which are considered to be historically seen as
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“republican obligations imposed on each citizen for the common
well-being”58 are deeply linked to the concept of citizenship which
is it self  not developed in the Community Law”. Stefan
Kadelbach, in his work on fundamental duties in the perspective
of  the European Court of  Justice, concludes that these duties in
Community Law “do not form autonomous counterparts to
fundamental rights”59.
Nevertheless, despite their rather “subsidiary” nature to rights
and freedoms, citizens’ fundamental duties cannot be considered
as mere moral obligations. We may find some evidence of  this
assertion in some countries case law, e.g. Finland, where two 1997
judgments referred to the constitutional duty to defend the
country regarding criminal guilt and sentencing60 and also in the
German constitutional parental duties which are enforceable by
the law, being considered not as mere limits to parental rights but
rather as one of  the elements that defines parental law61. We also
find European countries (e.g. Portugal) that have included a
fundamental duty to defend and promote health in the
Constitution (Art. 64/1), duty that is repeated in health ordinary
laws, showing that this fundamental duty towards health is not
seen as a mere moral obligation.
The importance of  a balance between patients’ duties and
health professionals’ rights and duties is not very often mentioned
as a tool to the implementation of  patients’ rights, but it was the
main concern of  the European Forum of Medical Associations
Statement on the “Declaration of Amsterdam” (Declaration on
the Promotion of  Patients’ Rights in Europe)62, issued during a
meeting with WHO, held in Stockholm in February 1996. This
statement, as we will show, is evidence that the medical
professionals feel the gap between all the weight given to patients’
rights and the lack of  any importance given to correspondent
patients’ responsibilities, mainly in what concerns their duty to
collaborate with health professionals.
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In the mentioned document, the Forum “recalls” that “an
essential element in the fulfillment of patients’ rights to health
care is mutual confidence between the health care professional
and the patient (implying mutual recognition of  the rights and
obligations of  both parties) and that the relationship between
professional and patient should be one of  partnership, with
the object of  achieving an appropriate improvement in the
health of  the patient” (§6 of  the mentioned document). The
Forum Statement also cherishes that the Declaration of
Amsterdam, in the part entitled “purpose of  the document”
draws attention “in particular to patients’ responsibilities both
to themselves (for their own self  care) and also to health
professionals (for providing them with al l  necessary
information for diagnosis and treatment, as well as for
recognizing that they are entitled to the same rights as other
citizens)” (ibid., §8).
B) The duties of  Portuguese patients
The already mentioned Portuguese Health Bases Law (Law 84/
90, of  the 24th of  August) gives a general responsibility to the
individuals in the accomplishment of  the right to health
protection (Bases I/1 and IV/3 of  the Law), but it also attributes
concrete duties to the patients. In Base XIV/2, the same Law has
a list where we find that the users of the health system have the
following duties:
1) To respect the rights of the other users;
2) To observe the rules of  organisation and functioning of  the
services and institutions;
3) To collaborate with the health professionals in relation to
their own health;
PAULA LOBATO DE FARIA
44
4) To use the services in accordance with the established rules;
5) To pay the charges that derived from healthcare deliverance
when due.
Being unusual in contemporary European Health Law, we may
find a reason for the list of  Portuguese patients’ duties if  we
consider that these duties where adapted from the Hospital
Statute (Decree Law 48,357, of  the 27th April, art. 81) that dates
from 1968, when Portugal was still not a democracy. This gives
force to the fundamental duties theory that these duties are
connoted as juridical features of  dictatorial regimes. The 1990
adaptation deleted the article of  the 1968 law that mentioned as
a legal obligation of  the patients the duty to comply with the
medical prescriptions and therapeutics prescribed to them.
However the 1968 Law was never explicitly derogated, and this
duty nowadays seems to be against the self-determination
principle and informed consent rules.
Note of the author
Portugal is under a constantly changing legal framework,
mainly in the social sectors of Health, Labor and Education.
Reforms come in rapid succession, sometimes without enough
time to be understood or implemented before being replaced by
a newer reform. An article on the legal framework of  the national
healthcare system has an inherent risk of  being (at least partially)
already outdated at the time it is published.
Health politics is in constant movement these days in Portugal.
Hence, health legislation in our country is constantly changing the
juridical shape of  the Portuguese Health System. The author
recommends that readers check for amendments of  the legislation
mentioned in this chapter before quoting it.
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List of  used abbreviations
ACES Agrupamentos de Centros de Saúde (Health Centers’
Clusters)
ARSs Administrações Regionais de Saúde I.P. (Regional Health
Departments, Public Agencies)
CRP Constituição da República Portuguesa (Constitution of the
Portuguese Republic — Constitutional — Law 1/
2005, of  August 12th)
D.R. Diário da República (Portuguese Official Journal)
DGS Direcção-Geral da Saúde (Directorate-General for
Health)
DL Decreto-Lei (Decree-Law)
DN Despacho Normativo (Order Implementing the law)
DR Decreto-Regulamentar (Decree Implementing the law)
e.g. exempli gratia
EEC European Economic Community
EPEs Entidades Públicas Empresariais (Entrepreneurial Public
Entities)
EU European Union
GDP Gross Domestic Product
i.e. id est
Ibid. ibidem
LO Lei Orgânica (Organic Statute)
MH Ministry of  Health
NHS Serviço Nacional de Saúde (Portuguese National Health
Care Service)
OECD Organization for Economic Co-operation and
Development
OPSS Observatório Português dos Sistemas de Saúde (Portuguese
Health System Observatory)
PORT Portaria (Implementing Order)
PPPs Parcerias Público-Privadas (Public-Private Partnerships)
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SA Sociedade Anónima (Joint Stock Company)
UNESCO United Nations Educational, Scientific and Cultural
Organization
USD PPP Purchasing Power Parity in US Dollar
USF Unidades de Saúde Familiar (Family General
Practicioner’s Units)
WHO World Health Organization
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1. European integration on health
The 1957 Treaty of  Rome created the European Economic
Community (EEC), and defined a common market, characterized
by the abolition, as between Member States, of  obstacles to the
free movement of  goods, persons, services and capital.
In practice, however, technical norms, health and safety
standards, national regulations on the right to practise certain
professions and exchange controls all restricted the free
movement of  people, goods and capital.
Progressively, most of such barriers were abolished and the
Treaty of  Maastricht, signed in February 1992, created the
European Union (EU), and effectively established a single market.
It also introduced new forms of co-operation between member
states, namely on defence and in the area of  justice and home
affairs. By adding this inter-governmental co-operation, the
Maastricht Treaty created a new structure, based on three pillars
— the European Council, the European Parliament and the
European Commission.
Since its foundation, the EU has been a magnet, attracting a
constant stream of  new members, culminating in its historic
expansion from 15 to 25 in 2004, and from 25 to 27 in 2007.
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Presently the EU embraces 27 countries — Belgium, France,
Germany, Italy, Luxembourg, Netherlands, Denmark, Ireland,
United Kingdom, Greece, Portugal, Spain, Austria, Finland,
Sweden, Cyprus, Czech Republic, Estonia, Hungary, Latvia,
Lithuania, Malta, Poland, Slovakia, Slovenia, Bulgaria and
Romania — and over 490 million people.
Firms are prevented from fixing prices or carving up markets
among them by the European Union’s anti-trust policy. People
can move around more freely for work because member states
recognise many of  each other’s academic and professional
qualifications. Governments have also agreed to take decisions
affecting the single market by a system of  majority voting rather
than by unanimous agreement — which is much harder to
achieve.
Following the rejection of  the European Constitution by
France and the Netherlands in 2005, and a two years period of
reflection, the EU leaders agreed on a detailed mandate for a new
Intergovernmental Conference, whose task will be to draw up a
Reform Treaty by the end of  2007.
The EU evolved, expanded and revised the original Treaty, but
its member states’ social systems never obeyed a common policy,
contrary to what occurred in vast areas of  economic and financial
policy, of  which the creation of  a single currency for the set of
countries that adhered to it — the Euro — is an example.
Several attempts have been made, in particular by the European
Commission, to homogenise the social policy in the various
countries, but they have encountered strong opposition, both from
national governments and public opinion, concerned with the
potential loss of  the specificities of  their national social systems.
Some progress has been made, however. The 2005-2010
Agenda covers policies designed to provide jobs, fight poverty and
promote equal opportunities for all, including mobile workers, so
that they can enjoy the same social security and pension rights
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throughout the EU. These policies are designed in partnership
with public authorities at every level — from local to national -
, employer and worker representatives, and non-governmental
organisations. It is also a framework for supporting member states
in reforming pensions and health care, tackling poverty and the
employment and social issues resulting from ageing populations,
as well as fostering equal opportunities, and eradicating inequality
and discrimination.
Consumer policy is part of  the EU strategic objective of
improving the quality of  life for all its citizens. In addition to
direct action to protect their rights, the EU ensures that consumer
interests are built into its legislation in all relevant policy areas.
Some effort has been made to coordinate actions among
state members in terms of  public health, which explicitly
appeared as a European matter in the Treaty of  Rome. For
instance, when a pandemic threatens to spread, the EU draws
up a co-ordinated response plan as it did, for example, for
avian influenza. The European Centre for Disease Prevention
and Control, headquartered in Stockholm, identifies, assesses
and communicates information on current and emerging
threats. It works with national health protection bodies to
develop Europe-wide disease surveillance and early warning
systems. By having a central agency rather than relying on
informal networking arrangements, the EU can react faster,
which can make the difference between a minor outbreak and
a serious epidemic.
For other areas of  the health care sector, however, policies
have been mainly developed on a national level, without particular
concern for homogenisation across the EU.
As for the future, there have been contradictory signs. On the
one hand, people tend to refuse any loss of  national sovereignty,
and the progressive enlargement of  the EU makes it even harder
to achieve common agreements. On the other hand, the Court of
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Justice of  the European Communities has been building —
mainly through jurisprudence — the foundations for the
possibility of  free choice of  health care providers in the EU
territory for all citizens of  its member states.
In the late 1990s, the Court ruled that patients could seek
medical treatment in another EU country and be reimbursed
when they returned home. The EU judges declared that patients
did not need prior authorisation from their own health authority
or health insurer before seeking treatment elsewhere, as it was
understood that such a requirement would run counter to EU
rules, designed to break down national barriers between member
states.
Naturally, the extent to which patients will look for health
care abroad will depend on a range of  factors, such as the
availability of  suitable services, the distances to be travelled,
the languages spoken in the chosen country, and the amount
of  the reimbursement at home. The latter variable is of
considerable importance, as the judges deliberately established
that patients going abroad for treatment would be reimbursed
in line with the rates which apply in their home country — a
proviso designed to reduce the impact on national social
security systems. Therefore, if  receiving health care abroad
turns out to be more expensive, it will be the patient’s
responsibility to pay the difference.
National health systems will have to deal with a more fluid
population as an increasing number of  patients in their catchment
area seek treatment in another EU country and other EU citizens
come to use their own services. Pressure will rise on the most
efficient systems to deal with a growing demand, and on the least
desirable systems to cope with underused capacity.
In order to limit this problem, the European Court specifically
determined that non-emergency treatment can be refused to
patients from other countries in the EU if  it can be shown that
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the extra demand would jeopardise access to proper health care
for the country’s own residents.
Two cases were brought to the Court by citizens from
Luxembourg. In the first case, Nicolas Decker complained that his
insurance company had refused to reimburse him for a pair of
spectacles he had bought across the border in Belgium. The
judges decided that this refusal violated the EU rules on the free
movement of  goods.
In the second case, Raymond Kohll sued his insurance
company after it turned down his request for his daughter to be
treated by an orthodontist in Germany. The European Court
ruled that the treatment was to be considered a service and that
the company’s refusal was illegal since it amounted to an unfair
barrier to the orthodontist’s right to provide services. (Busse,
Wismar and Berman, 2002)
To bring some light into the matter, the European
Commission launched, in 2006, a consultation paper to clarify the
terms and conditions under which citizens of  the European
Union can get health care in other member states.
Although currently only around 1% of  citizens seek care
outside their own countries, numbers are likely to increase, for
various reasons. For instance, demand has risen as more people
from northern Europe retire to sunnier parts of  Europe and as
more people commute to work across borders. The creation of
budget airlines have also boosted travel.
The aim of  the EU health services initiative — which will
inform forthcoming draft legislation — is to define which medical
services entitle patients to cross EU borders and what quality of
care they should expect, and to clarify who will pay for it. It is to
be expected, however, that the Council will try to limit the
exercise of  this right by patients, as it would cause a significant
increase in expenditure, especially in countries with large waiting
lists and waiting times for elective care.
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The European Commission, on the other hand, has been
influencing, as a regulator, health-related areas such as the
environment, scientific research, the requirements for one to
become a care provider,  and the harmonisation of  the
qualifications required for an individual to practice as a health care
professional.
2. Health care systems across the European Union
One of the main reasons for the absence of common health
policy derives from the fact that each national health care system
developed, through decades (or even centuries), its own economic,
political, social and cultural specificities. Even so, it is possible to
identify two main public insurance models in Europe — one of
them initially proposed by Bismarck in the late nineteenth century
Germany, and the other by Lord Beveridge, in the aftermath of
the Second World War, in the United Kingdom.
In 1883, Germany adopted a new law, innovative world-wide,
which forced employers to contribute to an insurance scheme for
their employees. At first, this was exclusively directed at low-
income employees, and later expanded to cover higher-income
groups as well. It was, in a word, the first ever social State-
imposed security system.
This movement subsequently evolved into a compulsory
insurance system, financed through shared contributions from
employers and employees, which covered temporary illnesses,
permanent disability and premature death. Insurance was
therefore associated with employment and not citizenship or
residency, and coverage was obtained through regular
contributions, leading to immediate or future benefits.
In 1911, in the United Kingdom a health care financing model
was created that was based on workers’ contributions towards
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mutual insurance companies which were then responsible for the
payment to providers. Later, in the mid-20th century, a new model
emerged based on a higher responsibility from the State and a
larger range of  services included. This was possible at the time
due to very specific circumstances resulting from a strong feeling
of solidarity among the British people at the end of the Second
World War, an increasing concern with equitable policies, and the
acceptance of  a stronger State.
The 1942 the Beveridge Report, entitled “Social Insurance
and Allied Services”, defined health care provision as a pillar
for the creation of a viable social security system in Britain.
The Report was based on the assumption of  an intervening
State. It was a more complete model than the one proposed by
Bismarck, in the sense that it intended to cover a wide range
of  risks, “from birth to the grave”, including the situation of
social exclusion.
The National Health Service (NHS) was created in 1948,
following the 1946 NHS Act, which was a cornerstone for many
health care systems around the globe, based on five nuclear
characteristics: (1) the public responsibility for the provision of
free access to health care; (2) the comprehensiveness of
coverage, as the Department of  Health was expected to
“promote a comprehensive health service for the improvement
of  the physical and mental health of  the people of  England and
Wales for the prevention, diagnosis and treatment of  illness”;
(3) the universality principle, meaning that the system covered
the whole population; (4) the equality principle, as all citizens in
need should have access to the same quality of  services, without
any economic, social or geographic discrimination; and (5) the
autonomy of  health care professionals, and in particular clinical
independence, which allowed the most appropriate use of
modern technology towards the population welfare, without any
administrative interference.
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Despite being an essentially British phenomenon, the rise of
the welfare state provided a demonstration effect that impelled
other countries towards similar movements. In Europe, we can
find three main health care system models, two of  which are
based on the principle of public insurance:
1) Social health insurance, with compulsory income-related
contributions, shared between the employer and the
employee. Contributions are collected by health insurance
funds (which are normally not-for-profit organisations),
independent from g overnment and which are also
responsible for health care provision — either directly, or
by contracting with private providers. Public authorities
assume a role of  regulation and supervision in this context.
For instance, they may intervene in case of  risk coverage
disparities between different insurance funds. Traditionally,
access to different funds depended on the individual’s
profession, religion or area of  residence. In several
countries, social health insurance covers most of  the
population, even though universality is not necessarily an
objective.
2) National health service (NHS), financed from taxes.
Payment is compulsory, and determined by income. The
State is responsible for the management of  the NHS, and
generally (but not necessarily) for the direct provision of
care.
3) Private health insurance, covering individuals or groups,
with contributions based on the level of risk. In the various
EU members, this type of  insurance exists as well, but
tends to complement public coverage. Top-up private
insurance may cover public sector co-payments, better
hospitalisation conditions, private care provision, and/or
services excluded from the statutory health care system.
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As we can see from Table 1, in eight EU15 Member States
taxation is the main source of funding for health care. Taxes may
be national (as in Portugal, Ireland and the UK), mainly regional
(Denmark and Sweden), a combination of  both (Spain and
Finland), or related to the payment of  insurance premiums (Italy).
In the Netherlands, health care is financed from a combination of
social and private insurance; in Greece and Belgium it is financed
from a mixture of  taxes and social insurance; and in Germany,
France, Luxembourg and Austria a mandatory social insurance
system is in place.
Table 1





Austria 24.1 54.1 17.5 14.1 –
Belgium 38.1 36.1 – 17.1 9.1
Denmark 80.7 – 11.9 17.4 –
Finland 62.2 13.1 12.2 20.8 1.8
France 13.6 71.6 17.1 16.5 1.3
Germany 11.1 64.8 17.1 17.3 9.8
Greece 33.3 24.1 12.1 40.4 –
Ireland 68.1 17.3 18.6 13.9 2.1
Italy 64.6 – 12.6 31.2 2.4
Luxembourg 30.1 49.8 12.1 17.9 2.8
Netherlands 10.1 68.1 15.1 17.1 –
Portugal 55.2 16.1 11.4 37.4 –
Spain 59.3 15.3 17.1 16.3 1.7
Sweden 69.7 13.4 – 16.9 –
United Kingdom 78.8 12.3 15.6 13.2 –
Source: Mossialos & Le Grand, 1999 (adapted).
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3. Health expenditure
Total health care expenditure in EU member states has risen
steadily from as little as 4.8% in 1970 to 8.8 % of GDP in 2004,
as we can see from Figure 1.
This growth is more pronounced in public expenditure, which
increased from 3.5% in 1970 to 6.6% of GDP in 2004 (Figure 2).
Private health expenditure also grew during this period,
although at a smaller rate, having gone up from 1.7% in 1970 to
2.7 % of GDP in 2004 (Figure 3).
As for the future, the OECD (2006) presents projections for
the public expenditure on health care and long-term care (and its
increase in terms of  % of  GDP) for 2050, based on two different
scenarios: one in which no policy action is assumed, the “cost
pressures” and a “cost containment” scenario that embodies the
assumed effects of policies curbing expenditure growth.
Figure 1
Total health expenditure — Average % GDP, in EU15 (1970-2004)
Source: OECD Health Data, 2006.
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Figure 2
Public health expenditure — Average % GDP in EU15 (1970-2004)
Source: OECD Health Data, 2006.










Private health expenditure — Average % GDP in UE-15 (1970-2004)
Source: OECD Health Data, 2006.
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As we can see from Table 2, in the “cost-pressure” scenario
average health and long-term care spending across OECD
countries is projected to almost double from 6.7% of GDP in
2005 to 12.8% by 2050. In the “cost-containment” scenario,
average expenditures would sill reach around 10.1% of  GDP by
2050 (OECD, 2006).
The European Commission (2006) estimates the impact of
ageing populations, between 2004 and 2050, for the EU25
member states. Table 3 presents the estimated demographic
impact on public expenditure on health care and long-term care
Table 2
Public Health and long-term care spending in % of  GDP
HEALTH CARE LONG TERM CARE TOTAL
2005 2050 2005 2050 2005 2050
COST- COST- COST- COST- COST- COST-
PRESSURE CONTAINMENT PRESSURE CONTAINMENT PRESSURE CONTAINMENT
5.7 9.6 7.7 1.1 3.3 2.4 6.7 12.8 10.1
Source: OECD, 2006.
Table 3
Demographic impact on public expenditure on health care
and long-term care, as %GDP, between 2004 and 2050
(European Commission)
PUBLIC EXPENDITURE ON HEALTH CARE PUBLIC EXPENDITURE ON LONG-TERM CARE
2004
VARIATION BY 2050 DUE
2004
VARIATION BY 2050 DUE
TO DEMOGRAPHIC EFFECT TO DEMOGRAPHIC EFFECT
EU 25 6.4 1.6 0.9 0.6
Source: European Commission, 2006.
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(European Commission, 2006). Public spending on health care is
projected to increase 1.6 percentage points of  GDP and public
spending on long term case 0.6 percentage points between 2004
and 2050.
4. Determinants of  health care expenditures
There is a wide range of  factors that contribute to the increase
of  health expenditures. On the demand side, we can identify three
main reasons:
1) Ageing populations. The consequences of demographic
projections must be carefully interpreted, as they will
depend on the actual use of  health care, on services made
available to older people, and on technological change. In
fact, many countries have been trying to alleviate the use of
hospital beds by promoting the availability of  long-term
care facilities and home care for elderly people.
2) Increasing levels of  income. As income increases, so do
individual expectations regarding the quality of  care and
the level of  services consumption, regardless of  their
insurers’ changes in terms of  coverage characteristics.
There is significant literature on this topic — for
instance, the OECD estimates an income elasticity of
demand of  around 0.2, while a number of  other studies
also point at low elasticities, suggesting demand for
health care to be relatively inelastic (Folland, Goodman
and Stano, 2003). For the United States, Newhouse
(1992) also supports a coefficient of  elasticity that is
positive but lower than one.
3) The widening access to health care and insurance coverage.
Nearly all OECD countries — with the relevant exceptions
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of  the US and Switzerland — have State-supported health
insurance systems in place. Coverage steadily increased and,
in the late 1970s, it was already close to 100% in many
countries. On the other hand, out-of-pocket expenses
decreased during the 1960s and 1970s, followed by a slight
increase in the 1980s. If  we combine the average public
share in total health expenditure with the increasing
coverage level, it is possible to estimate the public financial
effort with health care.
On the supply side, we can also add the following reasons for
a health care expenditure rise:
1) Technological change, including new methodologies, new
drugs, new equipments and new medical interventions
(Newhouse, 1992): it is not easy, however, to evaluate its
impact on expenditure, as some of  it may actually allow
for higher efficiency, thus resulting in savings, especially if
we take indirect costs into consideration. For instance,
new medicines may, in some cases, reduce the need for
surgery, others may reduce the need for the hospitalisation
of  mental patients, and vaccines may prevent the spread
of  contagious diseases (OECD, 1995).  Economic
evaluation, important as it is, still has a long way to go in
terms of  determining the cost-effectiveness of  new
technology.
2) An increasing health care provision, accompanied by some
degree of  supplier-induced demand. For instance, the
number of  hospital beds increased considerably in the
1960s and 1970s, due to better coverage, an optimistic
perspective on demographic growth, propensity to favour
hospital care as opposed to preventive and primary care,
and a financing system that, in some countries, effectively
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promoted hospitalisation. By the end of  the 1970s,
however, many countries had to face a surplus of  hospital
beds, due to decreasing natality rates, a reduction on average
lengths of  stay for inpatient care, and the growing use of
ambulatory care. Taking advantage of  the asymmetry of
information present in this sector, a possible solution for
this excessive supply was to artificially induce additional
demand.
The OECD (2006) estimated the impact on the public health
expenditure increase of  its main determinants, for the period
1970-2002. The most important results are presented in Table 4.
The income effect is very significant, while the effect of  ageing
populations is much smaller.
5. Cost containment measures in EU member states,
in the early twenty-first century
Given the clear imbalance between the growth rate of
expenditure and available resources, governments have been
forced to implement cost-containment measures. Such measures,
which were sometimes integrated in wider reform strategies, can
Table 4
Impact of  the main determinants on public health expenditure increase
(1970-2002)
INCREASE RATE IN PER CAPITA
DECOMPOSITION OF THE EXPENDITURE INCREASE
PUBLIC HEALTH EXPENDITURE AGEING-POPULATION INCOME- RESIDUAL
EFFECT EFFECT EFFECT
Average OECD 4.3 0.4 2.5 1.5
Source: OECD, 2006.
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be divided into two groups, depending on whether they intend to
influence the demand or the supply side of  health care. The most
commonly used measures are presented in Table 5.
1) Limits to public resources
Most EU members adopted co-payment systems in order to
control the expenditure on drugs, dental care and, in some cases,
Table 5
Cost-containment measures adopted
by EU member states since the late 1990s
Limits to public resources:
• Increasing co-payments or user charges;
• Tightening of  co-payment exemptions;
• Explicit rationing decisions;
• Escalating role of  voluntary health insurance;
New budgetary techniques:
• Introduction of  fixed budgets;
• Combination of  fixed budgets and production-related payments;
• Budgets for individual providers as opposed to sector-related budgets.
Controlling methods:
• Control on wages and fees;
• Control on inputs;
• Control on the number of  hospital beds;
• Introduction of clinical guidelines;
• Reference pricing system;
• Limits on average hospital length of  stay and development of  alternative
care methods.
Source: Mossialos & Le Grand, 1999 (adapted).
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inpatient and ambulatory care. However, and despite increases in
the use of  co-payments, these have never been the most
important mechanism for cost containment.
The development of positive and negative lists for prescription
drugs, to determine which are entitled to public reimbursement
was also a wide-spread measure, integrated in an effort to
establish priorities in the health care provision. Apart from the
pharmaceutical and dental care areas, most countries do not use
treatment restrictions as a way of shifting spending onto patients.
However, there have been some moves towards establishing
priority-setting frameworks or guidelines for decision making, to
help explicit rationing decisions.
2) New budgetary techniques
Most EU governments, especially since the 1980s, have
tightened the control over hospitals, given the share of  hospital
care on total health expenditure. However, the growth of
expenditure on ambulatory care and medicines forced them to
widen their intervention to these areas as well.
Cost control measures seem to be most efficient when a single
financing source for health care is in place, and when measures
such as the imposition of  financial ceilings, restrictions to the
construction of  new hospitals and to the acquisition of  expensive
equipments, the reduction of the number of  acute-care beds, and
the control of  staff  numbers and payments to professionals are
implemented.
In ambulatory care, payments to professionals are now
negotiated centrally in some countries, while others opted for the
imposition of  ceilings to global payments to doctors, in order to
compensate for increases in the volume of  care. The same
measure was also adopted for the payment of self-employed
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nurses and diagnostic exams. Prices for medical interventions
inside and outside hospitals were also adjusted and limits were
defined.
3) Controlling methods
• Control on fees — in Belgium, for instance, the
government reduced fees by 3% in 1996, for doctors
working for insurance funds.
• Control on inputs — some countries control wages, staff
numbers and capital expenditures, and most member-states
impose numerus clausus limits in medical schools and in
hiring doctors;
• Control on the number of  hospital beds — most countries
have actually reduced the number of  acute-care beds in
recent years;
• Development of  clinical guidelines — in 1993, a new
system for therapeutic consensus was introduced in France
for a set of  diseases, techniques and treatments, intended to
evaluate medical practice outside hospitals and, later, to be
extended to all clinical activities. But the guidelines do not
apply if  the annual contract between government and
doctors has not been agreed. These guidelines, also adopted
by other EU members, specify when and how certain
procedures, diagnostic exams and medicines related to a
given health problem should be used.
• Implementation of  reference pricing – under this payment
system, similar prescription medicines included in the same
list are reimbursed by the State based on the price of  the
reference drug (which is normally either the cheapest or the
second cheapest in the group, depending on the country).
If  a more expensive medicine is prescribed, patients must
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pay the excess. This method intends to increase both
patient and doctor’s sensitivity to actual costs.
• Control over hospital lengths of  stay and promotion of
alternative care — evolution in medical knowledge and
technology allows continuous reductions in the average
length of  stay for a given inpatient treatment. Similarly, new
alternative care — such as ambulatory care — may reduce
costs, avoid hospital-related infections, hospitalisation-
related stress and anguish, and allow for a quicker recovery
and return to work.
• In the EU there have been attempts to control the
acquisition of  expensive medical equipment, by creating the
so-called health maps, which determine how such
equipment should be distributed in a country’s territory,
therefore avoiding waste and over-capacity. In addition,
several countries have established independent bodies to
assess new technology, namely in terms of  its cost-
effectiveness.
6. Conclusions
Even today, health policy remains largely a responsibility of
individual member states within the European Union, even
though some common efforts have been made concerning
efficiency and the rational use of  limited resources.
Most countries — if not all — are under constant pressure
because health care expenditures show no signs of  declining, and
available resources remain scarce.
The concern in controlling health care costs has been a key
stimulus for the health care reforms in Europe since the 1980s.
Cost-control measures are left to national decision makers, but
will certainly remain on the EU agenda, if  for nothing else
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because national budget deficits must remain below 3% of
GDP.
Naturally, there has been a degree of  convergence in the
chosen measures to contain the cost of  health care. However,
methods employed by different countries differ according to the
way in which their heath care systems are organized and
financed.
If  Europe intends to preserve its welfare state model and to
continuously improve equity, access and quality of  care, efforts
must be made to make a better use of  available resources.
Even so, health care expenditures will continue to rise, due to
ageing populations, technological change, and increasing income
and expectations. If, having achieved maximum efficiency,
resources continue to be insufficient to guarantee a
comprehensive coverage to the whole population, difficult choices
will have to be made, and member state governments will need to
either increase resources (namely by increasing taxes or health
care-related contributions), reduce the set of  services included in
public insurance, or even question its universality.
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SOCIAL SOLIDARITY AND PERSONAL RESPONSIBILITY IN HEALTH REFORM
Social Solidarity and Personal Responsibility
in Health Reform*
WENDY K. MARINER**
In the United States, calls to expand access to health care, when
not simply ignored, typically result in bills or legislation to reform
health insurance. We are in the midst of  just such a transformation
today. Several states have adopted reform laws to make insurance
available to most of their residents.1 Presidential candidates are
offering their own proposals for the nation’s health care system.2
Former Treasury Secretary Paul O’Neill even declared that health care
should be a right, adding that wealthier people should help pay for
those who will never be able to afford their own care.3 Most
Americans cannot afford to pay for more than minor medical
procedures out of their own pockets. Insurance is the vehicle that
finances the rest.4 Thus, insurance has come to stand for health care.5
Yet buying insurance is not the same thing as buying health care.
Conflating the two can exacerbate disagreements about the
responsibilities of government, business, and individuals for health and
health care.6 Health reform proposals reflect different philosophies
about who should be responsible for certain health conditions —
society at large or the individual herself. Current health insurance
reform proposals borrow from both camps, combining provisions
* This article is adapted from Mariner, W. K., 2008. Social solidarity and
personal responsibility in health reform, Connecticut Insurance Law Journal, 14.
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based on actuarial fairness with provisions promoting social solidarity
by prohibiting certain forms of risk rating and underwriting.
This essay argues that amalgamating reforms that serve
inconsistent goals can perpetuate, rather than resolve, conflict. Part
I suggests that combining commercial indemnity insurance and
social insurance forges a contract for traditional indemnity
insurance plus discretionary personal services — an “insurance +
services” contract — which pulls the system in opposite directions.
Part II examines a recent example of  the service side of  this
insurance + services contract — coverage of  so-called “wellness
programs,” which base premiums, discounts or rewards on meeting
specific standards of  behavior. Often justified on grounds of
actuarial fairness, they foster the idea that certain health conditions
are matters of  personal responsibility. Yet, there has been virtually
no discussion of  what principles ought to govern the choice of
conditions targeted by wellness programs. Experience to date,
however, suggests that such programs are likely to disadvantage
those most in need of  social assistance. In the context of  rising
health care costs, such personal responsibility provisions may
unravel the social solidarity that prompted reform in the first place.7
I conclude that using commercial insurance to provide access to
care encourages reforms based on actuarial fairness promote the view
that health is each person’s personal responsibility. These reforms
may return to us to the days before health insurance, and have the
potential to undermine social solidarity beyond the insurance sphere.
I. Social solidarity and personal responsibility
in health insurance
There are many explanations why the United States has never
adopted a system for universal access to health care, much less
national health insurance.8
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Underlying much of  the political disagreement are very
different views about the nature of  health care. At one end of  a
wide spectrum is the view a person is (or ought to be) responsible
for her own health and pay for her own medical care like other
ordinary consumer goods.9 At the other end are those who find
health is somehow special so that society should be responsible
for ensuring everyone access to care, regardless of  ability to pay.10
Health reform proposals reflect these opposing views, and the
difficulty of  reconciling them undoubtedly has stymied agreement
on reform. Without greater clarity about whether insurance
should reflect social solidarity or personal responsibility, or which
health conditions deserve social insurance coverage and which do
not, gridlock is likely to continue.
Recent trends in health insurance in the United States reflect
both these competing values. 11 On one hand, there are signs that
the country is moving toward universal health insurance coverage
for reasons of  social solidarity. Public opinion polls report that a
large majority of  Americans favor universal access to care.12
Health care is no longer affordable for most Americans without
insurance.13 Employment-based health insurance covers a
declining proportion of  nonelderly Americans.14 This decline,
however, has been offset by expansions in public (state) Medicaid
and SCHIP programs.15 Several states have adopted or are
considering legislation to increase insurance coverage.16 But state
level reforms are limited by ERISA preemption,17 and recent
proposals for national reform at the federal level suggest that
momentum for universal coverage is building.18 Even employers
may support reforms that include universal coverage.19
At the same time, a competing trend has emerged favoring
increased personal responsibility for health and health insurance. The
beginning of  the twenty-first century saw a return to more traditional
indemnity health insurance following the late 1990’s backlash against
managed care.20 Although most health insurance plans still include
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procedures for managing care, most private insurance companies see
their plans as commercial insurance products covering specified
losses, and not as a mechanism for financing universal access to
care.21 Continuing health care cost increases also put pressure on
insurers, government, and employers to reduce the need for care, tie
premiums to claims experience, and shift more costs onto insureds.22
Health savings accounts are popular among some employers, because
they make employees responsible for a portion of  their health care
expenses.23 A recent innovation, wellness coverage, offers discounted
premiums or rewards for employees who participate in programs to
prevent health risks, such as smoking cessation programs, exercise
programs, and blood pressure and cholesterol screening programs.24
These programs, however, expand the concept of  personal
responsibility from financial liability to responsibility for one’s own
health status.
Social solidarity
Given the complexity of  medicine and disease, there may be
good reason to create health insurance structures that aim for
both universality and some degree of  personal responsibility in
coverage. Nonetheless, those two goals pull insurance in opposite
directions. This tension affects both private commercial insurance
and public benefit programs, like Medicare, Medicaid or Veterans
and military health benefits that are not formal insurance plans.
The concept of social solidarity embodies goals of mutual aid and
support.25 The idea is that we are all in this together, and no one
should be abandoned. Such aspirations inspired early mutual aid
societies to spread and share financial risks.26 Where people are
considered to be equally and randomly at risk for medical problems,
it makes sense for everyone to chip in and make sure that, when
injury or illness occurs, help is available to anyone who needs it.27 To
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fulfill their responsibilities to their populations, governments often
adopt social insurance systems to finance health care.28 The principle
of mutual aid and support is evident in rules for universality of
coverage and uniform premium rates. Most systems bar medical
underwriting to exclude people from coverage and prohibit or limit
segmented markets and risk classification. The defining feature is that
people are not excluded or asked to pay more because of  their own
health status, health risks or medical claims experience.
Even in the absence of  universal social insurance in the United
States, state and federal laws move commercial insurance toward
social solidarity goals. For example, laws requiring guaranteed
issue preclude insurers from excluding certain people from the
pool.29 State laws requiring coverage of  specific services
(mandated benefits) embody social policies about what coverage
must be available to all (except self-insured employee group plans
exempted under ERISA). Most state laws forbid charging higher
premiums to women, even if  women are more likely than men to
use medical care on average.30 Many states also prohibit premium
discrimination on the basis of  genetic information.31
The federal Health Insurance Portability and Accountability Act
(HIPAA)32 prohibits certain group of  health plans from
discriminating in eligibility or premiums on the basis of health status
factors, such as medical condition or claims experience.33 More
general anti-discrimination laws also foster social solidarity. For
example, the federal Americans with Disabilities Act prohibits
discrimination in employee health insurance coverage solely on the
basis of disability.34 Title VII of  the Civil Rights Act of  1964
prohibits discrimination in employee benefits on the basis of  race,
color, religion, sex, or national origin.35 Employee group health plans
generally offer the same premium rate to all employees, regardless of
age, health status, or claims experience. Offering the same coverage
for the same premium regardless of  age is a significant example of




Commercial insurance captures the concept of  personal
responsibility in efforts to achieve actuarial fairness. Here, the idea
is that each person should pay for his own risks and no others. In
contrast to social solidarity, the personal responsibility principle is
that people are different and we should not be responsible for
those who are different from us. Actuarially fair insurance policies
classify and segregate insureds into groups according to the type
and amount of  risk they represent, with different coverage,
exclusions, and premiums.37 In health insurance, this means that
the market for insurance is segmented into multiple categories
with multiple products.
Commercial insurers use medical underwriting and risk rating
to classify people. Medical underwriting, used primarily in
individual policies in the United States, avoids insuring specific
individuals for predictable (non-fortuitous) risks.38 For coverage
of  other risks, actuarial fairness aligns premium rates with the
individual’s level of  risk. Other payments, like the cost-sharing
devices of  deductibles and co-payments, serve both to discourage
unnecessary medical care (and claims) and to engage the insured
in effectively “insuring” her own losses to some degree. Coverage
limits, although strictly a matter of covered losses, can also serve
to discourage unnecessary care and claims.39 For example, limits
on services restrict the number of  inpatient hospital days or
physician office visits covered. Caps on paid claims, such as
annual or lifetime limits on the dollar amount of  health care
expenditures covered, provide a ceiling on the insurer’s risk.
The complicated terms of  commercial health insurance
policies may be an inevitable consequence of  the difficulty of
determining what should count as a loss. While a broken limb or
heart attack presents an unmistakable claim on the need for
medical care, many health conditions are more ambiguous. What,
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if  any, care is needed can often be debated, making the insurer’s
risk more difficult to calculate.40 Moreover, the cost of  care varies
significantly around the countr y, yet continues to rise
everywhere.41 Such concerns may not be unique to health
insurance, but are undoubtedly more intense in assessing health
insurance claims. Indeed, health insurance may push the
boundaries of insurable risks.
Insurance policies and service contracts
Fundamental to the concept of  insurance is the premise that
covered risks should be fortuitous — that is, unplanned and
unanticipated.42 State laws and market demand, however, have
crafted exceptions to the principle in many health insurance
policies. The consequence may be confusion about what counts as
an insurable risk.
The best known exception is coverage of  preventive services,
such as immunizations, disease screening (e.g., mammograms),
dental cleaning, prenatal care, well baby visits, and annual
physical examinations. There are undisputed social policy
reasons for these exceptions; such services can prevent disease
and keep people healthy.43 Requirements for insurance coverage
are generally based on concerns that many people, especially
low-income groups, would not obtain such services if  they had
to pay for them out of  pocket. Insurance coverage encourages
prevention by paying for it. Moreover, preventive services
typically cost less than treatment for the disease. These are
sound rationales for encouraging prevention, but they do not fit
insurance well.
The use of  insurance to achieve desirable public policy goals
challenges the nature of  commercial insurance. Preventive care
is not a typical insurable risk, because it is predictable and under
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the control of  the insured. The specific services are explicitly
paid for whenever the insured chooses to obtain them. Insurers
can predict the cost of  such coverage, but assume no risk,
removing the agreement from of  the realm of  insurance.
Instead, the insurance payments to health providers function like
assets of  the insured to pay for a defined set of  services. The
result looks more like a service contract than an insurance
policy.
Health reimbursement accounts (HRAs) expand the service
contract concept beyond preventive care.44 A particular type of
HRA, the health savings account (HSA), has become more
attractive to individuals and employee group health plans since
receiving favorable tax treatment.45 Although not yet widespread,
HRAs are the current paradigm for so-called “consumer-
directed” care, described as giving consumers more choice than
they had with regular health insurance, primarily managed care
plans.46 Both supporters and critics agree that such accounts are
designed to make consumers more cost-conscious by forcing
them to pay for a portion of  their care.47 Although there is as
yet little data about how most individuals spend their account
funds, it is likely that most are spent in preventive care, as
described above, as well as less expensive, acute medical services,
such as treatment for a sprained ankle, which are more
discretionary or less costly than hospitalizations.48 Shifting this
kind of  care out of  the defined benefit package trims health
plans of  their coverage of  some non-fortuitous risks. While
there are limits on the type of  care for which the funds can be
used, HRA accounts move responsibility for seeking and paying
for care back onto the individual.
Health reimbursement accounts embody the view of some
health economists and policy analysts that health insurance is a
personal financial asset that can be used to buy medical care at the
consumer’s discretion, a view at odds with that of  insurance
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purists. In these commentators’ view, insurance distorts the
market for health care by enabling, even encouraging, individuals
to buy more care than they need, or at least more care than is
economically efficient for the country.49 Their focus of  analysis is
the purchase of  health care; insurance is merely a source of  funds
for payment.
In contrast, the traditional insurance industry view is that its
product is a promise to pay only for specified losses. In this view,
an insurance policy is not a cash equivalent to pay for whatever
the insured chooses to buy. Therefore, HRAs, like coverage of
preventive services, distort insurance. While health economists
argue that consumers should be deliberate, rational purchasers of
care, insurers expect to pay only for fortuitous losses. Pairing
HRAs with defined benefit insurance policies couples very
different conceptions of  the function of  insurance.
Economists concerned about national health expenditures
object to generous insurance policies on the ground that they
buy too much care.50 But, the reason we have insurance is to
pay for losses that we could not otherwise afford. If  health
care is a consumer good, freely bought and sold in the
marketplace, then it should not matter what resources
consumers use to buy it. Wages, daddy’s trust fund, and health
insurance are all cash equivalents. Moreover, if  health care is a
consumer good, who cares what people buy? Why not let the
market determine what services people value? Of  course, the
main reason for objecting to unrestrained spending is that it
raises the price of  care so that not everyone can afford it.51 Yet
unaffordability matters only if health care is something more
than an ordinary consumer good, something that should be
available to everyone regardless of  ability to pay. Thus, the
economic argument against buying too much care supports the
idea of  social solidarity in ensuring access to care for everyone.
Paradoxically, however, the solution offered to rising health
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care costs — making people responsible for more of their care
— weakens social solidarity.
Summary
The exceptions to traditional indemnity insurance for
insurable risks are usually justified on two grounds: cost (to
society at large, government or private insurers, or employers
who contribute to premiums); or social policy (to improve
health, encourage “good” behavior or discourage “bad”
behavior). In many cases, both reasons are intertwined, so that
is difficult to disentangle one from another, as may be seen in
the example of  wellness programs discussed below. Adding
exceptions for these reasons may make some sense in a universal
social insurance system, where everyone is in the pool, to
remove financial barriers to important services. Adding them to
private insurance sold in the commercial market outside the
context of  a universal social insurance system, however, may
simply widen the sphere of  personal responsibility.
Neither social solidarity nor personal responsibility principles,
by themselves, can explain or justify the package of  health
insurance reforms put forward today. Coverage of  some
conditions and services reflect social solidarity, while other
provisions encourage personal responsibility and treat health care
as a consumer good. Implicit in this division of  reform provisions
is the idea that some conditions are socially acceptable, such that
all society ought to share (at least financial) responsibility for their
prevention or consequences, while other conditions are socially
unacceptable, so that individuals should shoulder the burden
themselves.52 Yet there has been no significant debate about what
principles ought to govern classifying particular health conditions
as either an individual responsibility or a social responsibility.
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II. The peculiar case of  wellness programs
The most recent examples of  allocating health conditions to
the personal responsibility side of  the equation are wellness
programs. 53 Although often offered as part of  a health insurance
plan, such programs function like service contracts, with the
individual earning rewards for performing specific tasks (or
incurring a loss for failing to do so). For example, those who get
screened for hypertension or high cholesterol might receive a
discount on their health plan premium. Those who attend regular
exercise programs might avoid paying the plan’s deductible. Those
who take medication as prescribed might have their drug co-
payment waived. Those who fill out a personal health history and
agree to be monitored by a disease management group may get
cash prizes. Some employees welcome the programs, while others
object that they are intrusive and unrelated to job performance or
consider them a mechanism to get rid of  the employees most
likely to incur expensive medical claims.54 Even the Wall Street
Journal worried in print that employers may be overreaching by
monitoring employees’ health.55
A wellness program uses risk data to selectively modify rates
for individuals who are already in an insurance pool. In theory, it
is the insured, instead of  the insurer, who changes the rate—by
complying with the program’s requirements. Generally, however,
everyone in the group who does not have a particular risk factor,
like smoking or diabetes, receives a discount or reward. The effect
is to charge higher rates to individuals with specific health risks or
behaviors. The specific conditions for which financial differences
are allowed offer some insight into what we hold people
personally responsible for.
A well-publicized example was the plan adopted by Clarian
Health, an Indiana hospital system, to charge employees bi-weekly
fees if  they failed to meet target health standards, beginning in
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2009:56 US$10 if BMI ≥ 30; $5 for blood pressure > 140/90; $5
for glucose levels > 120; $5 for low density lipoprotein
Cholesterol > 130; $5 for smoking; and $5 for not completing a
health assessment. After public opposition to its plan, Clarion
made the plan voluntary and withdrew the penalties on those who
fail to meet the targets. Instead, it will offer the same amounts as
bonuses to those who voluntarily meet the targets.57 The effect,
however, may be the same.
Laws forbidding medical underwriting and basing premium rates
on individual health risks would seem to prohibit this result.
Nevertheless, wellness programs have joined preventive services as
an exception to the fortuity principle in many health insurance
plans. The tension between rewarding wellness and banning
discrimination based on health risks, however, may be reflected in
the fact that it took the federal government more than a decade to
issue final regulations under the federal Health Insurance Portability
and Accountability Act.58 Like several health insurance reform
proposals, the Act prohibits discrimination on the basis of health
factors while simultaneously allowing group health plans to offer
financial rewards for “adherence to programs of  health promotion
and disease prevention.”59 The regulations attempt to reconcile the
exception for wellness programs with the general prohibition
against discrimination on the basis of any health factor.
The difficulty of  reconciling the two can be seen in examples
of  acceptable programs described in the regulations. Even
programs that base rewards on an individual satisfying a health-
related standard can qualify for the exception if  they meet four
criteria, which, judging from the examples, appears to be relatively
easy to do.60 The regulations approve a hypothetical wellness
program that waives the $250 annual deductible for participants
who have a body mass index (BMI) between 19 and 26. Those
who are unable to lose enough weight for medical reasons can
earn the reward by walking 20 minutes a day 3 days a week. A
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medical condition prevents individual E from meeting either
standard. The regulations approve a result in which the “plan
agrees to make the discount available to E if  E follows the
physician’s [unspecified] recommendations.”61
It is hard to argue that this program does not discriminate on the
basis of  a health factor. The conclusion that it is not discriminatory
relies on the idea that, if  all else fails, health plans can force
participants to follow a physician’s recommendations. Although it is
doubtful that employers could require employees to obey their
physicians as a general condition of employment, some employers are
refusing to hire smokers because smokers in general have higher
health insurance claims than non-smokers.62 The same reasoning
could be applied to similarly costly conditions, such as obesity.63
One might argue that wellness programs simply offer rewards
that would not otherwise be available. However, some programs do
impose penalties. More important, the distinction between rewards
and penalties is often in the eye of  the beholder.64 All these
programs create incentives to conform to specific standards as a
condition of employment or as a condition of  obtaining insurance
coverage. In principle, it is only the price of  coverage, not coverage
itself, that is conditional on compliance. Yet, if  the costs of
coverage depend on satisfying specific health standards, then costs
are based on health factors. They are the same risk factors that
insurers would ordinarily take into account in determining premium
rates, absent a legal prohibition against discrimination. In effect,
therefore, wellness programs reintroduce the very risk rating that
legislation aimed at social solidarity initially forbade.
Wellness program goals
First adopted by a small (now growing) number of  employee
group health plans,65 wellness programs are intended either to
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keep employees healthy and productive or to reduce premiums (or
both). State Medicaid and commercial insurance reform laws that
allow financial incentives for wellness programs may have been
adopted for either health or financial goals.66 Private employers
who support health goals, however, may need to see a financial
return (or reduced costs) in order to sustain wellness programs.67
Whether wellness programs can achieve better health or cost
savings remains to be seen. Their promise may not be realized
without a long-term investment. Set up costs are concentrated in
the early years, with savings beginning years later when (and if)
participants avoid expensive services.68 Full benefits to the insurer
or employer depend on long-term enrollment by individual
participants. In the United States, about 17 percent of  participants
in private health plans change plans every year.69 This weakens the
financial incentive for any single plan to offer wellness programs,
unless competing plans have similar programs.
One probably ought not to expect financial miracles from
wellness programs. Unless such programs stave off  illnesses that
are more expensive than other diseases not targeted, they may
simply shift the causes, not the costs, of  illness.70 Preventive
measures cannot guarantee good health or immortality.71 Nor do
they affect the cost of  care, including preventive care, that is
provided, which continues to rise.72 Perhaps the best that may be
hoped for is disease compression — postponing debilitating
illness to very short period before death at a ripe old age.73
Implications for social solidarity
In addition to introducing personal responsibility into
insurance pools, wellness programs depart from social solidarity in
at least two other ways. First, to the extent that they succeed in
improving health and reducing costs, they may benefit the federal
93
SOCIAL SOLIDARITY AND PERSONAL RESPONSIBILITY IN HEALTH REFORM
government more than the private sector, further dividing the
country along lines of  coverage. Current wellness programs target
risk factors for chronic diseases, which account for about three-
quarters of  the costs of  medical care in the U.S.74 In general,
chronic diseases and disabilities are more prevalent among
populations who are low income, uninsured or covered by
Medicaid or Medicare (including the elderly), than among those
with commercial insurance.75 This suggests that government has a
larger financial stake in reducing the cost of  chronic conditions
than the private sector.76 The Centers for Medicare and Medicaid
and presidential candidates are already emphasizing disease
prevention over expanding insurance coverage.77 If  these efforts
do not reduce costs, government may consider more direct
measures to ensure compliance with health standards.78
Another way in which wellness programs depart from social
solidarity is by targeting risk factors that are more prevalent
among disadvantaged populations than among those of  higher
socio-economic status. Health status is strongly correlated with
income.79 Chronic conditions are more common among lower
income populations.80 Diabetes disproportionately affects African
Americans, Hispanics, Native Americans, and Alaska Natives.81
Smoking is more prevalent among lower income groups.82 Thus,
the people most likely to be subject to wellness program
requirements may be those who need insurance the most and can
least afford higher costs. While such groups may benefit from the
improved health promised by such programs, their circumstances
raise questions about whether their participation is truly voluntary.
Risk factors that wellness programs target can be seen as
conditions for which society holds individuals personally
responsible. Such conditions change as science identifies new
sources of  risk and society alters its norms of  behavior.83 For
example, smoking moved from a relatively common habit to
pariah status in a few decades.84 The fact that obesity is now called
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an epidemic suggests little public tolerance for the overweight.85
Diabetes, once considered out of  anyone’s control, also appears to
be moving into the realm of  personal responsibility. Significantly,
however, wellness programs have not yet targeted other health
risk factors, such as job stress and shift work.86
It is instructive to examine the conditions that are not (yet)
considered suitable for personal responsibility. Among the health
factors on which HIPAA prohibits discrimination are “participation
in activities such as motorcycling, snowmobiling, all-terrain vehicle
riding, horseback riding, skiing, and other similar activities.”87 It is
possible that sports enthusiasts use less medical care or less costly
care than people with chronic diseases.88 Nonetheless, one might
suspect that their exclusion from risk rating is based more on social
preference than on financial considerations. Making sure that
victims of  injuries are covered for medical care seems like simple
justice, even when they assume the physical risk of  injury. But, then,
why single out other conditions, especially those that are less likely
to be voluntarily assumed? The only plausible reason would be the
comparative cost of  coverage. Yet, if  cost is the real reason, then
any comparably expensive condition, regardless of  how acquired,
should be treated in the same manner. 89 Of  course that would
return the entire enterprise to classifications based on individual
health risks.
The absence of  empirical support for distinguishing among
conditions on the basis of  costs and savings suggests that wellness
programs may rely on unstated, perhaps unrecognized, bias
against disadvantaged groups of  people.
III. Conclusion
The peculiarly American mix of  entitlement and personable
responsibility in today’s health reform proposals may be evidence
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of  our ambivalence about social solidarity and personal
responsibility for health. It may also mask deep divisions in beliefs
about whether society or the individual ought to be responsible
for health. Trying to have it both ways may make it impossible to
agree on sustainable reform.
What is missing from current health reform debates is any
serious discussion of the role of insurance in defining
responsibility for health. The use of  market-based, private
insurance to provide universal access to care has encouraged
reforms based on actuarial fairness, which make everyone
responsible for his own risks. A focus on medical care costs
confuses the use of  insurance with the purchase of consumer
goods. Attempts to cabin the cost of  medical services by
selectively inserting elements of  risk-based cost-sharing into
insurance policies chip away at the general goal of  universal
coverage. Increased cost sharing encourages the belief  that health
is the personal responsibility of  individuals, and not the
responsibility of  all society.
So far, increased cost sharing has been applied selectively.
People are slotted into the actuarial fairness side of  the equation
ostensibly for reasons of  public health or social costs. But, an
underlying motivation may be prejudice against historically
disenfranchised groups. Combining wellness programs with
insurance tends to disadvantage those most in need of
assistance, undermining social solidarity. In the long run, people
may be excluded not only from affordable premiums, but also
from jobs or eligibility for government services. In the absence
of any explicit standard for selecting the conditions subject to
higher payments, there is no principled limit to the scope of
personal responsibility for one’s health. If  the standard is cost,
however, then efforts to insert personal responsibility for health
into social insurance reforms may presage a return to an era in
which everyone was responsible for his own costs. After all, the
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original argument for coverage based on cost was actuarial
fairness.
Alternatively, if  services to prevent illness and promote health
and fitness become an accepted part of  health insurance coverage,
insurance may be transformed from its indemnity function into
the role of  financing personal services. In such circumstances, it
will be difficult to place any boundaries on the demand for
services or their costs. If  preventive measures push expensive
illness to later ages, then the federal government will have even
more incentive to bring younger, healthier people into its risk pool
in to spread the costs of  the population it finances. In that case,
the initial effort to achieve actuarial fairness may ultimately yield
a form of  government-sponsored social insurance.
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The great myth of  American health care is that “Americans
don’t ration health care.” The truth is that Americans ration
medical care all the time: by price, by insurance coverage, by
geography, and even by race and ethnicity. But because as a
culture we want to believe that we put such a high value on health
and autonomy, we cannot admit that we ration even to ourselves.
Even those who know how the system works call it “quiet” or
“silent” rationing.1 So when Americans talk about rationing, we
almost always complain about how the government is preventing
people from getting needed medical care by its arbitrary rules.
And the most consistently savaged government agency is the
Food and Drug Administration, the agency whose job it is to
make sure that drugs and medical devices are “safe and effective”
before they are allowed on the market.
The thesis of  this chapter is that Americans will never be able
to face explicit medical rationing until we can face our mortality,
and, as illustrated by the all-too-common case of  cancer, we are
nowhere near being able to come to grips with our mortality
today. Thus, rationing American style, that is, “quiet” rationing,
will remain the rule in the United States for the foreseeable future.
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The inability of  Americans to accept their mortality, and our
concurrent belief  that simply spending more money on medical
care will somehow prevent death, is no secret. J. M. Coetzee’s
violent, anti-apartheid Age of  Iron, for example, is written as a
letter by a retired classics professor, Mrs. Curren, to her daughter
who lives in the United States. Mrs. Curren is dying of  cancer, and
her daughter advises her to come to the United States for
treatment. She replies, “I can’t afford to die in America. No one
can, except Americans.” Dying of  cancer has been considered a
“hard death” for at least a century, and there have been national
efforts in the United States to cure cancer that date from the
establishment of the National Cancer Institute (NCI) in 1937,
later intensified by the declaration of  a “war on cancer” with the
National Cancer Act of  1971.2 More recently, calls for more
cancer research have followed the announcement by Elizabeth
Edwards, wife of  presidential candidate John Edwards, that her
cancer is no longer considered curable.
Frustration with the methods and slow progress of
mainstream medical research has helped fuel a resistance
movement that distrusts both conventional medicine and
government, and that has called for the recognition of  a right for
terminally ill cancer patients to have access to any drugs they want
to take. Prominent examples include the popularity of  Krebiozen
in the 1950s and of  laetrile in the 1970s. As an NCI spokesperson
put it more than 20 years ago when thousands of  people were
calling the NCI hotline pleading for access to interleukin-2, “What
the callers are saying is, ‘Our mother, our brother, our sister is
dying at this very moment. We have nothing to lose.’”2 Since then,
more novel drugs have become available, and some have
demonstrated evidence of  at least months of  prolongation of
progression free survival in clinical trials. Families search the
Internet for clinical trials, new drugs, and even untested chemicals,
such as dichloracetate, that seem to offer them some hope. In
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addition, basing advocacy on their personal experiences with
cancer, many families have taken out their frustrations on the
Food and Drug Administration (FDA), which they see as a
government agency denying them access to potentially life-saving
treatments.
In May 2006 some of  these families won an apparent major
legal victory when the U.S. Court of  Appeals for the District of
Columbia, in the case of  Abigail Alliance v. Von Eschenbach,3 agreed
with their argument that patients with cancer have a constitutional
right of access to investigational drugs. This opinion occasioned
heated controversy, including new FDA proposals to make
experimental drugs more easily available to patients not enrolled
in research protocols.4 Ultimately however, the opinion was
vacated, reargued, and reversed by the full bench of the U.S.
Court of Appeals for the District of  Columbia in July 2007.5 The
debate fostered by the opinion nonetheless opened a recurring
question at the heart of  our anti-rationing medical system: do
cancer patients for whom there are no effective treatments have
a right to take experimental drugs their physicians think might be
beneficial, even in the absence of  evidence of  effectiveness?
The constitutional controversy
A lobbying group named the Abigail Alliance for Better Access
to Developmental Drugs (the Alliance) sued the FDA to prevent
it from enforcing its policy of  prohibiting the sale of  drugs that
had not been proven effective to competent adult patients who
are terminally ill and have no alternative treatment options. The
Abigail Alliance is named after Abigail Burroughs, who was
diagnosed with squamous cell carcinoma of the head and neck
when she was only 19 years old. Two years after the diagnosis, in
2001, she died. Before her death she had tried unsuccessfully to
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obtain experimental drugs on a compassionate use basis from
ImClone and AstraZeneca, and was accepted for a clinical trial
only shortly before her death. Her father founded the Abigail
Alliance in her memory.6
In 2003 the Alliance had asked the FDA to promulgate new
regulations that made post-Phase I new drugs available to
terminally ill patients who were not in clinical trials. The FDA
rejected this suggestion, which led to the lawsuit which alleged,
among other things, that the FDA’s policy was resulting in deaths
and that terminally ill patients should have the right “to assume
the risks if  their physicians advise them that a treatment may save
or prolong their lives and if  they have no other viable options.”3
The trial court dismissed the Alliance’s lawsuit for failure to
state a proper legal claim. The appeals court, in a two-to-one
opinion written by Judge Judith Rogers who was joined by Judge
Douglas Ginsburg, reversed. They concluded that competent,
terminally ill adult patients have a “right to access to potentially
life-saving post-Phase I investigational new drugs, upon a doctor’s
advice, even where that medicine carries risks for the patient” and
remanded the case to the trial court to determine if  the FDA’s
current policy violated that right.3
The right to life
The appeals court thought that the relevant constitutional issue
was spelled out in the due process clause of  the Fifth
Amendment, which provides that “no person shall be...deprived
of  life, liberty, or property without due process of  law.” The
question, as the court put it, was whether the due process clause
“protects the right of terminally ill patients to make an informed
decision that may prolong life, specifically by use of  potentially
life-saving new drugs that the FDA has yet to approve for
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commercial marketing but that the FDA has determined, after
Phase I clinical human trials, are safe enough for further testing
on a substantial number of  human beings.”3 The court
understood that new fundamental constitutional rights are not
easily found, and must be capable of “careful description,” but
thought that Abigail Alliance’s proposed right qualified because,
“the Alliance asks only that the decision to assume these known
or unknown risks [of  a post-phase 1 drug] be left to the terminally
ill patient [and his or her physician] and not to the FDA.”3
The court supported its conclusion by finding that this right
has deep legal roots, citing old British cases for the proposition
that there is a right to self-defense and a right to self-preservation,
and concluding that “Barring a terminally ill patient from the use
of  a potentially life-saving treatment impinges on this right of  self-
preservation.”3 (emphasis supplied) In a footnote, the court
restated this proposition: “The fundamental right to take action,
even risky action, free from government interference, in order to
save one’s own life undergirds the court’s decision.”3 Ultimately,
the court relied almost exclusively on the Cruzan case7 which
recognized the right of a competent adult to refuse life-sustaining
treatment, including a feeding tube, saying:
The logical corollary is that an individual must also be free to
decide for herself  whether to assume any known or unknown
risks of taking a medication that might prolong her life. Like the
right claimed in Cruzan, the right claimed by the Alliance to be
free of  FDA imposition does not involve treatment by the
government or a government subsidy. Rather, much as the
guardians of  the comatose patient in Cruzan did, the Alliance seeks
to have the government step aside by changing its policy so the
individual right of  self-determination is not violated.3 (emphasis
supplied)
The court concluded that another opinion, the 1979
unanimous laetrile decision, Rutherford, in which the U.S.
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Supreme Court held that Congress had made no exceptions for
terminally ill cancer patients in the FDA law governing drug
safety regulation, was not relevant.8 It decided this because the
Supreme Court never reached the question of  whether
terminally ill cancer patients had a constitutional right to take
whatever drugs their physicians prescribed, and ruled that even
if  it had, laetrile was not a similar drug because it had never had
a Phase I human trial.
The dissent
Judge Thomas Griffith, the dissenting judge, argued that the
constitutional right the majority found simply does not exist. He
noted, for example, that to be recognized as a fundamental right,
there must be “evidence that the ‘asserted right has any place in
our Nation’s traditions.’ Quite simply, the majority has provided
no evidence of a right, deeply rooted in our Nation’s history and
traditions, to procure and use experimental drugs.”3 He further
noted that the British cases are examples of  “abstract concepts of
personal autonomy” that provide insufficient evidence of  the
existence of  a fundamental right. Moreover, “The history of  drug
regulation in this country does not evidence a tradition of
protecting a right of  access to drugs; instead, it evidences
government responding to new risks as they are presented.”3
As to Cruzan, Judge Griffith argued that “A tradition of
protecting individual freedom from life-saving, but forced, medical
treatment [based on battery] does not evidence a constitutional
tradition of  providing affirmative access to a potentially harmful,
even fatal, commercial good.”3 As to the laetrile case, he noted
simply that the legislation governing the FDA has “no implicit
exemption for drugs used by the terminally ill.” He quoted the
Court: “the FDA generally considers a drug safe when the
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expected therapeutic gain justifies the risk entailed by its use. For
the terminally ill, as for anyone else, a drug is unsafe if  its
potential for inflicting death or physical injury is not offset by the
possibility of therapeutic benefit.”3,8
Finally the dissenting judge argued that if  the new
constitutional right is accepted, it is unlikely to be limited to only
terminally ill patients seeking post-Phase I drugs. Specifically, the
judge asked if  the right must also apply to patients with “serious
medical conditions,” to patients who “cannot afford potentially
life-saving treatment,” or to patients whose physicians believe
“marijuana for medicinal purposes... is potentially life saving?”
The judge continued, “Perhaps most significantly, what potential
must a treatment have in order for the Constitution to mandate
access?”3
Discussion
The stories of  dying patients trying unsuccessfully to enroll in
clinical trials are compelling, and the current U.S. system of  ad
hoc exceptions to safety and efficacy requirements is deeply
flawed. Nonetheless, the central constitutional question raised in
this case is more abstract and rests on determining whether this
case is or is not like the right-to-refuse-treatment case of  Nancy
Cruzan, a woman in a permanent vegetative state whose family
wanted tube feeding discontinued because they believed that is
what Nancy herself  would have wanted. I do not think Abigail
Alliance is like Cruzan. It is instead almost identical to the
physician-assisted suicide cases in which a terminally ill patient is
seeking to end his or her life using physician-prescribed drugs
because life has become intolerably burdensome.
The U.S. Supreme Court has decided unanimously that no such
right exists.9, 10 First, there is no history of  support for this right.
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And second, although the right seems narrowly defined, it is very
unclear to whom it should apply. Why only terminally ill patients?
Don’t patients in extreme pain that cannot be alleviated have even
a stronger interest in suicide? And why is the physician necessary,
or why are physician-prescribed drugs the only acceptable
method? None of  these questions can be answered by examining
the Constitution.11
Similarly in Abigail Alliance, as the dissenting judge suggests, the
new constitutional right proposed is much more like a policy
statement than a constitutional right. Again, why just terminally ill
patients? And why involve a physician at all? If  it is the patient’s
right to autonomy, why isn’t the requirement of  a government-
licensed physician’s recommendation at least as burdensome as the
requirement of  the FDA’s approval of  the experimental drug?
And why would this new constitutional right only apply to access
to post-Phase I drugs? Why not access to medical devices, like the
artificial heart, or even to schedule I controlled substances, like
marijuana or LSD? If it is a constitutional right, these should be
available too, at least unless the state can demonstrate a
“compelling interest” in regulating them.
This reasoning explains why the full Circuit Court reversed this
opinion (with the 2 judges previously in the majority becoming
the two dissenting judges in the new 8 to 2 opinion of  the full
bench).5 The Circuit Court upheld the FDA’s position and rejected
the creation of  a new constitutional right for terminally ill
patients, for the same reasons that the U.S. Supreme Court had
rejected the “right” of  terminally ill patients to have access to
physician-prescribed drugs they could use to end their lives.9-11 The
U.S. Supreme Court then ended Abigail Alliance case in January
2008, when it refused to consider an appeal of  the Circuit Court
decision.
This is not, however, the end of  the matter. Attempts to
change the law will continue in other forums, similar to the
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physician-assisted suicide cases, in which the fight just shifted to
the states (although only one so far, Oregon, has provided
physicians with immunity for prescribing life-ending drugs to their
competent, terminally ill patients).12 In this case, the debate will
continue in the forum in which it began — the FDA — and in
Congress, which created the FDA in the first place.
Congress
Congressional action also had its birth with the story of  one
cancer patient, and was also heavily influenced by a controversy
over the removal of  a feeding tube. “Terri’s Law” was enacted
in Florida in 2003 to try to prevent the removal of  a feeding
tube from Terri Schiavo, in a case substantially identical to
Cruzan, which is the case primarily relied on by the majority in
Abigail Alliance. Terri’s “case” went national two years later.13 In
the midst of  it, in March 2005, the Wall Street Journal asserted
editorially, “If  Terri Schiavo deserves emergency federal
intervention to save her life, people like Kianna Karnes deserve
it even more.”14 The title of  the editorial was, “How About a
‘Kianna’s Law?” Kianna Karnes was at the time a 44 year old
mother of  four who was dying of  kidney cancer. Her only hope
of  survival, according to the editorial, was to gain access to one
of  two experimental drugs in clinical trials, but neither company
running the trials (Bayer and Pfizer) would make the drugs
available to her on a compassionate use basis. This was because,
according to the Journal, the FDA “makes it all but impossible”
for the manufacturers “to provide them to terminal patients on
a ‘compassionate use’ basis.”14
Almost immediately after the editorial appeared both drug
manufacturers contacted Kianna’s physicians to discuss the
appropriateness of  releasing the drugs to her. But within two days
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of  the editorial, she was dead. The Wall Street Journal editorialized,
“isn’t it a national scandal that cancer sufferers should have to be
written about in The Wall Street Journal to be offered legal access
to emerging therapies once they’ve run out of other options?”15
It noted that Mrs. Karnes’ father, John Rowe, himself  a leukemia
survivor, was now working with the Abigail Alliance on a
“Kianna’s Law.” That law, formally entitled the “Access,
Compassion, Care, and Ethics for Seriously Ill Patients Act” or
the “ACCESS Act,” was introduced in November 2005 and is an
attempt to make it much easier for seriously ill patients to gain
access to experimental drugs.16,17
The proposed Act began with a series of  congressional
“findings” — statements that Congress asserts as facts – including
most centrally that “Seriously ill patients have a right to access to
available investigational drugs, biological products, and devices.”
The Act does not define “seriously ill patients,” but one of  its
findings suggests that they include “patients who face morbidity
or death from their disease,” which would seem to cover just
about every person with a “serious” disease. The Act permits the
sponsor of  an investigational drug, biological product or device to
apply for Tier I approval based on (i) data from a completed
Phase I trial, (ii) “preliminary evidence that the product may be
effective against a serious or life-threatening condition or
disease...”, and (iii) an assurance that the clinical trial will continue.
The standard to be used in approving the application is that “the
potential risk to a patient of  the condition or disease outweighs
the potential risk of  the product, and the product may possibly
provide benefit to the patient...”17
The labeling of  the product shall state that it is for use by a
patient whose physician has documented in writing that the
patient has exhausted all approved treatment options and has
been unsuccessful in obtaining treatment with an investigational
drug for which the patient is a reasonable candidate. The patient
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must provide written informed consent, but must also sign “a
written waiver of the right to sue the manufacturer or sponsor of
the drug, biological product, or device, or the physicians who
prescribed the product or the institution where it was
administered, for an adverse event caused by the product, which
shall be binding in every State and Federal court.”17
Although Congress is the proper forum to address this issue,
this initial attempt has some of  the same problems as the Abigail
Alliance decision: first, the patients it applies to are not well
identified, although the group is much broader than terminally ill
and seems to encompass virtually any sick person without a
conventional treatment that works; and second, treatment is
confused with research, and clinical research is equated with
clinical care. Most troubling, however, is that patient-subjects are
asked to take on all of the risks of  the uncontrolled experiments;
current research rules — which prohibit mandatory waivers of
rights by research subjects — are to be amended to require such
waivers as a price of  obtaining the investigational agent. This is
ethically wrong, and an attempt to convert the FDA from a
patient-protection agency into a pharmaceutical and biotech
industry promotion agency.
FDA proposal
After the FDA lost the May 2006 decision in Abigail Alliance,
it began to consider amending its rules to encourage more drug
manufacturers to offer their experimental agents through
compassionate use programs.4 These programs had first come
into prominence during the early days of  HIV/AIDS when there
were no effective treatments and AIDS activists demanded that
they have early access to investigational drugs because, in the
words of their inaccurate slogan, “A Research Trial is Treatment
GEORGE J. ANNAS
130
Too.”18 In early December 2006 the FDA issued a set of  proposed
regulations with a press release entitled “FDA Proposes Rules
Overhaul to Expand Availability of  Experimental Drugs.” The
title of  the proposed regulations could have been taken from an
ACT-UP agenda: “Expanded Access to Investigational Drugs for
Treatment Use.”19
The FDA’s Expanded Access proposal adopts the expansive
language later used by Congress in terms of  covered patients,
defining them as “seriously ill patients when there is no
comparable or satisfactory alternative therapy to diagnose,
monitor,  or treat the patient’s disease or condition.”4
Manufacturers are required to file an “expanded access
submission,” and the product must be administered or dispensed
by a licensed physician who will be considered an “investigator,”
with all the reporting requirements that role has.3
Of  course, the major problem with expanded access or
compassionate use programs has never been the FDA; rather, it
has been the manufacturers who have no incentives to make
their products available outside of  clinical trials, because this
may make it more difficult to recruit research subjects, could
subject the manufacturer to liability for serious adverse
reactions, and cost recovery has been uncertain. 4, 16, 20 The drug
companies are right to worry that the approaches of  the
judiciary, Congress, and FDA will probably make clinical trials
more difficult to conduct, because few seriously ill patients who
have exhausted conventional treatments would rather be
randomly assigned to an investigational drug than have a
guarantee that they will receive the investigational drug their
physician recommends for them. This could result in significant
delays in the approval and overall availability of  drugs that
demonstrate effectiveness — a result no one favors. Even if
patients with cancer are willing buyers, drug manufacturers are




The cover story for all of  the proposed changes is patient
choice. But without scientific evidence choice cannot be
informed, and fear of death will predictably overwhelm fear of
unknown risks. This is understandable. As Jay Katz, the leading
scholar on informed consent has noted, when medical science
seems impotent to fight nature, “all kinds of  senseless
interventions are tried in an unconscious effort to cure the
incurable magically through a ‘wonder drug,’ a novel surgical
procedure, or a penetrating psychological interpretation.”21
Another Wall Street Journal article, entitled “Saying No to
Penelope,” illustrates the impossibility of  limiting access to
unproven cancer drugs to competent adults. The article tells the
story of  4-year-old Penelope, who is dying from neuroblastoma
that has proved resistant to all conventional treatments. Her
parents seek “anything that has a prayer of  saving her.” In her
father’s words, “The chance of  anything bringing her back from
the abyss now is very low. But the only thing I know for sure is
if  we don’t treat her she will die.” With Penelope hospitalized and
in pain, her parents continue “searching Penelope’s big brown
eyes for clues as to how long she wants to continue to battle for
life.”
It has been suggested that a physician’s supervision can
safeguard against “magical thinking” and help make informed
consent real.22 But as Katz has noted, although physicians (and
he could have added, drug companies) often justify such last-
ditch interventions as simply being responsive to patient needs,
they “may turn out to be a projection of  their own needs onto
patients.”21 This certainly seems to be the case in the provision
of  Kianna’s Law that requires the patient to waive all of  his




Government and the market
There is another recurrent theme: the belief  that government
is hurting its citizens by preventing them from getting access
to medicines that can help them, and that the market if  left
alone would be a better solution. The last time the U.S.
Supreme Court dealt with the rights of  terminally ill cancer
patients to obtain unapproved drugs was in the context of
laetrile. The Abigail Alliance court was correct to note that
laetrile had never had a phase l trial, but every indication was
that the drug, known as vitamin B17, was harmless, albeit also
ineffective against cancer.
Laetrile itself  became a legal cause celebre in 1972 when the
Alameda County California district attorney arrested physician
John A. Richardson and charged him with multiple violations of
the state’s cancer quackery laws. Richardson was a member of the
John Birch Society, and this organization quickly formed the
Committee for Freedom of  Choice in Cancer Therapy, ultimately
setting up 127 committees nation wide.23 It took another seven
years before the FDA prevailed in its case before the Supreme
Court.8 The basic arguments against FDA regulation remain the
same today, i.e., the FDA follows a “paternalistic public policy that
prevents individuals from exercising their own judgment about
risks and benefits. If  the FDA must err, it should be on the side
of  patients’ freedom to choose.”24
Public policy
The FDA will prevail before the U.S. Supreme Court again,
should any future case like this get reviewed there. This is not only
because there is (and can be) no constitutional right to access to
whatever substance a patient, and/or a patient’s physician thinks
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might be helpful in the absence of evidence. And even if  there
were, the state has the same compelling interest in approving
drugs as it has in licensing physicians, i.e. protecting the health of
the public. From a public policy viewpoint, the original Abigail
Alliance court, Congress, and the FDA all seem to be suffering
from the “therapeutic illusion” in which research, designed to test
a hypothesis for society, is confused with treatment, done for the
best interests of individual patients.21,25,26 Of  course there is a
continuum, and it is understandable that many patients with
cancer, told that there is nothing conventional medicine can do
for them, will want access to whatever is available in or outside
the context of  a clinical trial. But this is a problem for patients,
physicians, the FDA, and drug manufacturers. First because
terminally ill patients can be harmed and exploited; there really are
better and worse ways to die. Second, it is only through research,
not “treatment,” that cancer may become a chronic illness that is
treated with a complex array of  drugs, given either together or in
a progression.27,28 The right to choose in medicine is a central
patient right: but the choices can and should be limited to
reasonable medical alternatives, which themselves are based on
evidence.
This is good public policy, but it is much easier said than
done.29 Death is feared, and even dreaded in our society, and few
of  us are likely to be able to die at home, at peace, with our loved
ones in attendance, without seeking the “latest new treatment.”
There is always something new to try, and there is almost always
anecdotal evidence that it could help. This is one reason that even
extremely high prices do not affect demand for cancer drugs, even
ones that add little or no survival time. And of  course, as long as
Americans, and their health insurers, are willing, even eager, to pay
almost any price for even a low probability of  a brief  extension
of  life, rationing any more beneficial forms of health care will not
even be considered, at least not openly and honestly.
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When does caring for the patient demand primary attention
to palliation rather than to long-shot, high-risk, investigational
interventions? Coetzee’s Mrs. Curren, who rejected novel
medical treatment for her cancer and insisted on dying at home,
told her physician, whom she saw as “withdrawing” from her
after giving her a terminal prognosis — “His allegiance is to the
living, not the dying.” — “I have no illusions about my
condition, doctor. It is not [experimental] care I need, just help
with the pain.”
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Introduction
Racial classifications are increasingly being used in the
development and marketing of  drugs by pharmaceutical
companies that portray their products as necessary tools for
reducing health disparities among racial and ethnic groups in
the United States. Significant gaps in the health status of
such groups in the United States have persisted over the last
several decades, despite indications of  overall improvement
in the health of  white Americans. It is generally recognized
that such disparities exist and reducing disparities is a
national priority.1 Whether race based drugs are a solution to
the problem is highly debated by scientists, clinicians and
policy analysts. In 2005 the Food and Drug Administration
(FDA) added to the controversy when it approved the drug
BiDil specifically for use in treating African-Americans with
heart failure.  This essay uses the example of  BiDil to
illustrate the dilemmas presented by the development of  race
based medicines and to examine the meaning of  race,
particular ly the relationship between race and genetic
variation. It concludes that the evidence weighs against using




BiDil is the trade name for an anti-hypertensive drug that
combines two older generic drugs (hydralazine and isosorbide
dinitrate) into one pill.2 Federal approval of  the drug in 2005 was
newsworthy primarily because the FDA identified BiDil as an
adjunct therapy for treating severe heart failure in self-identified
Black patients.3 The FDA had never approved a drug for use by
a specific racial group before, and reactions to the decision ranged
from celebration to outrage. Not surprisingly, the celebratory
camp included NitroMed, Inc., the company in control of the
patent rights for the drug at the time of  the FDA announcement,
and others who had been involved in bringing the drug to market.
NitroMed had estimated that annual sales from BiDil could reach
$350 million within a few years.4 With a patent that would run
until 2020, the company had reason to cheer its investment in the
drug. Given the long history of  the drug’s development (discussed
below), others involved in bringing the drug to market were
undoubtedly also relieved to finally reach this positive endpoint.
But those who were financially invested in developing BiDil were
not alone in reacting positively to the FDA’s approval of the
combination drug. Many clinicians and health care analysts hailed
the drug as an important advance in efforts to improve outcomes
for African Americans suffering from heart failure and applauded
the FDA’s decision as the only responsible action it could have
taken.5, 6
Despite such favorable responses, the FDA’s evaluation of  the
drug has also been the target of  significant criticism. Some
analysts faulted the FDA for making a decision based on
questionable science.7 Others viewed the agency as succumbing
too readily to pressures from a company intent on capturing a
niche market and a society in need of  interventions to reduce
racial disparities.8 Another group of  critics focused on the
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harmful effects that the message implicit in identifying a drug as
race specific — that race is biological — would likely have on
efforts to reduce the health disparities experienced by racial and
ethnic minorities it the United States.9 A review of  the history that
preceded the approval of  BiDil is helpful in understanding the
bases for these criticisms.
BiDil’s complex history
The story of  BiDil began 30 years ago when Jay Cohn, a
cardiologist from the University of  Minnesota, pursued his idea of
using a combination of  two vasodilators (hydralazine and
isosorbide dinitrate) to develop a more effective treatment for heart
failure than the standard therapies.10 Throughout the 1980’s Cohn
studied the effects of adding this “H-I” combination to standard
treatment regimens in the Veterans Administration Cooperative
Vasodilator Heart Failure Trials (V-HeFT I and V-HeFT II). At the
conclusion of  V-HeFT I, Cohn, along with other researchers,
reported a reduction in mortality in the group receiving the H-I
combination, but admitted that the difference in mortality between
that group and the placebo arm of  the study was of  only
“borderline statistical significance”.11 In the V-HeFT II trial, the H-
I combination as an adjunct to standard therapies was compared to
another adjunct, enalapril, an angiotensin-converting enzyme (ACE)
inhibitor. At this trial’s conclusion, the ACE inhibitor seemed to
exceed the effects of  Cohn’s combination drugs for some patients.12
But those who do not respond to or are unable to tolerate enalapril
were still in need of  effective therapies, and Cohn stuck with his
investment in the H-I combination and faith in the drug’s potential
to help those patients.
While the V-HeFT trials were underway Cohn had obtained a
patent for a method of  combining two blood pressure medications
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to treat heart failure in the general population and subsequently
licensed that patent to Medco, a pharmaceutical company that
developed a pill (under the trade name BiDil) that combined the
two drugs in a fixed dose. Medco then sought FDA approval to
market BiDil as a treatment for heart failure. Their new drug
application (NDA) was based on the data from the V-HeFT trials
showing that the combination drug had benefited some patients.
However, the FDA concluded that the data was not sufficient to
satisfy its approval criteria and in 1997 rejected the company’s
application. Medco subsequently abandoned its efforts to
commercialize the drug and the property rights reverted to Cohn.
Still clinging to his belief in BiDil, Cohn revisited data from
the V-HeFT trials to compare the response of  Black subjects to
White subjects in those prior studies. This retrospective analysis
led him to conclude that ACE inhibitors seemed to provide
benefit for White subjects and that the H-I combination might
have a similar advantage for Black patients.13 Although responses
to the drugs were not uniform within either racial group, he
concluded that prospective trials conducted with a significant
number of  African American patients were warranted to
determine if  his observation about the combo drug had real
merit. Such trials became possible after Cohn licensed rights to
the drug to a different company, NitroMed, Inc.
Once NitroMed obtained a property interest in BiDil, the
company consulted with the FDA about seeking approval of
BiDil as a race-specific drug.14 The agency confirmed that its
approval would be contingent upon a clinical trial demonstrating
efficacy for African American patients. However, the agency didn’t
think that a study comparing Black and White patients would be
necessary given the results of  the V-HeFT studies and encouraged
NitroMed to conduct a single population trial instead.1515 Temple,
R., Stockbridge, N., BiDil for Heart Failure in Black Patients: The
U.S. Food and Drug
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In the meantime, Cohn and another cardiologist, Peter Carson,
obtained a revised patent for the same drug combination but as
a method to treat heart failure in African American patients. Since
that patent runs to 2020, (whereas the original patent would
expire in 2007), it provided the economic incentive for NitroMed
and its investors to sponsor the clinical trials necessary for its
NDA to be submitted to the FDA.
The African-American Heart Failure Trial (A-HeFT) was
started in 2001 and conducted at 161 centers across the United
States to see if  BiDil (as an adjunct to standard therapies) would
reduce mortality and hospitalization rates for self-identified Black
patients who had moderate or severe heart failure.16 Designed to
run until 2005, the study included 1050 subjects who were
randomly assigned to receive either BiDil or a placebo in addition
to standard therapy. In July of  2004, the study’s Data Safety
Monitoring Board identified such a lower mortality rate in the
subjects receiving BiDil that the study was terminated earlier than
planned.17 As reported by the study’s investigators, the data
generated up to that point showed a 43% improvement in survival
in the BiDil group based on 32 deaths (out of  518 subjects)
compared to 54 deaths (out of  532 subjects) in the group
receiving placebo.18 Additionally, rates of first hospitalization for
heart failure differed significantly between the two groups: 16.4%
in the BiDil group compared to 24.4% in the placebo group.19
Based on this new data, NitroMed submitted its application for
approval of  BiDil to the FDA.
In June 2005 NitroMed’s application was reviewed by the
FDA’s Cardiovascular and Renal Drugs Advisory Committee.
When the review was completed, all nine members of  the expert
panel voted in favor of  the FDA approving BiDil for treatment
of  heart failure.20 However, two panel members voted against
labeling the drug as indicated for Black patients out of  concern
that the restriction would be over interpreted to mean that the
PATRICIA (WINNIE) ROCHE
142
drug’s effects were due to racial identification rather than biology
and because it could impede use by other patients who might also
benefit from the drug.21 Since the FDA is not bound by the
conclusions of  its advisory panels, it had the option of  approving
the drug for treatment of  heart failure in the general population
and rejecting the racial indication in labeling. However, on June 23
the FDA accepted the panel’s recommendations and approved the
drug as “indicated for the treatment of  heart failure as an adjunct
to standard therapy in self-identified black patients to improve
survival, to prolong time to hospitalization for heart failure, and
to improve patient-reported functional status.”22
The wisdom of  this decision quickly became the topic of
debate in the popular press, national news shows and various
science, law and public policy journals. The heart of  the
controversy was over what relationship, if  any, race has to biology,
and in the context of drug development, what relationship race
has to variation in drug responses.23 Given its stature as an agency
that is obligated to make decisions based on science, by approving
BiDil as indicated for Black patients, the FDA can be seen as
sending a message to the public that it supports the view that race
is biological. This is particularly problematic as it is at odds with
the predominant views of  modern anthropologists, evolutionary
biologists and geneticists on the meaning of  race.
Race and biology
The idea that there are varieties of humans distinguishable one
from the other on the basis of  physical characteristics originated
with 18th century naturalists,  but it was 19th century
anthropologists who introduced the term “races” for subdivisions
within the human race and posited that the races were not of
equal rank or value.24 Although different labels have been used for
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racial groups over time, the notion of  natural, hierarchical
categories of  humans persisted in anthropology for well over a
century and was used beyond that discipline not only to explain
differences among humans but as a justification for the injustices
of  colonization and the atrocities of  slavery and the Holocaust.
Over the course of the 20th century this institutionalized idea of
races as discrete and unchanging populations was increasingly
challenged by biologists’ explanations of  human evolution, so that
eventually the social scientists who had in effect invented the
concept of  race as biology were compelled to disown the idea.25
This is reflected in a statement issued by the American
Anthropological Association in 1998 declaring that “inequalities
between so called ‘racial’ groups are not consequences of  their
biological inheritance but products of historical and
contemporary social, economic, educational, and political
circumstances.”26
The acknowledgement by anthropologists that race is a social
construct contributed to what Troy Duster has characterized as
the “do away with race bandwagon”.27 This refers to recent trends
in the humanities, medicine, science and even politics to either
redefine the concept of  race or banish it from established
discourse. The bandwagon gained some momentum with the
completion of the Human Genome Project and the explosion in
genetic variation research that has followed. With these
developments the public’s attention and hopes have shifted from
the social sciences to genetics to provide insights on what it
means to be human and to “rescue us from race and ... racism”.28
When directly asked about the biological basis of  race the leading
experts on genetics have been quick to respond with the
conclusion reached by Craig Venter, former researcher at the
National Institutes of  Health and president of  Celera Genomics,
who said: “Race is a social concept, not a scientific one. We all
evolved from the same small number of  tribes that migrated out
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of  Africa and colonized the world.”29 Other geneticists put it
more bluntly and dismiss the idea that humans can be divided into
racial subgroups with unique, biological differences as “bogus”30
and therefore not seriously entertained by credible scientists.
It is tempting to accept such pronouncements on their face,
especially when they fit with one’s own understanding of race and
come from individuals highly respected in the field. Moreover
non-scientists may feel ill equipped to challenge their assessments
on scientific grounds. But blindly accepting these conclusions is
unsatisfactory, because it leaves some questions about race and
genetic variation unexamined and unresolved. Most importantly,
if  racial classifications are not scientifically valid, why do we
continue to see references to race and racial groups in genetic
studies published in established medical and scientific journals,
particularly studies that purport to demonstrate variability in drug
response based on race or ethnicity?31 It would seem that either
race correlates with biological differences related to health or it
doesn’t.  Probing the scientific evidence behind the
pronouncement that race is not biological is important for
answering that question and resolving the public policy issues
raised by the experience with BiDil.
“Race” and genetic variation studies
One way to test the notion of  race as biologically determined
(hence genetic) would be to take DNA from many individuals
across the globe and have molecular geneticists analyze the
samples and sort them into clusters according to genetic similarity
without regard to how the sources of  those samples might
identify with any racial or ethnic classification. Then re-link the
racial identifiers to the samples and have the analysts re-group
them according to racial classification and compare the results of
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each data set. If  the samples in part one fell into neat discrete
groups and/or those groups were highly correlated to the racial
groups in part two of  the exercise, it would seem to indicate that
there is a biological basis for racial classifications. And if  they did
not, it would refute the notion. As it turns out, studies with a
design similar to this hypothetical exercise have been done with
interesting but complex results.
For example, Lynn Jorde and Stephen Wooding examined
DNA samples from populations in Europe, Asia and Africa32 to
explore the relationship between genetic variation and race.33
When the population identifiers of  the samples were over laid
onto the clusters arranged by genetic similarity (based on
distribution of  over a hundred alleles) they observed that “all
Europeans, East Asians and Africans were correctly placed
according to their respective continents of  origin.”34 Nevertheless,
they cautioned against concluding that this verified traditional
concepts about race. They pointed out that when samples from
individuals who occupy geographic regions intermediate from the
geographically discontinuous regions of  Europe, East Asia and
sub-Saharan Africa were added to the data, those samples did not
fall neatly into any of  the prior categories and instead
considerably overlapped more than one category. The researchers
noted that while an individual might have a 90% probability of
sharing ancestry with other members of  one cluster, he or she will
also have a 5% probability of  assignment into each of  the other
clusters. As they explained:
[H]uman genetic variation... tends to be geographically
structured, such that most individuals from the same geographic
region will be more similar to one another than to individuals
from a distant region. Because of  a history of  extensive migration
and gene flow, however, human genetic variation tends to be




Consequently, they concluded that geographic ancestry, rather
than race provides “a more subtle and complex description of  an
individual’s genetic makeup”.36 When David Goldstein and Joel
Hirshorn analyzed published studies to see if  gene variants have
different effects among racial or ethnic groups, they reached a
similar conclusion about the genetic similarity of  humans overall:
there are no sharp genetic boundaries in the human population
and when gene variants are present, they have similar effects in
different groups.37
As demonstrated by Jorde and others38 genetic variants can be
present with different frequencies in different groups and genetic
clusters can generally correspond to regional affiliation or
geographic ancestry. On that basis, it may seem reasonable to use
ancestry when needing a tool for inferring genetic variation.
Geographic ancestry has the advantage of  being easily discerned
by simply asking an individual what his or her ancestry is. Thus
it would appear to be a somewhat robust proxy for genetic
variation and as such could have a legitimate and useful role in
research and clinical decisions. There is, however, disagreement
among scientists as to when it should be used to infer genetic
variation and when it should not. There is also a lack of
consistency among scientists on what they mean by ancestry in
this context and that makes it difficult to know when their
recommendations for using ancestry should be adopted or
rejected.
There are variation experts who think that genetic ancestry as
represented by racial or ethnic identity is frequently a suitable
proxy for genetic variation in medicine and research.39 Although
these experts recognize that indiscriminate linkage of  racial and
ethnic categories with genetics has potential social costs, they
endorse such categories as starting points for understanding
disease prevalence and responses to treatment.40 Other experts
recognize that self  reported identifiers such as race or ethnicity
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might in some cases have a correlation with ancestral origins but
don’t subscribe to general use of  such identifiers as proxies for
genetic variation. They are careful to emphasize that the
connection between ancestry and genetics can be “quite blurry”
particularly when an individual’s ancestors originated from many
different parts of  the world.41 Because using population affiliation
as an indication of  the presence or absence of  a genetic variant
related to diagnosis of  disease or to predict drug response would
often result in faulty conclusions where analyzing the gene of
interest might not, they warn against using such proxies.42
The gene CYP2D6 illustrates this hazard. The gene encodes
for enzymes used by the body to break down toxins and
metabolize many drugs, including codeine. Individuals with
certain alleles (null CYP2D6 alleles) are unable to convert codeine
to its active form, morphine, which means they get little or no
pain relief  from taking the drug. While there is substantial
variation between populations (the median frequencies of these
alleles is 26% in European populations, 7% in African populations
and 6% in Asian populations43), Jorde and Wooding emphasize
that the variants are in all populations and reliance on population
affiliation alone is “at best, a crude and potentially inaccurate
indicator of response to codeine and other CYP2D6 —
metabolized drugs.”44
A similar problem results from relying on population averages
for predicting responses to ACE inhibitors as Cohn did when he
reanalyzed the V-HeFt studies described above. Data from several
studies demonstrates that many African Americans would respond
better to ACE inhibitors than many European Americans would.45
For this reason, labeling a drug, whether it is an ACE inhibitor or
BiDil, as indicated for use by one racial group may create more
problems than it solves.
If  the results of  an open label extension study announced by
NitroMed a year after BiDil went on the market are substantiated,
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genotyping may replace racial profiling in prescribing the drug.46
A common polymorphism (C825T) on the gene for the G protein
beta 3 subunit may account for the positive results reported in
subjects of  the A-Heft trial which was the basis for the FDA
approval of  the drug. While this polymorphism appears to be
more prevalent in subjects who self  identify as African Americans,
it is not exclusively present in African Americans.
Of course there will be times when it is not feasible to do an
individual g enetic assessment prior to making clinical
recommendations or decisions. The gene variants associated with
susceptibility to a disease or response to a drug may not yet be
identified. When the technique exists, it may be too time
consuming for the decision at hand or not affordable for the
individual. In those circumstances, relying on self  reported
identifiers such as race, ethnicity or geographic ancestry may seem
to be the best that physicians can do. But such use will have to
be informed by careful, critical assessments of  studies that
purport to demonstrate links between affiliation with a racial or
ethnic group and the relevant susceptibility or treatment response.
“The general public, including policy makers, are easily seduced by
topological thinking, and so must be made aware of the genetic
data that help to prove it wrong.”47 It is up to physicians as well
as other scientists to provide that awareness.
Conclusion
So should the FDA have rejected the submission of  an NDA
that was supported with studies on one racial group or at least not
have agreed to label a drug for use in one racial group? Either
action would seem to be more consistent with the understanding
of  race endorsed by modern anthropologists and many prominent
scientists, particularly those involved in studying genetic variation
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in humans, that race is a social construct, and not a biological one.
Those who object to the FDA taking such a stance, at least in
regard to BiDil, are quick to point to the implications this would
have had for those patients who would have been denied the
benefits that BiDil has to offer if  it had not been approved. The
choice is presented as this: either endorse race in this way or
deprive patients (in this case African Americans) who need
treatment of  a drug that could benefit them. The problem is that
at least in regard to this drug, there were other ways for the H-
I combination to reach patients who might benefit from it. The
results of  V-HeFT trials had been published, and physicians could
prescribe the two generics for patients who might have benefited
from them at that point. Most importantly, the FDA could have
approved BiDil for use in the general population, but avoided the
race label. Data from the A-HeFT trial would still have been made
available via the prescription labeling information. That
information clearly suggests to physicians that it might be of
benefit to some self-identified African American patients not
responding to standard therapy but it doesn’t suggest it should not
be considered for non-African American patients not responding
to other therapies. On a practical level, that would also mean that
prescribing for non-African American patients would not be
considered “off  label” use. Depending upon the terms of  their
prescription benefits some patients might encounter problems
getting coverage for such “off  label” use. Approval by the FDA
for use by the general population would avoid those obstacles.
If  the goal is developing more effective interventions it would
be better to focus efforts on discovering the genetic variations
underlying development of  disease and variation in drug
responses rather than racial differences. At the same time it is
important to recognize that although a better understanding of
the biological differences among individuals may be a necessary
step in developing effective treatments, developing new drugs will
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not be sufficient to reduce disparities in health. Understanding the
social and economic policies and environmental factors that affect
health and access to health care and instituting strategies that
address these factors will be equally important and necessary.
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Introduction
Let me start with the conclusions of  this exploration into the
human right to health. I will argue in this paper that health is
inextricably linked to human rights status. One cannot have a
healthy population without due consideration of  the human rights
status of  individuals within the state, and human rights cannot be
protected and upheld unless the population is healthy. I will also
argue that there exists a human right to the highest attainable
standard of  health as a moral obligation, legal duty, and as an
international human right.
Historically, rights were often described in two categories:
negative or civil and political rights, and positive or economic,
social, and cultural rights.1 Negative rights are the civil and
political rights to noninterference that protect the individual
from the state, while positive rights are the economic, social,
and cultural rights that obligate the state to progressively
provide for its population. Many states have distinguished
between these two types of  rights, though the distinction is in
fact a false dichotomy, as most scholars recognize. Positive
rights and negative rights are interdependent and indivisible.
For example, the negative civil and political rights to freedom,
* Cofounder, Global Lawyers and Physicians, Professor of  Bioethics and
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liberty, protection, and due process cannot exist without
positive investment by the state in building institutions like
law enforcement and a judicial system to enforce these
rights.
In the history of  human rights discourse, debate primarily has
focused on whether and how rights can be prioritized and
balanced. The issue of  prioritization of  rights has played out as
a debate between developed nations, which often emphasize civil
and political rights over economic, social, and cultural rights, and
developing nations, which tend to stress economic, social, and
cultural rights over civil and political rights. Again, these two types
of  rights truly work together, and emphasizing one type at the
expense of  the other is detrimental to the cause of advancing
human rights and the benefits that accompany them. This paper
will focus on both the positive and negative right to health, in
addition to describing what the concept of  health entails. It will
also focus on how moving beyond the right to health care toward
the right to healthy conditions is necessary for respecting a right
to health.
What characteristics of  health make it of  special concern to
us? Why is health so important? Health is a universal and
primary human good, as fundamental to the satisfaction of  our
needs as food and shelter. Health is a precondition to pursuing
and achieving whatever life goals one might have, and it
increases the range of  available opportunities in much the same
way that education does. The highest attainable standard of
physical and mental health is a fundamental human right, yet
health is unpredictable and unevenly distributed across the
population. While some need little health care, others may have
overwhelming needs. But the human right to health is universal,
and all are entitled to the highest attainable standard, as has
been articulated in international human rights for nearly sixty
years.
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History of  the righr to health
Since the end of  World War II and the establishment of  the
United Nations, a new era of  international human rights has
begun, grounded in the notion of  human dignity. This new era
was ushered in with the ratification of  the International Bill of
Human Rights, which includes the United Nations Universal
Declaration of  Human Rights (UDHR), the International
Covenant of  Civil and Political Rights, as well as the International
Covenant on Economic, Social, and Cultural Rights. The
Universal Declaration of  Human Rights expresses both positive
and negative rights in the same document, and both the
International Covenant on Economic, Social, and Cultural Rights
and International Covenant on Civil and Political Rights recognize
a right to the highest attainable standard of  health. The rights
outlined by these documents are integral to what it is to be
human, and as such, they ought to compel universal respect
regardless of  whether such respect is demanded.
The first explicit mention of  the right to health is in the
Universal Declaration of  Human Rights of  1948. 2 This seminal
document asserts that “everyone has a right to a standard of
living adequate for the health and well-being of  himself  and of
his family, including food, clothing, housing, and medical care and
necessary social services.” A series of  major international human
rights instruments followed the UDHR in further enumerating a
right to health.
The International Covenant on the Elimination of  All Forms
of  Racial Discrimination of  1965 states that parties must
undertake to prohibit and eliminate racial discrimination in all
forms and to guarantee the rights of  everyone without
discrimination as to race, color, national or ethnic origin.




Article 12 of the International Covenant on Economic, Social, and
Cultural Rights of  1966 “recognizes the right of  everyone to the
enjoyment of  the highest attainable standard of  physical and mental
health”.4 In an important step to achieving that end, the covenant
outlines specific items necessary for realizing the right to health,
mandating state parties to take steps to 1) reduce still birth rates, infant
mortality, and provide healthy development for children; 2) improve the
environment and industrial hygiene; 3) prevent, treat, and control
epidemics, endemics, and occupational and other diseases; and 4) create
conditions to assure medical service and attention for illness.
The International Covenant on Civil and Political Rights of
1966 defines the role of the state in protecting life and obligates
states to undertake measures to eliminate epidemics.5
The Convention on the Elimination of  All Forms of
Discrimination Against Women in 1979 directs state parties to
take all measures to eliminate discrimination against women in
health care.6 Parties must ensure a policy of  access to health
services, including family planning during both the pregnancy and
the postnatal period.
The Convention on the Rights of the Child in 1989 extends to
children the provisions of  the right to health articulated in the
International Covenant on Economic, Social, and Cultural Rights.7
It asserts the state’s obligation to diminish infant and child
mortality, with an emphasis on primary care, combating disease
and malnutrition, providing clean drinking water, and combating
environmental pollution.
General comment 14 to Article 12 of  the International
Covenant on Economic, Social, and Cultural Rights in 2000 is
perhaps the most important document in establishing the right to
health in that it explains what is meant by a right to the “highest
attainable standard of health”.8 A special United Nations
rapporteur on the right to health works to establish benchmarks
and monitor states’ observance of  the treaty.
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The right to health is also expressed in several national and
regional human rights instruments, such as the rulings of  the
European Court of  Justice and the South African constitution,
which has permitted successful lawsuits that have forced the state
to provide certain medical services.
The World Health Organization (WHO) has also recognized a
right to health. In the preamble to its constitution it declares,
“The enjoyment of the highest attainable standard of  health is
one of  the fundamental rights of  every human being without
distinction of  race, religion, political belief, economic or social
condition.”9
The right to health
The concept of  a right to health or health care is of  recent
origin. It is estimated that it was not until 1910 that one had a
more than 50% chance of getting better after going to a random
US health care facility, as opposed to not going at all. Initially, in
the United States health care was not considered to be a
government concern and was provided by laypeople, family, and
clergy. Few options existed for safe and effective health care.
When the US government began to take direct action to protect
the health of the populace, it was not due to a concern for
individual welfare, but rather for national defense. Thus, the US
first took steps to provide care for the armed services and
national defense forces to protect the interests of  state security.
Later programs for the working class were implemented to
achieve a more productive labor force.
As set forth in the International Bill of  Human Rights, the
right to health contains both freedoms and entitlements.
Freedoms include the right to have control over one’s health and
body, as well as a right to be free from nonconsensual medical
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treatments and experimentation. Entitlements, on the other hand,
include a right of access to an equitable health care system.
Moreover, the right to health is indivisible, interdependent, and
interrelated with other basic human rights, such as the rights to
food and education. In the public health perspective, the right to
the highest attainable standard of health also includes the rights
to property and to primary health care, appropriate and equitable
health services, basic immunizations, adequate nutrition, adequate
housing, and freedom from violence. Also included are sexual and
reproductive health information and services, such as family
planning. Rights that provide the preconditions for health are also
crucial, like the right to safe water and adequate sanitation, and
generally, the right to a clean and safe environment, as well as to
information about health care.
Audrey Chapman, a researcher at the American Association for
the Advancement of  Science in Washington D.C., raised three
important questions about the right to health.10 The first question
is whether the concept of  highest attainable level of health is an
average or a basic minimum, and whether it refer to the individual
or the entire population. The right to health cannot simply mean
the right to be healthy, as this may not always be possible. Health
depends not only on state responsibility, but also on the actions of
individual factors in society, such as behavior or heredity. A second
question is who ought to determine the content and scope of  the
highest attainable level of  health. Certainly views vary across
societies and among different groups. Opinions also differ on what
constitutes health and what type of healthcare appropriately reflects
a given set of  social, cultural, political, and economic circumstances.
Third, how is the highest attainable level of  health is to be evaluated
and measured? Should it be correlated to levels of  development and
available resources? Is there a minimum or, for that matter, a
maximum level of  investment in the health sector required by all
state parties? With innovations in technology and treatments, to
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what extent are countries, particularly affluent ones, obliged to
make these high tech inventions widely available? Although
increasing attention has been paid to these questions, they have not
been definitively resolved.
Medical and public health approaches for a right to health
The health status of  a population is related to its human rights
status. The language of  rights is powerful. Rights entail the
obligation of  the state to respect, monitor, promote, and ensure
that the rights of  individuals are protected. How does the state
carry out its obligation to respect, protect, and fulfill the right to
health? The two fields most directly involved with health take
different approaches to answering this question. Medicine’s
therapeutic focus translates to an approach to the right to health
that expands access to health care, whereas public health’s focus
on prevention leads to a right to health approach that protects
health and provides preventive services. Let us assume that health
care, whether therapeutic or preventative, leads to some
improvement in health, so that access and availability of  health
services becomes important to health status. Health status may
also be a function of medical care, but it is estimated that this
accounts for less than 10% of  the population’s overall health.
Additionally, it is estimated that only one sixth of  the years gained
in life expectancy in this century is attributable to improvements
in medicine and medical care and only ten percent of  preventable
premature deaths are a result of  lack of  medical care. Health
status is a function of  a number of  things, but particularly of
public health measures that protect basic human rights like the
rights to primary health care, appropriate and equitable health
services, basic immunizations, adequate nutrition, adequate
housing, and freedom from violence.
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Health status is strongly associated with socioeconomic status,
educational background, and discrimination, especially racial and
gender discrimination.11,12 This holds particularly true for women.
Women comprise 50% of  the world’s population, yet they are
responsible for over two thirds of the world’s working hours, earn
less than 10% of  the world’s income, and own less than 1% of
the world’s property.13 Public health interventions cannot be very
effective when they are laid onto a foundation of  socioeconomic
inequalities and rights violations. Only after attention is given to
these structural factors influencing health should the focus turn to
basic public health interventions, such as providing adequate food,
clean water, appropriate sanitation measures, and shelter. Public
health measures such as immunizations, followed by antibiotics
and high-tech medicine should be the last measures taken to
improve the health of  a population. The public health model
deals with population problems upstream, promoting prevention,
while medicine is more narrowly concerned with individuals, using
downstream approaches focusing on treating disease. Health
promotion and disease prevention are more important and more
cost effective than treating disease after it has already taken hold.
Whether for a geographic area, a community, or an individual,
health status is heavily dependent upon inputs and factors
seemingly unrelated to health services. Poor countries can more
effectively and efficiently raise health standards by first providing
clean water, sanitation, vaccinations, and other simple public
health measures, rather than providing curative medical care to
only a small fraction of  the population. Even industrialized
countries can gain much more from health promotion and disease
prevention than from downstream, “rescue medicine”.
Though commitment to free and equal health care is an
important step for human rights and social justice, it is unlikely to
single-handedly overcome marked health inequalities in society. In
Britain, inequalities of  health status in lower occupational groups
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persisted some 30 years after the introduction of  universal health
care, and these inequalities applied to all stages of  life.14 Access to
curative health care is not enough. The focus must be on social,
economic, and cultural rights by putting an emphasis on
prevention, primary care, and community health. As such, the
right to the highest attainable level of  health is interrelated with
other rights such as the rights to food, housing, education, safe
working conditions, good nutrition (particularly in childhood), and
the women’s right to education — one of  the most successful
ways to improve the health of  women and children.
The cost of  a right to health
In 1978, the WHO established a campaign of health care for
all by the 21st century.15 The WHO recognizes translating the right
to health to specific core provisions of  human rights instruments
as necessary for the campaign’s success.  In the World
Development Report of  1993, the World Bank outlined a package
of  essential public health and medical services.16 This minimum
care package would expand immunizations, cover HIV
prevention, and guarantee prenatal care, delivery care, and family
planning services. If  implemented, it is estimated that this package
would eliminate 32% of  the disease burden in low-income
countries and 15% in middle-income countries. The package
outline for low-income countries costs $12 per capita per year and
in middle-income countries costs $22 per capita per year.
Is the provision of  this health care package possible? This
depends on the commitment of  nations and individuals to social
justice and respecting the right to health. The amount of  money
needed to fund the health care package proposed by the World
Bank pales in comparison to the immense wealth circulating in the
hands of  the world’s most developed nations and wealthiest
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individuals. According to the United Nations Human
Development Report of  2005, the 500 richest individuals in the
world have a combined income exceeding that of  the poorest 416
million. The poorest 2.5 billion people, comprising 40% of  the
world’s population, live off  less than $2 a day and earn only 5%
of  the world’s income. Combining these data with those from the
World Bank proposal for an essential health package we can see
that providing an essential package of  medical and public health
services to this poorest 40% of the world’s population would cost
approximately $30 billion per year, or less than 0.2% of  the
income of  the richest 10% of  the world’s population.
As of  2005, the United States was spending nearly $2 trillion
or approximately $6,700 per capita on health per year, accounting
for 16.0% of  the gross domestic product.17 Yet, of  the
industrialized countries, the US has the lowest percentage of
population and government assured health insurance. Some 47
million Americans, or one sixth of  the total US population, lack
access to health insurance.18 Moreover, despite high levels of
health spending, the US generally compares poorly with other
industrialized countries on health outcome indicators and even
worse than some developing countries.19 Mozambique, one of  the
poorest countries in the world, in 1999 vaccinated more than 3.6
million children against a wide range of  diseases, covering
virtually the entire eligible age group.20 In contrast,  only
approximately 80% of  infants and toddlers in the United States
receive the full course of  recommended vaccinations for
diphtheria, tetanus, polio, and measles.21 The example of  healthcare
in the United States reveals a disconnect between health resources
and basic health outcomes. Funding must be translated to the
most effective and just forms of  health care if  a right to health
is to be realized. But despite the various enumerations of  a right
to health included in the UDHR and other instruments, explicitly
defining a right to health remains a challenge.
165
THE HUMAN RIGHT TO HEALTH
Moving forward: the human rights approach to health
A human rights approach to health emphasizes that effective
and sustainable provision of  health-related services can only be
achieved if  the state is willing to participate in designing policies
and programs that implement the right to health. Human rights
and health can be improved by paying special attention to the
process through which health care policy decisions are made. For
the protection and benefit of the public, health policies and
programs must also include the input and participation of  the
community. Participation and empowerment go hand in hand.
Necessary tools include enabling the public to have a legitimate
voice in the public realm, participation in decision-making, and
raising legitimate demands based on human rights claims. The
main effect of the human rights approach to health is the framing
of  basic health needs as health rights, in other words, establishing
that health is a social justice issue which involves concrete
governmental obligations. Furthermore, a human rights approach
to health also recognizes that every human being is endowed with
a set of  human rights, a worthy end in itself.
Increasing governmental accountability for the health of  the
populace is a crucial component of  the human rights approach to
health. A central advocacy principle used by nongovernmental
organizations employing a human rights approach to health is
holding governments accountable for their obligations under
international law, regional law, national constitutions and legislation.
By ratifying human rights treaties that affirm the right to health, the
state agrees to be accountable to the international community as
well as to the people living within its jurisdiction for the fulfillment
of  these obligations. Failure to fulfill these obligations can be
challenged in national and international forums.
Certain international obligations apply uniformly to all states
and require immediate compliance, while others can be realized
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progressively, depending on conditions in the country concerned.
Progressive realization must be understood as an obligation of
states to move as expeditiously and effectively as possible towards
the full realization of the right in question. An example of an
obligation that a state must immediately observe is the duty to
ensure freedom from discrimination in health related matters and
to allow participation in decision-making processes that affect the
public’s health and well-being. States agree to take deliberate,
concrete, and targeted steps towards the full realization of  the
right to health. Also included in many states’ immediate
obligations is the duty to ensure that people can enjoy the right
to health at an essential level, as through the provision of  essential
primary health care. These immediate obligations are known as a
minimum.
Increased attention must be immediately paid to the health
needs of  the poor and otherwise vulnerable, and attempts must be
made to rectify unacceptable imbalances in the health statuses of
different population groups. Under General Comment 14, states
have obligations concerning maternal, child, and reproductive
health, healthy and natural workplace environments, prevention,
treatment and control of  diseases, and health facilities goods and
services.22
Monitoring is key to realizing the right to health, and requires
assessing the numbers, policy, and distribution of  functional
public health and health care facilities.  Monitoring of
nondiscrimination, monitoring of  economic accessibility, and
monitoring of  physical accessibility and quality are paramount.
Conclusion
In conclusion, our primary goal should be to focus on the
positive right to health. This means not just medical care, but
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health care, and also the rights to the highest attainable level of
health. A health Bill of Rights is required that is not just a series
of  negative rights, but also includes positive social, cultural, and
economic rights.  A human rights perspective calls for
governments to respect, protect, and fulfill their obligations. The
current agenda should focus on the improvement of  maternal and
child health, particularly reproductive health. Placing priorities on
public health measures such as preventing, treating, and
controlling epidemic, endemic, and occupational diseases is
essential, as well as providing basic primary care for all, and
curative medical services for those who are ill.
Health must be seen as a global issue. Our world is
interdependent. The movement of  toxic waste, greenhouse gases,
radiation, and infectious disease knows no boundaries. An
international bill of  health and human rights that includes not just
civil and political rights, but economic, social, and cultural rights
is needed if  a right to health is truly to be realized.
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The International Human Right to Health
in Domestic Constitutional and Statutory Law
ELEANOR D. KINNEY*
I. Introduction
The predominant and probably most effective method of
recognizing, implementing and enforcing international human
rights has been through the legal architecture and culture of  the
legal infrastructure of  nation states. Most international human
rights treaties — which are generally international treaties between
nation states — place the responsibility of recognition,
implementation and enforcement of  treaties on the states parties
that sign and ratify the treaties.
This chapter first provides an overview of  the legal
implementation of  the international human right to health, of
which constitution making is a potentially important part. The
chapter concludes with obser vations about the role of
constitutions and law in the realization of  the international human
right to health.
* Hall Render Professor of  Law & Co-Director, William S. and Christine S.
Hall Center for Law and Health, Indiana University School of  Law —
Indianapolis. Much of  the commentary of  this article is based on several of  my
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health and health care in the constitutions of  the countries of  the world. Cornell
International Law Journal, 37 p. 285; Kinney, E. D., 2001. The international
human right to health: what does it mean for our nation and world. Indiana Law
Review, 34 p. 1457.
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II. The legal infrastructure
The elements of  an optimal legal infrastructure for the
recognition of  the international human right to health are:
• International and Regional Treaties
• National (and Provincial) Constitutions
• National Legislation and Regulation
• Provincial (State) and Legislation and Regulation
A. International and regional treaties
Since the 1940s and the close of  World War II, the United
Nations and regional international organizations have adopted
treaties and other instruments which have, over the years,
developed and articulated the contours of  an international human
right to health and health care.
As a matter of  international jurisprudence, the fundamental
statement of the international human right to health and health care
is stated in the Universal Declaration of  Human Rights adopted in
1948. The relevant provision is article 25.1 which provides:
Everyone has the right to a standard of  living adequate for
the health and well-being of  himself  and of  his family,
including food, clothing, housing and medical care and
necessary social services, and the right to security in the event
of  unemployment, sickness, disability, widowhood, old age or
other lack of  livelihood in circumstances beyond his control.1
As the Universal Declaration does not have the force of
international law, there are two international covenants to
implement it: the International Covenant for Civil and Political
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Rights (ICCPR),2 and the International Covenant for Economic,
Social and Cultural Rights (ICESCR).3
The later treaty, ICESCR, states the fundamental legal norm
establishing the international right to health and health care.
According to Article 12 of  ICESCR, the right to health includes
“the enjoyment of  the highest attainable standard of  physical and
mental health.”4 Article 12 of  ICESCR specifically provides that
states parties “recognize the right of  everyone to the enjoyment
of  the highest attainable standard of  physical and mental
health.”5. Article 12 then enumerates several steps to be taken for
“full realization” of  this right.6 These steps include:
• The provision for the reduction of the stillbirth-rate and of
infant mortality and for the healthy development of  the
child.
• The improvement of  all aspects of  environmental and
industrial hygiene.
• The prevention, treatment and control of  epidemic,
endemic, occupational and other diseases.
• The creation of conditions which would assure to all medical
service and medical attention in the event of sickness.
A human right to health is also recognized in numerous other
UN international human rights treaties that address the needs of
historically vulnerable populations that have often been the
subject of  discrimination. Such treaties include the International
Convention on the Elimination of  All Forms of  Racial
Discrimination of  1965,7 the Convention on the Elimination of
All Forms of  Discrimination against Women of  1979,8 and the
Convention on the Rights of  the Child of  1989.9 All of  these
treaties specify rights to health for the relevant populations in two
respects. First, they all prohibit discrimination in the provision of
health care services and, second, they often state affirmative rights
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to particular types of  health care services of  special importance
to the relevant population, such as obstetrical and gynecological
services in the case of  women. At Figure 1 is a list of  exemplary
regional treaties recognizing an international human right to
health and health care.
B. National (and provincial) constitutions
There is wide variation in constitutional provisions regarding
health and health care and lack thereof  in the constitutions of  the
Figure 1
Exemplary Regional Public International Organizations
and their Regional Treaties Recognizing
an International Human Right to Health
COUNCIL OF EUROPE
EUROPEAN UNION AN ORGANIZATION FOR SECURITY
AND COOPERATION IN EUROPE
European Social Charter of  1961 as revised (art. 11).
European Convention on Human Rights (1950)
ORGANIZATION OF AMERICAN STATES (OAS)
American Declaration of the Rights and Duties of Man (1948)
American Convention on Human Rights (“Pact of  San Jose, Costa
Rica”) (1969)
Additional Protocol to the American Convention on Human Rights in
the Area of  Economic, Social and Cultural Rights (“Protocol of  San
Salvador”) (art. 10) (1988)
ORGANIZATION OF AFRICAN UNITY
African Charter on Human and Peoples’ Rights (1981)
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countries of  the world.10 This phenomenon is mostly likely due to
the fact that national constitutions have been adopted at different
times and under different historic situations. Specifically, only 21
national constitutions that were in effect before World War II are
in effect today and, of  those, only nine have provisions regarding
health and health care in their constitutions.11 Currently, about 68
percent of  countries have constitutional provisions regarding
health and health care. Further, 54 percent of countries have
ratified ICESCR and 30 percent have ratified a relevant regional
treaty. 12
There does not seem to be much correlation between an
explicit commitment regarding health and health care in a national
constitution and the performance of  individual countries on
addressing the health care needs of their populations. Some
countries have detailed provisions while other countries, which
may have the highest annual expenditures for health care services
(a proxy for support of health care) have no provision regarding
health and health.13 Also, according to our study, countries that
expressed the greatest constitutional commitment to health —
evidenced by inclusion of both a statement of  entitlement and
duty — had an average government per capita expenditure for
health care of  $308 in 2000.14 The same average for countries that
had no provision regarding health or health care was $716.95. 15
Such findings suggest that there is no correlation between the
intensity of  constitutional commitments and average per capita
government expenditures for health and health care.
Nevertheless, a constitution can be extremely useful in
institutionalizing the international human right to health and
health care within a nation state. A constitution can establish and
define legal rights to health and health care. In our study, nearly
40 percent of nations specifically created a right to health and
health care within the constitution.16 Also, about 38 percent of
nation states established an affirmative and sometimes
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enforceable duty on the part of the state to provide health care
to the population.17
As a practical matter, the constitution must address some
issues if the nation state is authorized to proceed to enact
legislation. Specifically, the constitution must provide some
authority for health legislation. In the United States Constitution,
for example, the constitutional authority for federal laws
pertaining to all health related legislation and regulation is
Congress’ authority to enact legislation to spend money to
“promote the general welfare”18 and regulate commerce among
the states.19
Constitutions can also establish and specify in considerable
detail the nature of  government obligations to provide, promote
and protect health and health care as policy imperatives. The
constitutions of  several countries are quite prescriptive in actually
designing the health sector legal infrastructure for their nation
state.20
C. National legislation and regulation
Across the world, the allocation of  responsibility for health
and health care within specific nation statutes varies. In some
countries, the national government has predominant
responsibility. However, in much of  the world, the locus of
governmental responsibility for the health and health care of the
population lodges with regional or even local government.
Historically public health protections are the first focus of
government activity regarding health care. 21 Indeed, governments
had relatively limited responsibilities for health and health care
until the Twentieth Century. National governments became more
actively involved after World War II when national and regional
governments in more developed countries took on the
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responsibilities for regulating private health insurance and
providing health coverage through public programs.
1. Contents of national legislation
Ideally and regardless of  where the locus of  authority over the
health care sector resides, national legislation should at least
articulate the goals and objectives for a national health care sector
and address the following issues:
• Public health protection and promotion.
• Prohibitions against discrimination on the basis of  race,
religion, ethnic origin, gender, sexual orientation and
disability regarding access to public and private health care
services and health insurance.
• Regulation of providers to ensure safety and quality of  care.
• Regulation of  health insurance to address solvency and
other issues.
• Direct provision of  health care services or public health
insurance for vulnerable groups.
First and foremost, legislation at the national level should
provide for public health protection and promotion. The issue
should be addressed at the national level as the national
government will often be called upon by international and
regional international organizations such as the World Health
Organization to address international epidemics and other public
health crises. Also national governments increasingly are called up
to address public health emergencies such as a flu pandemic.
A second body of national legislation should include
prohibitions against discrimination on the basis of  race, religion,
ethnic origin, disability, gender and sexual orientation in both the
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public and private provision of  health care services.
Discrimination on any basis can impose a serious barrier to care
and often in circumstances where health care services of  good
quality and highly affordable are otherwise available.
A third body of  requisite law important for the national
realization of  the international human right to health and health
care is the regulation of insurance and risk-bearing health care
providers is regulation of  insurance. In most developed countries,
regulation of insurance is performed at the national level. In the
United States, for fairly idiosyncratic historic reasons, regulation
of  insurance has been lodged with states. This arrangement has
made it difficult to regulate health insurance in the United States
uniformly.
Finally, the international human right to health generally
implicates a government obligation to assure access to affordable
and high quality health care. Given the high cost of  health care in
most of  the world, government at some level will be pressed to
finance at least or at best provide health care services to some or
all of  the population. The allocation of  this obligation among
levels of  governments in nation states is obviously varied and
inevitably spread across local, regional and national levels.
2. UN Economic, Social
and Cultural Committee’s General Comment 14
The UN Economic, Social and Cultural Committee published
a General Comment 14 to ICESCR that outlines the content of
the international right to health and its implementation and
enforcement.22 Building on the typology of the content of  social
human rights developed by Asbjørn Eide in 1987,23 General
Comment 14 imposes three types or levels of  obligations: the
obligations to respect, protect and fulfill. The obligation to respect
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requires states parties to refrain from interfering directly or
indirectly with the enjoyment of  the right to health. The
obligation to protect requires states parties to take measures that
prevent third parties from interfering with article 12 guarantees.
The obligation to fulfill requires states parties to adopt appropriate
legislative, administrative, budgetary, judicial, promotional and
other measures towards the full realization of  the right to health.24
General Comment 14 clearly addresses implementation. It
imposes a duty on each of  the states party “to take whatever steps
are necessary to ensure that everyone has access to health
facilities, goods and services so that they can enjoy, as soon as
possible, the highest attainable standard of  physical and mental
health.” Implementation also requires adoption of  “a national
strategy to ensure to all the enjoyment of  the right to health based
on human rights principles which define the objectives of  that
strategy, and the formulation of  policies and corresponding right
to health indicators and benchmarks.” The national health strategy
should also “identify the resources available to attain defined
objectives, as well as the most cost-effective way of  using those
resources.” The national health strategy and plan of  action should
“be based on the principles of  accountability, transparency and
independence of  the judiciary, since good governance is essential
to the effective implementation of  all human rights, including the
realization of  the right to health.”25
There are also remedies if  states parties do not fulfill the
international human right to health. The comment explicitly
provides that a state party which “is unwilling to use the maximum
of its available resources for the realization of the right to health
is in violation of its obligations under Article 12” and places the
burden on the state party to justify that it has that it has made use
of “all available resources at its disposal” to satisfy its obligations
regarding the right to health. General Comment 14 also specifies
violations of  the Article 12 including “state actions, policies or laws
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that contravene the standards set out in Article 12 of  the Covenant
and are likely to result in bodily harm, unnecessary morbidity and
preventable mortality.” Violations of  the obligation to protect
include “failure of  a State to take all necessary measures to
safeguard persons within their jurisdiction from infringements of
the right to health by third parties.” Violations of  the obligation to
fulfill include “failure of  States parties to take all necessary steps to
ensure the realization of the right to health.”26
General Comment 14 accords remedies to individual parties.
Specifically, any person or group victim of  a violation of  the right
to health should have access to effective judicial or other
appropriate remedies at both national and international levels. All
victims of  such violations should be entitled to adequate
reparation, which may take the form of  restitution, compensation,
satisfaction or guarantees of  non-repetition. National
ombudsmen, human rights commissions, consumer forums,
patients’ rights associations or similar institutions should address
violations of the right to health.27
D. Provincial (state) and local legislation and regulation
Provincial and/or component states within a nation state will
have obligations regarding realization of  the international human
right to health. Historically, comparable local health authorities
have been engaged in public health protection and even
promotion before the rise of the nation state in the 18th and 19th
centuries.28
The legal authority for state and local health authorities vary
across the globe. In the federal system of  the United States, the
states have primary responsibility for the regulation and
promotion of  the public’s health. States’ authority for public
health regulation comes from the police power and the parens
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patriae power (to protect children and incompetent adults).29 The
state police power is the foundational power of  sovereign states
irrespective of  authorizing constitutional provisions.30 Basically,
the police power supports government authority to protect and
promote public health in many dimensions. The police power
includes protecting public safety, regulation of  risks to health and
safety in the environment, work place and other public venues.
Local governments basically function as “boots on the
ground” in the implementation of public health measures such as
safety inspections. They also work in conjunction with a vast
private health care sector including a variety of  health care
institutions and professionals in the provision of  health care
services particularly to the poor and vulnerable groups. Indeed, a
critical local institution is the local public hospital that has
responsibilities to care for the poor and uninsured in communities
throughout the world.
One very important role for states and, in particular, localities
is to establish networks of  personnel and resources to support
private providers that serve more vulnerable populations. Specific
local networks of  resources and personnel should include all the
relevant services needed for preventive case such as vaccinations,
acute care in hospitals in the event of  serious illness or injury, and
even long-term care. In the United States, the community health
center movement has done much to assure these networks for the
poor and uninsured.31 It is not surprising that the creation of
these networks has been an important component of  many of  the
proposals for health reform at the state and local level.32
IV. Conclusion
For full recognition and ultimate realization of the human
right to health, the nation state (which has the primary duties to
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respect and protect the right) must sign and ratify the treaties. It
is also the nation state that sponsors a process for making the
constitution of the nation state. In constitutional theory, citizens
of  a state can – in an established process – come together and
write and legalize a constitution. A constitution can establish the
nation states core values for the present and future. Legislation at
the national, state (provincial) and local levels is needed for
implementation of  these constitutional principles. However, the
real work of realization comes from the work of  policy makers,
administrators and health sector workers to establish the kinds of
networks and resources to assure accessible to high quality,
affordable health care for all – the ultimate criterion for realization
of  the international human right to health and health care.
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PATIENTS’S RIGHTS IN EUROPE
Patients’ Rights in Europe
HELENA MELO*
The first question we can ask when we speak about “patients’
rights in Europe” is to know what is meant by “patient”.
A “patient” is a person, i.e., a human being. We have been
discussing in European Philosophy, for the last XXI centuries, what
being a person means, and there is still no consensus in this field1.
Nevertheless, we can consider that a “patient” is a person who is
receiving medical treatment or that is registered with a particular
physician — a person who suffers or may suffer from a disease
or health problem.
The concept of “health” generally used by European Law is
the one that was given by the World Health Organization’s
Constitution (WHO) on 7 April 1948: health is “a state of complete
physical, mental and social well-being and not merely the absence
of  disease or infirmity”2. As Karl Jaspers stated, that kind of
health does not exist, because according to the given definition,
“everyone is always diseased”3.
As a matter of fact, each epoch has defined its own concept
of  health in accordance with its own scientific knowledge, and
therefore each concept can only be understood within the context
of  a certain period of  medical knowledge. Each concept has, as
well, reflections in the social and juridical understandings of
health and disease. “Disease” does not exist by itself, but is
* Helena Melo is Professor of  Health Law and Bioethics of  the New
University of  Lisbon and of  Biolaw of  the Faculty of  Medicine of  the Oporto
University. She has a MSD and a PHD in Public Law.
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constructed by Medicine after analyzing a set of  symptoms shown
by people, and can lead to the stigmatization of  the ill person4.
Having this in mind the Legislator at the European Union and
the Council of Europe usually considers that the patient is a person
who is in a vulnerable situation — because she or he is diseased —
but that does not lose her/his status as bearer of  rights.
If  we analyze the existing legislation in the field of  patients’
rights we conclude that a distinction can be drawn between the
rights of the patient as a “person”, and the rights of the patient
as a “diseased person”.
As a “person” the patient is a full citizen that has the rights that
are recognized in the main texts of  international law, such as
Universal Declaration of Human Rights5, Universal Declaration on
the Human Genome and Human Rights6, Universal Declaration on
Bioethics and Human Rights7, International Covenant on Civil and
Political Rights8, International Covenant on Economic, Social and
Cultural Rights9, Convention on the Rights of  the Child10,
Convention for the Protection of  Human Rights and Fundamental
Freedoms11, European Social Charter (revised)12, and Charter of
Fundamental Rights of the European Union13.
According to these juridical texts every patient has the specific
rights to life14, to physical and mental integrity15, to liberty16, to
personal identity17, to respect of  her/his privacy18, to work19, to
social security20, and to protection of health21.
Having in mind the general texts on human rights, the
international organizations have adopted specific documents that
recognize more detailed rights of  persons who are in a particular
situation — who have a disease and therefore belong to a group
that is vulnerable and frail because of the suffering it causes and
of  the fear of  not recovering. Examples of these texts are:
— Resolution 37/194 on Principles of  Medical Ethics22;
— Convention on Human Rights and Biomedicine23;
187
PATIENTS’S RIGHTS IN EUROPE
— Additional Protocol to the Convention on Human Rights
and Biomedicine, concerning Biomedical Research24;
— International Declaration on Human Genetic Data25;
— Recommendation n.o R (81) 1 on Regulations for
Automated Medical Data Banks26;
— Recommendation Rec(2006) 18 of  the Committee of
Ministers to Member States on Health Services in a
Multicultural Society27;
— Recommendation Rec(2007) 7 of  the Committee of
Ministers to Member States on Management of  Patient
Safety and Prevention of Adverse Events in Health Care28;
Within this group of  people who suffer from a disease, the
European Legislator considers that particular protection should
be given to certain groups of  patients. These specific rights are,
for instance, recognized in:
— Additional Protocol to the Convention on Human Rights
and Biomedicine concerning Transplantation of  Organs
and Tissues of Human Origin29;
— Recommendation 779 (1976) on the Rights of  the Sick and
the Dying30;
— Recommendation 818 (1977) on the Situation of  the
Mentally Ill31;
— Recommendation n.o R (90) 13 on Prenatal Genetic
Screening, Prenatal Genetic Diagnosis and Associated
Genetic Counseling32;
— Recommendation n.o R (92) 3 on Genetic Testing and
Screening for Health Care Purposes33.
— Recommendation 1418 (1999) 1 on the Protection of  the
Human Rights and Dignity of  the Terminally Ill and the
Dying34;
— Recommendation Rec(2003) 10 on Xenotransplantation35;
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— Recommendation n.o Rec(2003)24 on the Organization of
Palliative Care36;
— Recommendation n.o Rec(2004)10 concerning the
Protection of  the Human Rights and Dignity of  Persons
with Mental Disorder37.
In the European Union patients’ rights are also recognized in
ethical texts approved by the World Medical Association (WMA)
and by the Council for International Organizations of  Medical







— International Ethical Guidelines for Biomedical Research
Involving Human Subjects44.
The referenced documents address terminal illness, on
biomedical research involving human subjects or persons
suffering from mental disorder, or on the general rights of the
patient.
Other ethical documents that recognize rights of diseased
people with rights are the European Charter of  Patients’ Rights45,
the Declaration on the Promotion of Patient’s Rights in Europe46,
the European Association for Children in Hospital’s Charter of
Children admitted to Hospital 47 and the Vienna
Recommendations on Health Promoting Hospitals48.
This recognition of  patient’s rights which seems so natural to
us today is a consequence of  the shift in European Law from a
paternalistic approach to medicine to an approach that favors the
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primacy of  patient autonomy, from an approach according to
which the patient only did what the physician told him was best
for her/his health to an approach that defends as a general rule
that no intervention in the health field can be carried out unless
and until the patient has given informed and free consent to it49.
The application of  the principle of  beneficence by the physician,
as stated in the Hippocratic oath (“I will use treatment to help the
sick according to my ability and judgment but never with a view
to injury and wrongdoing”), now also must consider the patient’s
preferences about whether to undergo medical treatment.
If  we study the above legal and ethical documents we will be
able to enumerate several rights of  the patient. The patient is,
according to European Law, entitled to:
— the right to respect of her or his person as a human being;
— the right to receive health care appropriate to her or his
needs;
— the right to information about health services and how to
use them;
— the right to a quality of  care marked by technical and
human standards;
— the right to be informed about her/his health status and
about the diagnosis, prognosis and progress of  treatment;
— the right not to be informed about the medical facts about
her/his condition;
— the right to choose who should be informed on her/his
behalf;
— the right to obtain a second opinion;
— the right to self-determination;
— the right to refuse or halt a medical intervention;
— the right to participate or not in scientific research;




— the right of access to her/his medical files;
— the right to require the correction, completion, deletion,
clarification and updating of personal and medical data;
— the right to have her/his privacy respected when medical
interventions are carried out;
— the right to continuity of  care;
— the right to have her or his moral and cultural values and
religious and philosophical convictions respected;
— the right to enjoy support from family, relatives and friends
during the course of care and treatment;
— the right to receive spiritual support and guidance;
— the right to access to safe health care;
— the right to complain when she/he feels her/his rights have
not been respected;
— the right to form associations with other patients to defend
their common interests;
— the right not to be discriminated against in the enjoyment
of  the referenced rights on any ground such as sex, race,
color, genetic features, language, religion, political or other
opinion, national or social origin, birth or other status;
— the right to humane terminal care and to die in dignity.
If  we consider this list of  rights, the most important, in our
point of  view, are the first and the last one: the right of every
patient to respect of her or his person as a human being and the
right to humane terminal care and to die in dignity. The respect
for this last right is essential, because, although Medicine has
added several years to life expectancy at birth, it has not yet
assured life quality to those added years. Special protection by the
law is required for the very elderly who frail and vulnerable and
have diminished capacity to exercise their own autonomy.
If  these rights are respected in the provision of  care, all the
other referred rights are, as well, observed.
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According to the World Medical Association’s International
Code of  Medical Ethics50, the physician “shall in all types of
medical practice, be dedicated to providing competent medical
service in full technical and moral independence, with compassion
and respect for human dignity”. The doctor-patient relationship,
therefore, has to be a “fully human” relationship.
Biomedical progress sometimes poses a risk to the humanity
of  the doctor-patient relationship. The multiplication of
diagnostic tests may reduce the physician to a mere technician and
the patient to the sum of  the results of the tests. The very
progress that can save lives can also make the human being
simultaneously invisible and transparent, since her/his genetic
constitution may be well known through genetic testing and
disease foreseen before any symptoms appear. In such
circumstances, the results of  the predictive genetic tests may be
used to unfairly discriminate against a person on grounds of  his/
her genetic constitution.
These situations may violate human dignity, which is the most
important value of  European Union’s law51. Its respect and
protection requires that the patient can never be seen as a research
object or a biological ruin.
The patient may be in a state of  weakness and dependency
because she or he is ill. Nevertheless she or he is entitled to
protection and support according to European Union’s law, since
there is a duty of solidarity among the members of  the welfare
states in order to protect the fundamental rights of  each of  its
citizens.
Good clinical practice means not only a good diagnosis of  the
problem and skillfully carried out treatment, but also a humanistic
knowledge and practice — it means that the doctor-patient
relationship is fully human until the last moment of  the patient’s
life. Thus being, the “last” right of  each and every patient is the
right to terminal care and to die in dignity.
HELENA MELO
192
The respect for this right is particularly important since
medical progress has made it possible to cure many previously
incurable or fatal diseases and to prolong a person’s survival, by
deferring the moment of  death. As a result, the “quality of  living”
of  the terminally ill and of  the dying is often neglected. In order
to enable a human being to die in dignity the physician shall not
— according to Council of  Europe’s recommendations and
jurisprudence52  on this issue — aim exc lusively at the
prolongation of  life, hastening or postponing death. He shall,
otherwise, provide palliative care that aims to achieve and
maintain the best possible quality of  life for patients.
“Palliative care” is generally understood in European Law as
“an approach that improves the quality of  life of  patients and
their families facing the problem associated with life-threatening
illness, through the prevention and relief  of  suffering by means
of early identification and impeccable assessment and treatment
of  pain and other problems, physical,  psychosocial and
spiritual”53.
The right to die in peace and with dignity that must be
respected by whomever provides this kind of  care is recognized,
for instance, in:
— Recommendation 779 (1976) on the Rights of  the Sick and
Dying;
— Recommendation 1418 (1999)1 on the Protection of the
Human Rights and Dignity of  the Terminally Ill and the
Dying;
— Recommendation n. Rec. (2003)24 on the Organization of
Palliative Care.
The obligation to respect the dignity of  the terminally ill and
of  the dying implies good pain management and taking into
account psychological, social and spiritual needs. It also implies
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not using disproportionate medical measures and ensuring that
relatives and friends are encouraged to accompany the person
who is dying. The fulfillment of  these needs will allow the dying
patient to give a personal meaning to the time that she/he still has
to live — will enable each person to “live” her or his own death.
Even if  no one asked us what we wanted before we were born,
there is no reason for doing the same in what concerns our own
death, and not to fulfill our needs before we disappear along the
road curve54.
References
1 Different definitions can be found in European Culture: from
the mask used in Greek theatre, to Boethius idea that persona est
rationalis naturae individua substantia, to Descartes’ concept of  cogito
ergo sum, to the personalists idea that a person is “what can not be
repeated twice”...
2 See: WHO, 2008. About WHO. Geneva: World Health
Organization. Available at http://www.who.int/about/en/.
3 Jaspers, K., 1986. Der Arzt in technischen Zeitalter.
München: R. Piper GMBh & Co. KG, p. 52.
4 Stigmatization caused by a disease is clear in the little dwarfs’
words in The Birthday of  the Infanta: “When the truth drawned
upon him, he gave a wild cry of  despair, and fell sobbing to the
ground. So it was he who was misshapen and hunchbacked, foul
to look and grotesque. He himself  was the monster and it was at
him that the children had been laughing (...)”. Wilde, O., 1997.
The collected works of  Oscar Wilde, Hertfordshire: Worsworth
Editions, p. 271.
5 All European Union’s member States are also members of
the United Nations and of  Council of  Europe. The Universal
Declaration of  Human Rights (UDHR) was adopted and
HELENA MELO
194
proclaimed by General Assembly Resolution 217 A (III) of  10
December 1948.
6 Adopted by the UNESCO’s General Conference on 11
November 1997 (UDHG).
7 Adopted by UNESCO’s General Conference on 19 October
2005.
8 Adopted and opened for signature, ratification and accession
by Assembly Resolution 2200A (XXI) of  16 December 1966
(ICCPR).
9 Adopted and opened for signature, ratification and accession
by the General Assembly resolution 2200A (XXI) of  16
December 1966 (ICESCR).
10 Adopted and opened for signature, ratification and accession
by General Assembly resolution 44/25 of  20 November 1989
(CRC). The protection of  the child on medical care is also given
by Recommendation 874 (1979) on a European Charter on the
Rights of  the Child, adopted by the Parliamentary Assembly on 4
October 1979.
11 Treaty opened for signature by the member States of  the
Council of  Europe on 4 November 1950 (CPHR).
12 Treaty opened for signature on 3 May 1996 (ESCREV).
13 The European Parliament, the Council and the Commission
solemnly proclaimed the Charter on 7 December 2000 (ECFR).
14 Art. 3 of  UDHR, art. 6 of  ICCPR, art. 6 of  CRC, art. 2 of
CPHR and art. 2 of  ECFR.
15 Art. 5 of  UDHR, art. 7 of  ICCPR, art. 3 of  CPHR and
art. 3 of  ECFR. About the concept of  torture in International
Law see Grodin, M. A., 2006. Caring for survivors of  torture and
refugee trauma in the United States and Portugal. In P. L. de Faria,
ed., 2006. The role of  health law, bioethics and human rights to
promote a safer and healthier world. Lisbon: Fundação Luso-
Americana para o Desenvolvimento, p. 64-65.
16 Art. 9 of  ICCPR and art. 5 of  CPHR and art. 6 of  ECFR.
195
PATIENTS’S RIGHTS IN EUROPE
17 Art. 2 of  UDHG.
18 Art. 12 of  UDHR, art. 16 of  CRC, art. 8 of CPHR and
art. 7 of  ECFR.
19 Art. 23 of  UDHR, art. 1 of  Part II of  ESCREV, art. 6 of
ICESCR and art. 15 of  ECFR.
20 Art. 22 of  UDHR, art. 9 of  ICESCR, art. 12 of  Part II of
ESCREV and art. 34 of  ECFR.
21 Art. 12 of  ICESCR, art. 24 of  CRC, art. 11 of  Part II of
ESCREV and art. 35 of  ECFR.
22 Adopted by the United Nations’ General Assembly on 18
December 1982.
23 Convention for the Protection of  Human Rights and Dignity
of  the Human Being with Regard to the Application of  Biology
and Medicine: Convention on Human Rights and Biomedicine,
opened for signature on 4 April 1997. See about patients’ rights
in International Law, MÉJICA, J. & Díez, J. R., 2006, El estatuto
del paciente, Navarra: Editorial Aranzadi, p. 17-20.
24 Opened for signature on 25 January 2005. Rights of  persons
who undergo medical research are also laid down in
Recommendation n.o R (90) 3 of  the Committee of  Ministers to
Member States concerning Medical Research on Human Beings,
adopted on 6 February 1990.
25 Adopted on 16 October 2003 by the 32nd session of the
General Conference of  UNESCO.
26 Adopted by Council of  Europe’s Committee of Ministers on
23 January 1981. The respect of  rights in the collection and
processing of  medical data is also guaranteed by
Recommendation n.o R (97) 5 of  the Committee of  Ministers to
Member States on the Protection of Medical Data adopted on 13
February 1997.
27 Adopted by the Committee of  Ministers on 8 November
2006.
28 Adopted by the Committee of  Ministers on 24 May 2006.
HELENA MELO
196
29 Opened for signature on 24 January 2002.
30 Adopted by the Parliamentary Assembly of  the Council of
Europe on 29 January 1976. On the same day was adopted by the
same assembly Resolution 613 (1976) on the rights of  the sick and
dying.
31 Adopted by the Parliamentary Assembly of the Council of
Europe on 8 October 1977. Council of  Europe’s Committee of
Ministers adopted on 22 February 1983, as well, in the field of the
rights of  persons suffering from mental disorder, Recommendation
n.o R(83) 2 concerning the Legal Protection of  Persons Suffering
from Mental Disorder Placed as Involuntary Patients.
32 Adopted by the Committee of Ministers on 21 June 1990.
About the rights of  people who undergo genetic testing see
Nunes, Rui & Melo, H. P. de, 2000. Genetic testing in the
workplace: medical, ethical and legal issues. Law and the Human
Genome Review, 13, July-December, p. 119-142.
33 Adopted by Council of  Europe’s Committee of  Ministers on
10 February 1992. The rights of  the participants in screening
programs recognized in Recommendation n.o R (94) 11 of  the
Committee of  Ministers to Member States on Screening as a Tool
of  Preventive Medicine, adopted by the Committee of Minster on
10 October 1994.
34 Adopted by the Parliamentary Assembly of  the Council of
Europe on 25 June 1999.
35 Adopted by the Committee of Ministers on 19 June 2003.
The protection of  xenograft recipients is, as well, guaranteed by
Recommendation 1399 (1999) on Xenotransplantation, adopted
by the Parliamentary Assembly on 29 Jannuary 1999, and by
Recommendation n.o R (97) 15 of  the Committee of  Ministers to
Member States on Xenotransplantation adopted on 30 September
1997.
36 Adopted by the Committee of  Ministers of  the Council of
Europe on 12 November 2003.
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37 Adopted by the Committee of Ministers on 22 September 2004.
Legal protection of adults who, by reason of  an impairment or
insufficiency of  their personal faculties, are unable to make
autonomous decisions, is also provided by Recommendation n.o R(99)
4 on Principles Concerning the Legal Protection of Incapable Adults,
adopted by the Committee of  Ministers on 23 February 1999.
38 The WMA Declaration of  Helsinki on the Ethical Principles
for Medical Research Involving Human Subjects was adopted by
the 18th WMA General Assembly, in Helsinki, on June 1964, and
amended by the 29th WMA General Assembly, in Tokyo, on
October 1975, by the 35th WMA General Assembly, in Venice, on
October 1983, by the 41st WMA General Assembly, in Hong
Kong, on September 1989, by the 48th WMA General Assembly,
in Somerset West, on October 1996 and by the 52nd WMA
General Assembly, in Edinburgh, on October 2000.
39 The WMA Declaration on the Rights of  the Patient was
adopted by the thirty-forth World Medical Assembly, in Lisbon,
on September/October 1981 and amended by the forty-seventh
WMA General Assembly, in Bali, on September 1995.
40 The WMA Declaration on Terminal Illness was adopted by
the thirty-fifth World Medical Assembly, in Venice, on October
1983 and revised by the WMA General Assembly, in Pilanesberg,
on October 2006.
41 The WMA Declaration of  Ottawa on the Rights of  the Child
to Health Care was adopted by the 50th World Medical Assembly,
in Ottawa, on October 1998.
42 This Declaration on Human Genome Mapping, Genetic
Screening and Gene Therapy was adopted in the XXIVth Round
Table Conference of  the CIOMS, in Inuyama City, on July 1990.
43 This Declaration that lays down guidelines for Physicians
concerning Torture and other Cruel, Degrading Treatment or
Punishment in Relation to Detention and Imprisonment, were
adopted by the 29th World Medical Assembly, in Tokyo, on
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October 1975, and editorially revised at the 170th Council Session,
in Divonne-les-Bains, on May 2005, and at the 173rd Council
Session, in Divonne-les-Bains, on May 2006.
44 Issued by CIOMS in Geneva on 2002.
45 This Charter, based on the current situation in the European
countries, was presented in November 2002 in Brussels by the
Active Citizenship Network.
46 A WHO European Consultation on the Rights of  Patients,
meeting in Amsterdam, from 28 to 30 March 1994, endorsed the
Declaration as a set of principles for the promotion and
implementation of  patients’ rights in WHO’s European Member
States.
47 Adopted by the European Association for Children in
Hospital in Leiden, in 1988.
48 These Recommendations were adopted at the third
Workshop of  National/Regional Health Promoting Hospitals
Network Coordinators, in Vienna, on 16 April 1997.
49 About paternalism v. autonomy see Stauch, M., Wheat, K. &
Tingle, J., 2006. Text, cases and materials on medical law. 3th
edition. New York: Routledge-Cavendish, p. 28-40; Jonsen, A. R.,
Siegler, M. & Winslade, W. J., 2006. Clinical ethics. 6th edition. New
York: McGraw-Hill,  p. 54. and Bilancetti,  M., 2006. La
responsabilità penale e civile del medico. 3rd edition. Padova:
CEDAM, p. 368-378.
50 Adopted by the third General Assembly of the WMA in
London on October 1949 and amended by the 22nd World
Medical Assembly in Sydney on August 1968, by the 35th World
Medical Assembly in Venice, on October 1983, and by the WMA
General Assembly in Pilanesberg, on October 2006.
51 Art. 1 of  Convention on Human Rights and Biomedicine
and art. 1 of  ECFR.
52 See the following cases of  the European Court of  Human
Rights: Case of  Glass v. The United Kingdom (Application
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n.o 61827/00), and Case of  Pretty v. The United Kingdom
(Application n.o 2346/02). These cases are available at: http://
cmiskp.echr.coe.int/.
53 WHO, 2008. WHO definition of  palliative care. Geneva:
World Health Organzation. Available at: http://www.who.int/
cancer/palliative/definition/en/print.html.
54 As a Portuguese Poet (Fernando Pessoa) wrote, “Death is
the road curve. To die is only not to be seen anymore”.
